var title_f20_54_21344="Early congenital cholesteatoma";
var content_f20_54_21344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Early congenital cholesteatoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Early in the course, the cholesteatoma is hard to appreciate; it may appear as a subtle whitish discoloration behind a normal tympanic membrane. As the lesion grows, it makes contact with the underside of the tympanic membrane and becomes more obvious. Panel B) The eardrum is reflected downward to reveal a white spherical lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21344=[""].join("\n");
var outline_f20_54_21344=null;
var title_f20_54_21345="Part patella tendon tear";
var content_f20_54_21345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Partial thickness patellar tendon tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ennlE8oE0mNx/iPrTBczngzScf7RpLn/AI+JeMfOf51HkZzigCU3E2f9bJ/30aT7TN2lf/vo0zPekHtQBJ58uf8AWyfXcaPtEw4818f7xqPrR7mgDrPCFwzZEk8owegJr1HT1U2ayeY2O4PWvIfCV0YLogkBT7V63Z3UEtghjVi469hQAsM+28/dtiMc5bmma3dSTabcb5WcD7vPFSlofPVym0YwRnrVfVYo2sLhoflBHTNAGF8KpJf+EqtBJIxPnD5c+9fd5iTy4XIQFV6kD0r4K+GL+V4yswPmHnLnj3r73kdVsDKcbVj3dM9qAPk74rXlvdeOLz7E5+U4YkY5riV8xmILEc9zWt4kn/tDxfqFwDkGRscYrOaF/tiKzA5PTrQB1eiwyiKPdIfp1rfLB4nXZHwOpFVdCRWjA6ECrVztCyfKF460AcpqchMUgyFx6VyGoyuPuyNk+9djqAXyJHOMDviuK1GQMCoXI9RQBiXcsqEgSNg9fmqn5kpYHzWA9ianuslirAf41W2gDjj6UAXIZZA4LyMx7fN0rpNJleVlCucDrk1zCIXKsoPucV0WiIFO4OAT2oA9A0a6ktxlGV1x901txRmeISkAE/w46Vm+HbKO7CF2Xj+Hoa6O6haNwqruGOMcYoAzWts3CneD/KrAYJKFCK7egHFTiJFURzrgk5+WiLdNeLHDCViXrIaACaFBAZHIx39BXC63eol2BG2R+tdr4jkMFrIVClTxk8Zry+7LSTlyBnPcdKAOj0yRlnSQIOfXvXU3MzweWfLjYOOmBxXLaMSyxlxn1966i6RmaMxr26HtQA23VJLghI/n6kYzVx9OkeBpflVR0XHWo4XWO5XDAP3YVqyXf71ejIfQcUAZWnRs5Ktgv/dIrReNIwA2z/gIpJCIbzO3hvSl2qbeQx53Z70AKUWWTbtQLjk4rjpYM6w72/3IzzuruLFE2gMDuIwQxzXFSTNb+IZoJFCRu2BuoA7G3k8yxEhXBPAAHNLb2+csQxY+varVhEn2NUU5ccjPero2sAPuY6gUAZV7ADa+Xld7evauU1tLWWAwhtt1H0I6Gup1zcseIxlR+dcBfrIbn93l+ec9B+NADrSOTykVZhHIWwR61T+MF6ILC2t4lA2J8xQ4yas2Eqi78yXG1PyrgviXqW7zHEhZmOADQB5rLdTO5xLJyf7xphuJgeJXB/3jUXcmgYx70ASCeXOTLJ/30aPtEhP+tkP/AAI1F2FBBFAEhml5Alk/76NJ50v/AD1f/vo0wDJ60GgCQTzY/wBa/wD30a0tNll8hv3sn3v759BWSM1p6ZnyG4/i9PYUAUbrJupfdz/Ooh0OOtS3fNzKB/fP86iIoAOvWl6UKPaggjigBM89aXbxnNAAxkdaOT1oA0/DsgTUEG3Of0r1PRnJG1GA4+leSaWcXsfPGa9O0YSb1d2QADgZxQBs3bIFB6t3zUyQCS2dCcq46Z5qN/LMe5x8xPAAzV2dVjsBKu3zFX7oPIoA4fRrj+yfFEflfKqyA89etfamr+IHs/hn/asQ8yVrYbeOMkY5r4bRzdeI1fByH5NfdfhXTYtR+HVhY3IzFLbBTQB8hI8t5qU00xHmSMWOOKkQst8qoO/TGTXffEX4ez+FNRF5CzPYO3XHSuWs7VX1iGRMmNjxQB22kWyW1rG5DFmGT7VHqUybJAEK5/iYVrQIDIUxudV45rC1VwIJWJyw6jHAoA5nVXAtii5x9K4vUvkyeBntXV6nO32TIdWX2ritTkEsnBIx60AYd4S0nyFhzzmm88YODTrqYFs8DHemB9/O4E0AWra4KSKj5Kk+ldVosCLMHwGTrg1ylkokmDE/KvU1t2lyFnBDEL2FAHpGlzpa7ZEJIJ6Y6V3cDtc2AngXc+Op6V5lpd6TGqgjB9q7fwVq0SzvZzybmf7vpQBajt5pUbemJSexzTpbsWgWGNCwH3yTWhdu8MrALtOeMd6xtUidFYy/KZBwVOaAOe8YagJl+ViU7KO1cbZSGS4KTHIPSr2sTyLM8D4wD94VlxttlSQnv1oA6jTSVdURMAHrXbPGJbeEx4Xjk1jabaRvYRSx4y45Yiuks3EtgYFVWdP4hQBBJa4Cnylx6inyLs2hl3D2HSrkDbIFE+QemaJF/eh/MTyx/CO9AFa4doZFIXJI44zToiJoisw5PZa0JJMxCRWVgeMAA4qCOJfN2ghQ38R60APeOQJE0Gxgn8OcmuK8Wk/21DLJEELEcGuw2qsu3cySA/LIvINYXjq2luRbSEosqen8VAHQ6dMVhgUqNrKOR2rR8tVywbiuajvlSwtWKMsigAj1roIZA9osjZ3HoCKAKGrbUKuWA46HvXHSanHZXE4Nsskbggg11euyF41QoobHc157fl2neMAnHUgUAUprwRmXyowEbnb6V5P47ujNehMbR1xXpN3PCttKGO3aOo5rx/X5/P1GQgkgcZzQBmjIoPXmnYz06UEehoAbzSj3pduRnFIeDxnNACHjpRjjk0pH96kPtQAH0BrY0gf6M3++f5CscD1rX0lc2zct98/yFAFC5INxMR13n+dQ4z0PNS3LETzDtuP86iww5xxQAUh9c0Hn2oGaADBpcj1OaQk+lCLnJyB9aALNmwW4jOcc8n0r0XRtr3EfmTBVxwT3rzWLG9SegPavRdA8uTySzhcAY3UAdpevaLbxiInze+O9RKfLt7iZhnCHk1HNHCVSSSVVx/dq1qs0aeGroxLn5ev4UAed+HEM+qzT4zmXjFffvg1fL8J6UGwMW6E+3FfA/gvCqXdtrNMP519SfF/xhPoPgPRrHSZxHcXcSqzKeQgHI/OgDpPib4ssxZT6Zarb3zMpEq7s7f8A69eQ+D9PjluHmkiZUU5VG61xujam63zecxLMOdpzzXW+E7p3vXWWZhEegPagDb1AvaXxZyNzDhVPSsPWyRZsEY4Y5ZsVZ1K4K37EfOoP3jWbfymZ85BHp2oA5DU3jEGzLD39a4+9cEsMlfQ12evhY4ju/KuIvcHJyTQBmzIAuSNwoVlwABg9gaHfjAYKfU0AtuAwMevrQBatJfKkG8AqTzit6CKMMHTBz/ernoomY7gOB2rpLKOOSCNWcI/bNAGxYOynA49a2bO5a2uIpx91SMkday0sZYFUNkE8hhyDQLhoXw3I9aAPbrC4tdUs4JWlCtjt3rI8SRvErGEkoo715vpeszWs4MErgZzt7GukuPFr3EOHRS+MYPSgDjdUYyXbyEYBqkqGR9ikVavrjzppCcDJqGxKm6j2tgZ5oA9P0AlvDSKpxs68da1fD1w0V95T7NjjjNY+kyvb2LLGu8sPlAHJ+lXPs15Bp6X1zayWzq3HmDBNAHQMVY3MQYOF5OBUdvHazWpXzAueBUieZcWscqGM+Yvzle1Z1kI7aSWIHKZyWPWgBLRprO4a0dssx4cdMVrqETCABgerHrVAskhxGVK9j3qeOcrhGILL3oAtxRhCY3QkHocdK5/xXEyGNNpMZ6P6Vq6tJK0KSwsyAfex3rP8UySSaJDMDhB2oAm0yaGa0SK5jSQR8gk4NX45vNfNum0fdG6uO1S3E+iQXMBcSg4JFdZ4fnaTRogYsMg5J6mgDL1+yIlRHlJDctzyK47xNqjW6fZLEKsQ4ZiPmNdlrskku7yIySBz7VznhzwPqvjC/mjtZYoYY+XkkPT8KAPONelEWnOzBQCMnFeTTPvmdueTXr/xd0eTw1NNp07xyvGMb4zkGvHcZ5zQAEkjGMCkHPelODSDgHgUALznrSjnqOKbjB65pV5PJwKAFJ5wBx6UDb3zntTWAzx0o+nWgAz6VraRn7M3zEfOf5CskHjpmtXSWItmxj756/QUAZ10d1xKf9s/zqPOTx0qS4wLiXnPzH+dR4HagBSccDOKb+NLzikPJ9KAFJHoaTtQcjrR6UAOHXPYV2Wl3cTWsODtIxk1xmK6nQVaexCxhAoPzZoA9BtoWkgt5I/mViBwK6bUrGSy0W5E6iQSREj24rG0+7+yadawWswZ8gnA6Vr+ONZkn0qEEjcI9rEDANAHk3h1X8u+kQDEcma9O8a3ct/4L0G8f5yilOvTmvOfBcE0q6qnGCGYZ712thKdS+HU0DcyWcmeOw5oAydOfy7jeeCRmuo0XURFcIzPlM+lcdbyjMXPykYJrtvDMAuNIuzFGHMQ3ZoAmvNRD3UgdgiN0Hasb7RNvYggAdKz76Z3fLPxnGPSnQcQlGb3BoATVJSbdzJ8oPc1x16YWXasjc98V0Gqb3ALE4XoDXL3rZckYyKAKMyqr5yGA7mpEIaMEgAdsVXEobcpjUCmrMyn7wGPbigDSR3BXGTWhBO0e1o/l55U1mI52qwPPqKvQOJJAFHPrQB3Oi6qyRJBOCYn6Z7VoXNjcKCTAWhPIkxXMaXqRgdVlCyRL1XvXo3h3UzcbZFuSLQjabY9RQBzH7naMRnK9wKoXDK8uEbDj8q6zxFbQ2N0zhw0UnOP7tcndvExPktwO5oAbgDAfr61B8qXKNyCD2qRJtyYdOOxqZYhLEVRR5g5zQB6z4WEwsrO+tohLIuFGexrtPEWj6zLprXuu3sckJXKR4xt/KuL8APPceH2iSURvF3rOj1/WJfEX2PW76a4swSqpIeB9KAN/wAOyRS2kkMLjKH5s0FVXUV5DRn+LsKzfD8zWviO5gBUxSdMiurks1kgZBGm7ORQBi3BC3pRFAPr61f8ndGruVUj+EVKsQjXa675R69qj5RMM2fWgBJCXXyIwdzDqOlU9QgSbQri2nfbsGcnrWiCWC+U+1R1AHJqrq+46ZckQjcF/E0AZvh0JP4ekgkYOiMdvrW9ZAW2nBFVmXHQ1yPgBGnhui2dynj2rsCXESl3Kj+dAHKardXESTNGxQjoBXHahqdw0Jks7me2uwfmMTFQa7XVIvtEcwjU5Gc46muCvyYbtCgBGeUoA848d6jcTIftMpmkPUscmuBHWu2+I5AvflAUN29K4rnrQArdOlIue1AJ780g6+tACsO2MGkXg807p3pAOeKAAnnA6UKOvSlJzSdKAEHStbSVBt2z/fP8hWSfatjRygtW3Hnef5CgDNuf+PiUYH3z/OosfNU11n7TKR2Y/wA6hOTzQANgGjIwMHmkxzRjGeKAF46GjpQfu0dRjmgAB561u6AyKpDsRuOcCsIDPXoK6DSraKPa5LHPYGgD0zwo8UsSIqg4I5at74gxIukQjKKu3lV6msXwLGk06qoBcc4bpWZ8Ttb36gsAQoo+VgvegDI8OzD7Q6xx5hIIJra8CXkdtrV/pc4xb3II59aq6PbJaaWbhsgN0A61jz3LQ67a3UIwS3JoA1Gt/s+pTwbThWOBXonw4lCQ3kZOVeMhlrkvEMOzVYJQuBMgY4711vwyOV1JtoxHGefSgDjdUZIr6aPaCm7igSiLYvJB/hokgW51Kd3JK7jwamzE7bIztVe5oAoavK0sJwNoFcVfYIbgnmuv1eSNIyqyBz3rjr98NkcDNAFLGCAqnfT2JYbXC574qQREuGGAD780skeWJjXp1oAmSREhCrzVizmLcfdX1rOBEfKkFj1B7VYgmVvlxhqANi3c5yrAfzro9EnmF1EkDOGY9RXL2rqJFO35vWt3SdVksrjCAZbvQB6pc6L/AGtZJbxyKb5F3bD1NcFqtnNBdNE0bJLHwysMV2HhTxBGt7bveRFmjOd68MKueLLdvEPiQahYkNHjBB4P5UAebRt8xRzn2Pap4ZDGyuOcVd1qxFtdSFlPJ5U9qz4dwbax/dtQB6x4BnVbVnCZR/vDtUHjrTDDqFpfWxZomYZyeFrI+Hmom2vms5GG1+gNegaxZx3+gXUJPzR/MuPWgDmdXjfSNa028uCWinAIcdO1dZNdMtwn2aPIYZ3GsiS1l1X4fxfatq3Nm37st1IzWnprtcaVayYxOq7W9KALC3YLku29z+lLKsbgNna/YVmsHjnk2sARVm3uYZYslVMy9W9KAJopsyhCP3nbAqrqE8scVywjyQpyTRb3BMrCNxkd2HNS387iDzwAQBhk7GgDk/h1fhtSvI2djuJ+XHFdzM48o4Iwvr0rzXwfdpF40lHypFJkFR2616HIRsnjjUbc9T3oA5O5vY7a7nl5dTwQOgrhtSUSXpmhJ5OfYV3GqxxiOUBQsePmrG0bT4E0fUb2U7oY1O1W9aAPB/HVy8uolXcnHauZxjoa2PFU5n1WY5yMnA9KxgeOaAHKcg88+lNx6ClA57CjbhuaAEIOPenEYX3pp6ZIyKA1AApyDnrSggjmk/n60p6f1oATkjNa2kR7rZjn+M/yFZGcVraSf9Hbr98/yFAGfdMPtMu08bj/ADqIk8HNPuebiXI53n+dRjj3oAMc5NGBjvQDSnjgdaAEAB70vOcZo74FB4HvQAh646Veshcq6+WSQenPFQ2dubqdY84Jru9H0HKRgLnJAxQB2Hw1iYRySSnJVCckdOK5nxoEvdQY52sG4zxmvadO8MxaF4VWa4ZE81M9eRxXhHiGYSa1KuTIik4YdqANKGZmto7FD8xHUU1tHunmjQQthGyXIo8NXlvaO0zgSTHhS3auo0/U7q9uUg3qqseSwwMUAN8TQKkdnMGyVTBrb0eX+yfB17csdj3A2r6movHFsY1tY1iPk4HzgcMad42jax8NabA0Lxl1yA3egDnbAEwDHzyOc470s8flO2VXn+EGnaSMuI4iPMA6+lWBZ4SaaXDAdfm5oA5PVgiKwAALelcvc9QFGR3rqdUjW4DMImVB3zXLXRUHbGDtB6ntQARqhOUXaB70+UBo9wB3Ckt8A46j1AqQgEnIwB3zQBSxuJ2rg+9Ph3btq/eqZEUuSSWNNZfLc4OAe1AFmByhI3H3rSs50WSM9SD+VYgYpjHOaswSDeR39QaAPefBDJfbGs7KNnRPnnfGFrT8O2Qn8VF4LjKq/wAwA4PNcl8Ptd/4p+fTrJMTPy7HqRiui+Elvf3XjRVRHFpE2X+Xj86ANf4y6A8F1bXP2Ty4ZBgyL3PvXk2p2psjtO7Y3IIr6j+MGp6TF4faG+lXzCcIo65r57kWJpVjkXzLWToepFAGPpN4sM0L52upHz969r0l457SK4jYNE6/Ng9TXil9p32W4eMklScpxXdfDPVgGNnOwBHQMeKAOnureWO5ZZnzbP8AdU9qtaUJLOQ2zkOj8jHapvEWHtkcAYB4x2pzSRLZxMrp5xHVfvUAZl+zpcO0aYRepJzmoNNKsHkUDBP3MVqmAsjuqkgj5gTnNULOJrd2dQFjJ5HWgC0sZjUOAu09c9qlkKcKSHjbjAqrPNk7QAIz6mpY3zCqoqgA9RQB5nfodM8ZK0aEAsMV6hBJGIzJLkjaDXDfEBFi1iyuEAA4z613SeXPp8DqCSyDp24oA5PXrhZIxFEMiRsYPBFZfxIuE0nwvbadA4DOu59vvWtNbrPrKRs28IcnHGK87+KN/HNfyojErGNoxQB4xqL+ZeSEEkZ6mqx4PBzTpTulZu5JppzigBQB1PSj60g6DOaVTg56+1ACgbjgA0hABx3pxc4OOPpUfWgBx+VvUUNjPSkNG4bfegBRjPIrW0sL9nbDEDee3sKyB+vrWxpLH7M2f75/kKAM27H+ky4GcOefxqv1NT3HE8vP8R/nUOKAFHHFH4kUgBzxzS9etAAPYZNKW7UnTkUZ5oA2fDYQXJaRtvYcZFey+B08ySKEqjFiMMRxXj/htVM370Zz90AV758PEFpo9yzIm/blQRkigCl8X/Eb2FsliJvuLjIPH4V4zp7s6S3DMSzdzWh8QtRfUdZZJG3BG9a537U2GRGGBxigDXTUIoQCvPPSt7wtqM2p6mLKOIuzY2npiuPtbbzlQy9M54r0H4JRJJ8S7FWTKbwAvrQB9X/CuztdT8Kww6vp8ElzZvtzIgb3B5rjP2ntIX7FpuoxrsVCY2I6Dv0r2Bv7P8Nabd31wwt7cfvJDjOOK5XW2tPiP4RuWtRHJpoJZJA3z7h6jtQB8v6TAZOQCVI++OpqW8dYUZlVjt6pnrV68kbTnliiKgxEqDgc1mXUstzaSMGRFP3jQBxmsXkszOcmNPQdqwiVdRtcse4rU1R4iCkZLAHk1TRWbG8AJ/sigCSJNqg5wPXFGz5jgNg9zU1uMkoB8vvS+WyS4Az9aAIUTy1LA5x3xShQ/P8AF71aji2sSMup6jHFK0SxgkEDPY0AUNgBzjmoW/ctlRuLcda0RHkElCT6iopIBsJ7+4oA3/AOoCO98ieTylkOC46ivpTwR4n0jSYhp1pIJZ2Gd4X7x9zXyGpe2uY5UJx3Fep/DC7N7r8CcjPr2oA6Hx1qJ1TxDci8uMOpISLqBXMgzWikhzkngnkCtrxZpDJ4onLttUMTv7mtSPRYbzTcpIFZehfvQBk2c39p2hiuJEa5QZUgVkxXMljqazIPnQ4IpZ0k0+9YgFXX071m3U8lxKWU4JPOaAPb9Evo9RsVYDdK4/i6A1K9uyEB0USA/wAPU15loWty23kQliFUjjpmvXtPuUvIY512nK/lQAkLKAF25jI5Gen1qnhFmlQsNg5GOas38CRsTGSzt/dPFUlXaQImG/uGoAR1gkQFBhh/e70illQhFAppdo5vL2gq3U1ArhJ3Q5IPQE0AYPjkLJbW0o2mRTz610WmXrPo1qcDdtxxXOeJbcS2Z8wcg8EHpWl4fkzoQj3A7B260AZGozm2e5YH52z8w7V5L40dhZyvjLHPzV6J4gcncqqwyeledfEYLHp8aZxkc4NAHmYJJznmkOTSZwelGeeelACgA454pcgcZ/GkHegDnBPFAAemBR7UY568UD260AIelHalbrmjHHUUAGeOa19Hx9lbJ/jP8hWOeOta+k7jbNgDG7+goAzbnJuJe3zn+dRkfnT7n/j5lzx85/nTFGXxn8aAEUkZFKRxmlyMnmmnrx0oAXOCD2pQAW47mmnrUtuoM8YcEgnoKAPQ/BOnhvKVId8jEcntXr2qyL4f8MySHaJ2THFee+AoBLf28JJjU4xjqa1/jHey2sC2SNtQDH1oA8dvZvtupTTSZyzHkVBFGXuSmzj+8auGDy1iZe/rWtp8AlcllzigCKJBDCOAMDq1d7+zgnmfEa3un2lEfOfSuN11x/Z5UALgY5rvf2drdmvzKkfI5zQB9NfG6Rx4CumhfCNgHHcV5h8E9QuNJ0W+kds27j/VFuCfWvVfHdg2sfDqcSsITHH5mD0OK+fdIlK2ZdblYypx5ZPBoAqa9HPdancyRKih3LbfSuP8QamUiNuQihRyV712d7NFEk0yH96Ryc8CvMddufPdixBbPUUAY6gTOx3HBPAqzEuVK8jFOtkOBkAn0q0FYggKM9hQBBCAOFUgHru61K53HaPmx6dqUcffX5qkIPBQc0AMiDgkupApw2uSGX5adlm4Y9O1NILMMY+tAC7OMgHA6YpG+bllwfXFPYkrxg4p3VVJUhvagDPuIv3D8c1o+C9Vk07Ure4V8eWw49aSRCyngFqypYXTdIoyR1x2oA9+1/TrzxBpo8RWsIEQHzhTmrXhyxuNb8PP9jhkMqHlgOlcb8F/ESyXqaPfysLW4+XYW4zXswu08DauLRhi2n5QKOKAPEPEFpd216y3AZmQ4JArHeZShbbgj2r3XxrYJqKfa7eHcX5+QZzXmF3oU6XDCaHyoz3YUAcusmArZ+avQvBWvlo1tZHP1rgru2EM7JG6soPXuKfYXU1rcK0R4HcUAe+zFZLZPKdWx781Rf8Adv8AdLE9T6Vg+HNTE8atNIHcdga3ZkyRMgLZ6rQBXDMjMFcEf3T1qJtpmDAYYdcmpmjikhKIrBjz9KrsFUhQQWHU0AVNZxPBIrYJxxis3QJDBDLGFOT61sSpG6SE4PHOKwUlNtKwKkKTwfSgCnqsUfmkuxU9a8w+JJDRfKOnevUNQlUfvJcSN29K8w+IpWSBn9R0HagDzT69aASKOvalGfSgApD09qdj86DwKAEHbrRyTnOKM+vSgDJ4oACD6Zpe2Tikzg4OcUuevGKAG9T2/GtbSgfs7Y/v/wBBWTyDWvpOfszf75/kKAM26GbmXH98/wA6jGRUl0wNxKP9s/zqPOOnNACZGKXnr2pTwKb14FAC8YzUtqP9KiwcHIqPac84FTWP/H3H04NAHrXg6R7fVbJypxuH41vfHSy8q7troAqkig4auW0eRGu7L5nyGGMdK9B+PdvKdC0qVjvHljigDw+V/MeNV4I59jXQaRErMC47c46Vhj/VKSvNb2kuDGAh28cg0AZnix1jgIQADPevX/2boyYZnIGdowT0rx/xUFEWWGee1ev/ALPl5BDb7SGEhxwelAHv/jtZW+GN6qOVbZ19RXzDZPLb24Cjcxboa+s/E0YbwRcIflDx9COma+afENgnh3RzM0geaUnGe1AHG+J71lP2dHGSOdvauVVFcHzATjuauMXurhpJCMHqKjZQc7QVA7UARRKQ4UfdPT2p7BgSqHLep6ULkcklvb0pJMnkggUAN24+82W9BUgV8ZIx6DNRwn58kfhU+0bSw6igBI2YjAXB96dkHhSOOppiAnknr/DT9hx8qYoAbCCZTnGB61MRwece9R/dGcDNPViFycHP6UAPBwucjIqsyh9wK5B7CrIwx2nAPrVdQFkKtkCgCPR4rmG7W7tTs8lt2c819e+ANQ0nx74VtXv9rX1uAj7uufWvknaIkdo9wz1rtfgz4w/4RzXkhvH22s7bXz2z3oA+h9d0G70a6S4tS0lp/cHOKhY2ep237yBC3cMMGvQlhEllHJayC4gkAZVPIIPpXNa/pMNoPtSKY3P3o/WgDzXxB4E0m7zNBIbe4PQD7pPvXD6v4FvbVCyEO/Yp0Ne0tEjxCaP5Qf4cVXu9kiBfJDkf3e1AHhOmS3Wl3IS4V1ZT2r0TRdVFzF8wDEjuavX/AIdg1JnZ0aKQfddP61iP4evrBvMjCMV7DvQBrs2xyUJVfT1qvcFEcSNwG6VR+3SMfKkXb65HSpABKoDklh0JPBoAHLkMFCsDz8tZt7b4iDKje+a1GjWIZV8N/Eoqheb5YWWPIjHUetAGTcKJQoIwPU1518R4/JhYccjtXpJyqFP4uwrgviHG81scDDAdaAPIcgcYoU4zxSyKUYhuDQcDHrQAE8cCkU880Z9aQdc0AOzjrikz144oJGOlC+9ABxjrQODnPFHfmgEZ5FABnJ6YrT0wgQNkA/Mf5Csw8njpWnpaH7O2CPvf0FAFC54upf8AfP8AOo84qS5z9pl/3z/OouvSgAPPvSqOeDRzxxxSDg0AGPQ1JHlXTtz2ph9+tKOMEHHuKAPTvDR+0C2CMqsCMFu9e2fFLSPtfw5sp875okGQhz2r578Kys1puds7ehPUV7/4PkOsfD+7tfMJkVTz+FAHzjHPiYxMCCtb2kyKFz6dqwNbt2tPETxvkDdjmtK3Yxy4429sGgCzr6rNAzHg44ArrvgNqAh1YRSHGTj6Vydx86/d4NdX8CLYP44gjdC2X4xQB9k3dumreHPLEpjV4wd5GOlfK3xcltomMAn82RDjg5r3/wCNmuS+Hfh/cNZuI7iTESEcYHfFfGrXct6/mzszOTzk0ANjwqqBnJ6047SCAcD1pUY7+x9DUcgQyHkhj1HagBvy54Jpp+VtxOKcEwSAMj3pDsZuR9KAGgZPB69zTlK4KbizClP50Bxn5MUAOTkdwBSkEdSSO1NHGW3HPpSMd2BnH1oAlRCwI4J96bt4yGwfSkyR8qn8adjHfHqTQA/Y/G0DmozkP8/UU9jswCefWmjG49zQA9AzfNx+NQtEDICDtYHPFPRjtYdvSnciMchT6CgD0bwN8Xtf8Lxx2LlbqwU9JOSo9jXtmm/GHwjrtmsWpNJbMVwTIucH2Ir5PwWxuUYo++QpPAoA+qk1CzjleSwv47m0c/KfarkDQ3SM1tNGW7qK8D8JeOoNCgFpeWC3Fq33yPvAe1d8s0UtoNe8GXUlxaJzcWr8sn4UAdxNujU4Cgeq9TWPKQLsCU/uz2PWr+k6la69pqXen7fNH+tj7qaoajFIzEtHlR/F6UAVdQsoLhWVNgbGVJrnSZbeXZcKqhT1q+LWZZcyF3U9PaoL+ETsY5QSV6MBQAwFPNEyHdnsaWZA74GEU9QO9VkjMduQ7EqOAo61DCxjkHzYB7E5oAWSMCTHy7fUCuY8cWAezZ4SRxzXYhIur9D0xxVTWbQPpUwmK8j5SKAPmLVYPJum+bqapED3xXS+J7IRzyCPs2ScVzbLtOAQaAEC/Sk4zzTie2BmkJBPSgAGSOOlITmlHzdTigD2JoAb0pfxowaMHr2oAB1rX0kA27cfxn+QrIHHetfSWUW7Z/vn+QoAzro5uJcf3j/OoQBUtxxcS8fxH+dMwOCTn2FACE5zSEUpHPtSfQ0AKeetAA9KTn1FO3HOKAOg8K3xikaNslMdMV9DfA29aWW4iADIyn5QK+ePCkMUsknnrLtxwUBr6K+AFqkVxcTEkIo9OaAPKfjFpEun+Lp5HHys5YY6AVzUcqttOPyr2/476VBfzNcxq2enA615j4T8NS3sgjO1PZjQBSQlyCQQMdK9m/Ze0kTeK7m7ZMpChIJHQnpXn13pDRXxgQbtvGVGa9y+AER0iO4juikPnkBRj5jQBd/aI/f6A8szAW8Jwoz1NfKcJJiL9Nx4FfSv7VTG20OyjRiEdiSvrXzNbyAxKoyMUAW0+YEMcYpsnyrkHJoTDA5P4mg5GMgfhQA0FwBjkHr7UhAPX86XJAJxj2FIvzKThg36UANy+/GBj1zS/dJJx9RSuFIXAJaglguCAAfWgBeMZwaUsS2So/GlXbgAL+tPcZ7ZPpQAxfmzjG6n5OMfzpFjKcggk9vSlVSRg8H1NAAMbuVLChipkypxQwZRkkcelNfkg7QPpQAsYG8sSce1SYHUA+1MRcZzwKkjye/AoAaxwwB+Yn36UqbWyCDuHQ0g8sknq/b0oSOQZOST6UAMk5Ul8r9K7X4JeKv+Ea8Yww3TBtPuz5UqnkYPeuLcq52jOe/tUT/IyTRfK8RyGFAH0d4v0+b4ceNItRsQTomot8yjop7j+orrL2XNtHLGqyWsy7kINUfCepQ/FD4Qy210Vk1K0j25/i3KPlb8RxWH8JNXW7t7jRdQkXz4CQm84x7UAX5iSu5QQQec1AIY5mKqfLJ/8era1CzNtcsWG+I9xyKzrpDgNGowOwNAGBNZOJXC5yPSsO+tjATIGNdpvUhmaNicdRxWLqFqMkkNh+1AGPb3W/YhBI9qs3jhrOVBtbj7vXFYc8klneNGRgHpzVywvFG4FA27gmgDyPxZCN0yjLcnpxivPHGHI6YNeweNbQpNIQoRG5wteT3ybLlwABQBX7e9BQ9ev0ox60oyOAeKAEIyM/rRkgZzRkkYxxSYGaAFNBPFKCCuOc0360ALWrpRxbthSfnPb2FZQzWrpLkW7fNj5z/IUAZ9wuLiXcP4j/OoiPSpbo5upc/3z/OosEcdaAFOP7tN6GjHag5oAOtKvXmk7UZoA73wKUjt2eULtHbPJr6G+EklqIJJIcLuGCpr56+Hu6eCWGG2Rn5y7tjFe1fCqYWt+ImAZc4Zs8CgCz8WdRS0ie3A2ySch2H8q4Pw1qENhbOvlG6u5OjA4C13vx9sAbeO6QFsrxxXgug6lLDK6tIQ2cUAenR6zKkwCpGGzlmxnFdboOuxnWrGaaYoVYfMo/nXmtoCxDq4YkcgnrXR2UjWOmyziNWk7Z7UAej/ALVEAvfCGnXsbb0U4JX3FfL9ltMMZbO3pkV9T3K/8Jp8ErhAu+7thux9K+WoB5TPG4wyNjA6UAWwzK54AHannIOTjmo8kpnqTT0ztBReO4NAAvLkdFHemuSOVOaVzubk4HoKZgA5wc0AOUMpFEhL8npRhiMinSEYUKM+tADThEUZ608scgBSc0mTuAUKV9T1FPZiPu9aAGSDHXKn0p4VkKmTGO3NNyWJJ+9TVAGW+Zj6GgB7Ehic1H52cjaRjvinsx4IHHpSr1IYYJ9aAIrkysA0bKF9TQGwoLSZ+lKWXHlgHOe9PRFjPIB9qAJE2lPlT8Sak3EphmxjstRIVAOQTmlwWHTGPSgAUhSdwH0pHGQOynt2pQNrFivPqaRwSoLcqD0oA9f/AGW9W+w+MLvS2OI7mIgAnuORXHfEl7rQfiLrcNrKY1EzFShx15pvwlvDZfEvSpIyQrSBfz4rb/ag0/8Aszxt9qA2pcoHz69qANL4ReN7jUG/s3U3aZWOEZjkg16reQbVZBEA4Gcg9a+WvAepjSdWiuc70DA19L6Rq8eu2okhkG7HIHWgCOHM6FTj5f4RwarXETqjEhT6Z7VoSxxKwaNTlfvYqKVUlhfyshu26gDzrxda7XWQA7zznsKw9Lmd5GSP5nHXtXoWuWRuLDG0Fl6ivMkmfTtXZVUENxQA/wAYPBLpoLcOvBFeK63GqXeUJwfWvXdYuI5oZlC7nHPNeTa85e4+YDg0AZnU0hPPoaD2FL05oAO/XrSYwaQHB44pc5HTmgBwwQcCmjGelGTjANIMetAAT9a1tJx9nbg/f/oKySfTpWvpGfszf75/kKAM26/4+Zf98/zphzgVNdc3E3rvP86gB5oAcz5AGAPcU05A5oPtSZBoAB9M0DntR/KlHHI6UAdR4Hlg/tBluXl2EYwpwK9z+GV1FBqhgWDzN5+QZzivnfw9cG31KJvL35PQ9K9q8MX81lrdtdLAlup/unNAHtfj7Tn1Xw9JD5Y81Fz05FfIfiCzOn6q6FSDu69K+utL8Vxy3BtL6JpoZhgOB61418bfCsVpcNc2YIR/mAPagDkPDF59pt9nDMnTJ5rrFui1qFmIA6YryjQrx7S+VsgYODXpUZFxZedEQysOo7UAerfArWRBqtzoty6tb3akLnpmvHfi34al8KeOLy3YEQSMWjYjgqea1NF1CSxuYL62lInt3DV7V8RtDt/il8O4Na0xFfVLWMkqOpx1X+tAHyxCGJIJ/GrIBCHFUkEkFy8N1uSZDjBFWt4IGxs56igBJBjaUP1NR7iCwzketWF2gHcCR6VXdRn5CdvpQAoZvLyBge9KM8EjBpEAc9xj1pWjGC2Tx3oAfGAASBk0rtkAHl/ambTtHr6Uq7icYA+lADiCV7D1o+dVwMYNKUIUFgSPWjEeQSTn0FADHKkY3kEe1NjDOMgF/c06XGGBXNEQJQBsKKAHIqj5nB3e1DLkZIx9aXnBwc1EhB5bdn0oAeF+YAHI71KQU4AwKFXZjoc9u9SOq4AYkD0oAjUEkBTz70kqsF55zT+M/IM0jAllVeB3oA2fACufH+kIgJfzlwo+tex/tWaYtxHp9y6AssZWvMvglYnU/inpyrlo4ZAxPpivdPjxZRalGFXDzRJgLmgD5O0mFY7qJIzks2Melex+H7ibSNQt1DGMEAkDvXJeGfBD3OoiSSQqA+Sg6ivRvGGmixexMaYG0AN3NAHYwT/bIDOHUR9Co60Kuf3bjhuVrk/CWomO9ls5mADjIBrrrZXaJgSrMD8poAq3UBkiKBQNvUdzXlvjOw8q/WSJNqk8ivU7qdocq8bKw5Y+tct4qS3vrH7VGCNnBBoA8x1OMMoVF2lhz715f4ltDBdtkYz717Dc263Cj5hz0zXm/jW0aKZg6YYdDQBxpPFIDninMe3BpueaAHAcdKQntigk45PFITQA75ec0g68UAUvHbNACHrjpWtpA/0Zv98/yFZWeeRzWppQJt26ffPf2FAGddf8fM3++f50zt05p9zzPLk8hz/Oo93pmgA7UijcaXknk0DAByKADOAaDQDx04oJ4yFGKAJIJDHKp3NgHtXqmg3UUlhDMHdp0x8hrycZIJHWu98BT3NxbtbRNGqjqWNAHvPh/VLnUNMRYzHM6gYi6Fa6TWfDl1rfhKU3EO2RVyN3OK8g0S6hjSSK4umhKnqnVq9w8KeI3bwzFFJMJLb7uGPzfjQB8heKNMOm3sqlCrBj2rc8A6yhY202Sp4Kmu3+N2jxNdtdWijYwzx0rxTRbt7LVFYEDDc5oA9ZiSJLqZFPynoK9H+DPi5fD93Ja3J/0eU4OTwK80DI8cF1H824cmrL5jbzIANjdcdaAPUPjd8K01WFvEvhNVLON80Sd/cV87qfLmaOZSkq8EGvob4YfECTQQlhqzGXTZTgE8lM/wBKu/Fn4TWniG2Ot+Fdgkcb2ROj/wD16APnMfNyrZFNiw+7pgdKbqEFzpV01pfwtFKp2lSO9JDg56E0AOAAPIyT0NSQKPOCzPiPvimYOMEgCl3qTxnIoAmmRPO/cnMfoetRN8jnaMA9aaMlhk4z3FTA7eMbhQBLHJ+6MY4BquRjIIAIp7PuwGXBHSowx38nce3tQAbGKE5pAiBf3g/KpUXGc8k0qJySBgUARof3e5huA6AUDDfMRsPoKljfDYCjFJKq7twJz6UAIpXg56VYZuAQAQfWoAApGQMHvUoOeAMgdKAGsMfKoBY/pVeZvLR5Tj5eKkY7ASR8x7elXvCHh268Z+JbXSdNVnXdmRuyjuTQB7V+yn4WbN34gukYcbIsjqT1rt/FDnUvHZtoFTyYh+9b14rr5I7TwH4E8m1UBLWLao6bn9fzryLUtYn0nwyL1ZU/tDUJMsw+8ooAmitYofEs7RNtiPAx61Z8U2Yu9JHlsXkiO459KpQTtvs5GO1SMsx/iNbkjo8TM/8AEMD0oA4LVUFgLHUoUwmQrn3rutAv4b0KY2CeYvBFUb2whvtKnsWVeQWVwOAa5bwdftYXMmny/eRvlPegD0W4ty4ZQWbb94EVzetwhLGZZ8CNgdoUd67SKRDFHN1GORWB4pKGFuFZiPlI7UAeP6hbbbdtvykHIrjPGEKXtjujBDoPmxXfaujrE6uGEjdD61zOrRBNPdHTa5HOBzQB4y67Wx0NIOD61NfRhLuVRnhu9Q/WgAPNHAFIfWheDnHFADgQF54NJ9OtBGOQaBk57mgAXBPJxWlpg/cNjP3u30FZma2NIwLZuSPnP8hQBmXf/HxLg/xn+dRAjtmpbkYuJRjHzn+dR9+nFAAfzoOOKCOM4xQOuaAAkdqSlOO3SkHXJ5oAVWI4U4Fa3hu48nUFyCwPbOBWTjJ4FPjdo2DKOQc5oA9o0IA3HzbFVh+Vdalu3kAadeSSSZ+aMZGa838N3oms4mlnjWXgBQK7qPVItIEEkA825OCTjgUAdf4y8JXs/ghL+5XO1eU7ivl/VbP7NeSKMZznp0r688O/EY69pk+kapYxhDGVBXknj0r5q+IWlNZarcZUou47VYc4oA0fCF4LrTDDkl17ZrZZ5o4wET8a4Dw1eC1uV3NwTziu/gulhnRZE3QP3zQBJbTTToxiIG3qprvfhv8AEW58PsbSWQ3FiT88T9V+lcFfMWmD6cBsXqB1qTyYrm2NypWKccHJxmgD3TxV4S8N/ErTftWjSxJeAZOPvZ9CK+dPGPgnWfCl20d3as0Y+645BFbOmXeraLcLeaVJJDMOSVbhvwr0zw98TLXXYRY+L9OEin5WmA6e+KAPnWK4GSso2MKsB93Q8V77rPwa0LxKzXvhzVIo1bkRt/KvMvEPwo8S6G7lbR54R0aI7s/lQBx5yp4AJp6jeepFR3Ol6tZn9/Y3Ce5Q1CJp4s74XH1FAF8qxXaeffNNQAPtPyn1qstz+7zsO73GKdHd5kGVGf8AeoAsgbWOWIPY0qmQkkkbfUVEt2plIJGD2IppuYw5GeB6UAThgG4JU+pqQZc/KwJHr0qpNOpAcD5aZNfKiZLKBQBc3bTyAzevYVFJMqgsCAe/pVK3knvZRDZxyTSOcAIDzXrnw/8AgvqWoFNT8Vf6HpsfzlJG2DHvmgDifBvg/W/Guora6RGyxk/vbhx8qCvrz4Y/D/RvAml+VYbJr51xPckjcx9B6CvEvH/xc0fwppT+HvhmqPc42S3Sp8qf7vqfeua+F/iHxA00jXN7cPPMcs8shOfwNAHr/wAWtTvbm4NrdwlbTP7pUYcn1Nea+I7Kabw/G6JMZYDyFBJAr2nTvBkuqLaX17Kzzdcs2QPoKfaaTb6D4slt52aWC8jOWYcA46UAeX6Lcf2n4Ztn2EeSdrse1dRp8kKw+Ws3mpjO8jpXKeHrpbLxXrmilAIpGby1Ycda09GkSJGjbO9G+ZfSgDeLO8YePau08HGM1wXjWE6dqsOp2/Lk5cqK9AV43PGShHBNYfiS3W706VFCtKBxQBqeEdcGo2mQ67GXDD0NUvEMzoHh2DYeQ9eY6PqVxol62xiMH5kzXdx63BrsCmAgsg+ZGPSgDkfEc5EkD8sUPI9ai8ULY6lp8V5bssUwXDRAUmsx/aLtvKbOOo9KyG2FmjUEv60AeQeJ4hFqTEZGfasjv611PjmJkvAWU5z1xXLAZoAM5oB/CkpQuRwKAFwO7cU0+2ce9GMcEUvXjtQAg681qaUP9HbKk/Of5CszHPFamll/IbA/jP8AIUAULnieUHk7z/Oog3BqS5H+kSnP8Z/nTOvOKAE3cUL0PpS5yeRSGgA6jHelz2pv9aOSKAFzjPrQGNIDz82cUpORnGAKAOq8HmGVgkn3weO1emW0kciKj9UH3tvNeK6Nd/ZL+OTOBnrnpXqthfKTDKkjSgjlgvAoA7TwhqNpBrcYiQQzZxlxnNanxa8EnUbF9ThjkZyMuWGB+Fc3DdKl2l3BbqoHV2Fe8/D7Ux4r8PzWFyEmj27SdvTigD4dntTZ3Gx8ghuorsfDs41GP7O7kOo4JrU+NfhmPw/rs8cIJXdkMRiuM8O3ggmUhsEHrQB20JeHesIIdepPenpNBKuJkPmZ6g4q9HGJbZLsMuCMEVnzxxxTbQdwbv6UAacd8saIjKzbehB/nUN3NNdEuFWMjoU4FUInKbl3fL71Nbl88Nknt2FAFvSdX1GykK20spc91yCK67SNe15Y3e71Se3jxwGJcmuNe6jhXZC+6dupUdK67QvDWs39n5/2O4kixneQaANGy8S6w7gXUlvdW5OMSQA1k+OPHum2AFrFoOnXEpHzSGJRj6DFchf6tf6Zq7xwPtMbcq44/KtHUdX0DxJBD/bdl9jli+9Nbnl/wFAHOS+J4rmYSSaParB3AIXNWY9U8J3UoS48P3oZu9vcZ/8AZavXlz4Rtgi6bpd3ckfxTSEA/hiqdz4muyoi0yzsrNB0PlKzfnQB0emfD/wzrqbrLUL7Tn67bqJiB+PFWZ/hDpECb38SwsO5C4/rXnF/4k16RsTXjgD0XiqkGtag4cTXQP4UAeqJ8LvCCBPP8UOc9VAI/rW/pPgf4W2E6rfalPdEdQ0hx/KvEItSG4G5nbPseKWfVIDLvWfmgD6am1bw1oVkU+HukabcX4GEeYqMH8a8c8e3PxP8XSm21aZzAOltY/LHj3CnmuNtdfFud6Pl/Y4rXtvH9/aurW7yg/7JxQBiWOialoTyyXemTRyDo8kZI/WvR/hFa+U82tayGlgiOfKIxn6VHpvxcvWZU1Gzhu4R1WSMEmvS/B/jbwbryGynRNLkn+XayALn69qAOng+Kmnlore2jMMOMAZ5FWdU1aPV7A3EE224QjY7DpXh3xM8O3fgnXFLv5ljcHfBOvIIrb8I69JLo8pSZcgdHGQaAPQPi7p9npnh7TdYggiF+zqrzoACwIrHt7aJ/stxbNuWZAzk9a4bxV4tv7/TE0y8wbZWyhHOK7LwHfJcaGiPgtB0PtQBtLbqRlnYqDxUFzaoJM+U2GHQHrWi9xm2Z2jVh229KjtrwOoO0NIO3pQB4/4ysI7e7eSNXU56GsPT52tQ1xCzK3pmvV/GlnFcozhRuxk15JK5iuJIlCjnHNAGhp1zJP5srqfM7YqmGBuSxJDE8itLQkt2Do5cOOflqrdeUL9NsTbQ2M5oA5b4h6aEsVljLNuGcsOleZK5QnaccV718U4F/sm2P3cx5wBXg03EregNADc59KQEoetHbvQTkUAISSaUe+aVcdT+lNHWgB27HatbSGb7M2P75/kKxz9a09LOLdv97+goApXGBcS56hj0+tRZ96fdH/SJfTef50wDHTrQAn86B70ozk0nfmgAGMUZ9KCKD+QoAMZozxR9OKMH8aAF6HkZrvfB2pyXMa2UjrGvYEY/WuCHXmrWmXH2W8SQ5IB6A4zQB7b9vi+z/ZGZSqenetrwZrWpaTqkUmjPJE7EAx43Bvwrgbe/S6ghk8oQ465PJrtvBesfYdWhls0Adf42G4UAdH8fLaTU9Kt7ueH/AExl+f5cYr5xt0EMhVz8y19l+MV/4SPwfM7wjzgudwHWvjzxFC9lqhCqRhu9AHb+HrprzTHiDAFOmauyMk1soPEqn061yvhDUBaanEZMGKTg56V3OqWJtZDJD80coypFAGcI0cqOjVHcb4ZVU85/u1NtIjGFPmD2qJgzOOcsfXtQB6v8JPBFte3C6rdxGZB9yNhxn3rvPiV42TwJoLw23lPqdwu2JABtjHqRXEeBfEzeFPDskl85IPMYPQ/SvKvGXiGbxNrEt7cknn5RngCgDDup5ru6lubpt88zFnb61C65Q7R0qaPGC3X1pzR7Ezk7D2xQBWjDBcZLE085C4xjHbvQ2OxxUzhBGp6t/OgCu8QkXJBI9Kha0j/55gfQVcBYnKjC0EgtnOfYUAZrWMUoY7Bgds1WawTH7tQD6EVuNCVG5kIU+lDCPbyD9KAMcWkcYHygt3wKsQW64yUwO3FXPlBGBxR8rOBg0ARQxNuI289qmRdrfeHPXA6U5NoYq4PtU3Kx/ukBoA7bTNeGveFJvDmuSNKYxm0mc5ZD6Z9Kd8LtAvb2/k0qQkSEkI2OMe9cZAG3ZBwR0xXtf7O+qxXepyW1yii6j5Rj1IoA5fx54Zn8ParFp9yVZpRuUjoaveAWEV1NZSo3A6Cur/aCKf8ACR6QwdSwGCueQK5fQH8zxYzWwwqrk0AdbbXAUvCGwmehpwUJKDCcN6dqoi5S0uJLi4KqrNgCtXfE5XDrlhkAUAUb+NZ45YmQtKR9/PSvGvE8X2a8YgfKDyK90EaySqw5K8EV5r8UrALN5iAKCOw4oA5zSHXyS5OwEdajhkVNQhDHcGcc561R8PGS5WSBmGR0HrV4xPbahAXT7rDigDpviuDJbWcQRdvlAjivm3U08u+mXGMN0r6C8UagNSvIsEsqpgg9q8L8VxLFrEwVSATnmgDIJz0pCTjtS+gpM4NAB+dBI7UucnsKTvmgAOPxrW0oobdsjnd/QVk1paYf3Df7x/kKAKVyB9pl4/jP86ixipZyftE2f75/nUY54xQALxyQaU4pD0o96ADGDzQATxRn1FIRz7UAHTrQPrRxt96Oo60AH1NKvXOelNxS4oA7XRbu3eyQTMxcdAK9E8ManMsPlxpGI8ckjmvOfCy2f9mPvfM3YYruPBsohu4pc5CnJDdKAPafA93BqGn3FqjyoAOQ/f6V88/FKw+y63cKc/KxwpHNfQekTpJfLexIqKRjCjFeS/GuylGpyXMqbfM5BNAHlWmykx7lOdh79RXrPh2Y6ro6LuO+Md/SvJLHIZkAHP513vga9kt5jb7sA/w+tAGnOZY7llT5kHU4q5o1/Zi5EN1AHDH7x7VS1yUxXZwCmeorO05vtF8FjBJB60AdN8QZ4gsFtayb4AM7c9K4xSgbBXNa2tWsc84BmIlHrWY2l3ULeYwBT1FAAVyh2Ag+1OdZHjVcbsVGJTk7mIPtTvMwMu2fQrQA2aPaAWKr7U3jspdf5U9ArvvlJ2joKbK6s37snHp6UAI3A2gYP86RgeARj6U0HDdSD60NKxcKFGO9AE6yuU2swKAdO9QjI3AjcppUfDNkcCowdysTmgBShGB0FOXdnjHHpTI3GdqnA75p4yM5IGfSgBqsRISRke9XIVAU/McHvVMfeIzn3q0ZfKRUKnHrQBLCwKkkZx2FehfBvVIdN8V2rBVRXOGYmvNZ5EWJnLBcdBXaeFrU2Pgy61y4j2uDtiY9zQB1Xx01q01HxpbJAc+WgG4dzWT4cTUk1QSvGyRN0IHauV0Kc3+opc3YMkhb+OvXLW9McAw4RAOuKAI9QYC3LshmKclcVY0u4Elst1HGEJ4KnnFQPk/vkkwj8EHvUkcYhhzF82707UAbNk2fMBwrHkFuhrmfiDay3mi+dFtLRnBUVqw3brhJMEkVLIF/s64V4y0bg5B6/hQB4FpMjWmq5xyT09K3Z7jybpH3Fix5GOlZnia2+waqskKsqluprT1BGkgguEXcCOWAoA0Stu2oxTQgzIV+fHavHfiJCq69K0SsqEnrXpETyRkMX2g8cd64T4kRkXMcg+6aAOI70ZpSOB1pM4NAB1pCKUYzQSaAErX0kJ9mbd13n+QrJA71r6Tk2zfLn5z/ACFAGbc/8fEvb5z/ADqLp0qW6wLqbk/fP86iHWgBewFBFJnPal7UAJ3pcZoNNHvQApGKOppT6gfnR9etACHkUowDyKQ8+1Ke3egDrPCM0X2aeNkLHsBXoHgWWJdQiSYbo933DXnXhO7xLJEsZO5eSK7TwzKyamhRWYocgCgD322KO4a2gK7BwMcV5b8aLp7u3DFCsijHNd7Z6xqc1pvuLdYRjCkDGRXnXxJna4t9j5Ln1oA8ftXJdCqYI4JrodLuTa6jFNkkE9KzrW2WEusjAuTwKky67QT8wPFAHq5s7PU4UluC4Zv7tdJDp+g+H9FaaBA1xIv35cEj6V5voOqssKRFznpir+u3YFuoyzkj7rdqAMXUpTNeO6vwTwKh82fySrSErnoO1Qby0mQKSSQ7sqMY60APAGQQeO+aQMilsqSe1MD8cDg9c9qBwOvWgB4LP95hj09KVcZ2gZqJgFIYkkelKXB+YcUASfwnGB7Gm7VAGzO49c0xSwOVYEHqDSlvmwOaAFJGQM896cq84K4WqxYFj6ilVlPc7qAJNoBIHFLjdgBgRTAwz0JpVXDZ/wAigCVItrEq3A60O6JlycY9agmufKQlgCKpIlzq9xHDbRMyk8hRQBveFNHk8RasglO22Q5Y9sV0/jjWY5xDpGnDbYWw24Hc+tTOsHhPw6IVdDfTLgqOqiuOjfzC28ku3JJoAt6PdiDUYg+doPAFepebHJbI8bkcfMpryrQol/tIF+oPAr0RbhUZcDBxQBuJOWsvkUFB/CetSQ3EdxFhHKyjqpPSs15Fkt/MVsMvpVQzqrrKE3serUAdFbS+UcqysehJrUyzqgb5g3XFc3bOp+b5eefmrStpiTuPA/2TwaAOR+KumIIVuYQSF67axvDuoRyaDIksYc9BntXo3iC2TUtEuLZVG7aWFeVeE7cSXVzYzSiLGcMaAJECC4CT8xNyGXtXK+O7eJ1YbSQOhFdobZre7Mb4dc4z61Q1ew3rMVRTHt6dSKAPD26+goGM9as6ioiu5UA4DGqv0oADweaKU/nSDpQADrWvpJYWzYx98/yFZPatTSh/ozfe++en0FAGfcnNxKSed5/nUTVJc/8AHzLnj5z/ADpnpQAgPFBNBxQcDpQAflQTnnpQfakoAUdKOPXmgD1NHFACfjTgeMdqbS54oA3fCtxJFelI0DbgeK7XQbl7e4kJGxs9uted6O8iX0RjbaxOK9E0mGWGa2vLqCU2lxI0STkfI7oAWUH1AIOPQ5oA9N0rWXnsUE7ySY6ZPSuY8bTqE3vgg/nV2W7hXaIVOzH8Ncd4tvTLlWGQO3pQBz80aiVWQblb1poci9EcgyO1aFhCJIVcsCPT0qS4slR95xk9xQBe0fYlyJFGQOxq7rVyS4lBUZ42msI3ItV+U7R3Pc0kty1yivuDD0NAEm8KzNzlvSmBjyBlgaifcCGXAHv0p287eOM+lAEgb5cYp4lUoFYFcd/WoAWGMdfal3NnkAn3oAm37pBzwO1OKqDkknNRhgM4I3GkVgo2bjuPegB25Q2cYphyc8nB9KUkjuMVHvIPGMUAKAcE56UKwbJXg9+KY8hBwc49qjEmOc/hQBZDnnbjHcmmSXCxRlixU1Tu71IIzyCfSq9jZz6w+FJVM8k0ARzSS6ndxwx7ghPLCvTtI1K28L6YsUdshndf9Zjmudk0+20q2ijh5mPLMarXl350yRMQSo7mgCW6u5b69eadi7E5GegpVZWIG/DD0qsh5OO1PjYb+BQBcsGC6rGQdvPUV26z5PzPkY6V50WYXSFeBmutgn3RJkEcdRQBvwzeXEyc4boKgE5HyAAY6+lUoLpj8p7dKa9wVl+ZBk+lAHQW8wbG4hl9TV6ynXeyBsD0Fc5bzZUqTtHoBVqF8uvcDuDQB2drPmNcKip0JPU15ZrqHS/GJJH7uQ8Dsa7aO6LKVQBSOQWNcx8QY1mjtrxDudThmHagBodnnfzFJXqAPSrmoRSTWWYFjRCuCV7/AFqrAA0NrOrAI6gFieDV+3jaK5xIAYm/g7GgD5/8RQmHVLgNx856VljmvRfixoyW98Lq3+43UAdK876CgAHPHWkPBpec0E8UAJ1Fa+kswtm+9989PoKyucGtXSS32ZsbvvnofYUAZt1/x8S/75/nUfbpUlx/r5f94/zqPJxg9KAFFB4pDQBQAAf5zRzRgYoyTQAGjH0oIooA7jwR8K/F/jjSZdS8Naal1ZxTGBnNzHHhwASMMwPRhXQ/8M8/Er/oAx/+BsH/AMXXJ+E/iN4s8I6bJYeHNauLC0eUzNFGiEFyACeVPZR+VbR+N/xH7eKrz/v3F/8AE0AasP7P3xLilV10CPIOf+P2D/4uvo34P/DS5j+FOo+GvH2mrE9zfyXCosquyAqgWRHUnawIOD/Q18uj43fEfI/4qq8/79x//E19KfB74oNafBa58UePNWkupY76WFGYL5kxAXbGigDJPP6k8CgDyrxv4O1PwHqz2eou01q+WtL0LhZ0HqP4XHdfxHFeYeJJ2VGk3k7jXf8AjPxpqXjnWm1HVG2RAFbazVsx26eg9WPGW7+wAFebeIXHmFT90dhQBo6I/wDoa7V/M1duXwuSM1j6RMq2oznPbFWLm4JQnJoAzry7LvtAAFWLJiRt4NYrvm4Oc7Sa0rSTyxgAUAabspUqaZvwOp2jtVbzSTnH5UvPOT1oAm87GHBOD6U8vuA5JY1T34IBGPxqUuS4O3aB79aAJxId2CVAFSJIrKxxgj2qoHUkl8Z9Kcjgr8mQvvQBN5xZfYetNMmB8g4NReZltowTTXbAA/SgCYMVUgtkntVCa4wxGCcUlzMdxAO33qorGRsENjNAD4beTUbpVAwM12FrbrptpsH38VlaWFt4C2Bk9DmrAmdjuZic0AQ3N3LdHIJ+TruqGGUSTbgvOOTTNRuQh2j5QevFR2sqhe2P50AaUcm3O08elSpJkc9PbtVGO4OcFFANOMmyJznPHSgCSKZ59TRVxsXrXTCXjhuPQGuR0NwGdycHPQ1sCfI4oA2knCAHnP1qV5twErEg+1YwlCqGJOTUgucHAbPt2oA2IrhnkBDEe1W1upMZzg9iK56G4UvknDVcW9RkK9T9aAOit7tmdSSC3Q07U8XOk3EOB0yAK52G8KDAH41opdPyONrDGfWgCjorefpbW875EbZUZ6V01g5v4Fjc4MYwpzya4zTXW21KdJGUh+gzxW3ZyyJwh2MDnOetAGT8R5QNKdJk3SL07V42xr2fxq1vfWDYJ81R82e9eMSDDEDscUAJjjNB60nHelxg0AAHPJrV0rP2dtrcbz39hWVk4rU0oZt2PH3v6CgDPuf+PiQjgbj/ADphqS5GLmXjo5/nUNACkYo7Zozmg9hQAfhSClyKQcGgAH604nP19aaaUZFAAc0nSloAoABW5ZX882nW9pPNK1tbM7wRFvkjZsbiB6nAyfasPGR1qxZ5ySrYx1oA7GwuXKqA2VrL8QZLnYpOfWnafcKoGW46ZqPV8ysAGB9KAH6PK3l7M8989KmupAsbZJ+vUVmWb7JgjA/UVav2BXCcUAZStiQ5JOTxWpDI52g4A9+9ZRkKtgqpb2NWY5W2gsOf0FAGmX2c9/SnO4C7stnvgVnxyurjuD61M8mfusQO4xQBaQhxleffNKrlgckcVSikVc5J59OlSpIRjbgg0AWM8ggkn1p4mYHAUYqm0rAkMOaBKCuWO0igC5vC5bI5qrc3AjXcSM1WluNzHy+RVYuWyu3j37UASmUyNjnnoatWiZyu1sjvVWNgFCjaSO9XoZMr8u4kdaANCF02BW6D1qSWfCgR/KvrWd5mBnp7Gkec5CswK+3agCTUdsirJu6e3WqQmDuCpIAqaVkdCNw49ayo5m85k4C0AbsMoKjPzL60y7uB5Z7VSt268njv2qKabeeeRQBs6dNHFb4YEsehAq8kpIAzk1lWTqIQByalWYID/WgDSE7Iec496kEwIJz83t0rLErAZPIPTNEU+Mj9KANQTBFyealjlAbcCPbFYjTMx9FpbacDJDE0Ab8N0MlTx71ajvSGUZytc8LkBgSRT3uRvBU4oAv6nJ5d6rYznkVt2N8J1RZGAcehrkb+5Dqh3HNTLcsgQx4PHODQB1Ovxxi0fZscMOSDXkF4uy5kXHQ13El7viZQx5964rUkKXkm7uc0AVKUGj0oOM9KADjNaulFRbtkfxn+QrKOOvStXSt32dtvTef5CgDOuRi4kzx85/nUZ+v5VJc5FxL67j/OmLjvQAh60ZFBFA/WgAHSjjFHWkxQAvbrR1FAJFGce9ABkmj9aUEngUhzQAnUj0qWHO/g49zUYNBNAGzZSskRU7XBPapr1gI13gZPesuzmaORdvStGYrLkhhvx+FAFeOQpKPX1qxeNvjygz6isw5RiScuO1SSsNi7pDuPYUAQkBWwyYzU8cykYyeO3rVZupDDJPRqQHbwDzQBejny2d23/ZNThwR81UBIpwT17mplmXGSSwoAsebhsqBTt4JJwD7VUaQE5OcU3eqvmHJJ60AWZJQy4U9O9NlcsAdwHvVRiC+M7fX2p0rcARsCp6mgBzOdp2H6kUu0tGuDuPp6VCJMYVU59atRrkhlxjvg0ASxq38QBHqO1Sl9q4BGD6VXVw7EbTtHQ0jbRz1PtQBZD7enPuaRXAzjGaqRzb32nn3pQwQnd8i+nrQBZL/LnANUrrKOHjxzUizR4O0bW7e9NuG8xBgjPcUAIkuDgsxP04pskpLYdeKjjbgjA46GkVgynJwfQ0AacLEKu1j7YqaOfLENjPvVCObauN2TSCZWyxXkd6ANFZCT03c8c0rzFflIwazmnB2lhj0xS/aFOcjJ9aALfn7WAQk565p8kx3AIfwrOErhQwwVB5qQyqRu3YFAF4zlIzvI39hQlxkcnn2rKebdzgkU6ObZkgAZ9OlAF+S4LRsDg0ttdbVAyR61ms+8Hb17iohKyN1oA3DcJz1H9axL5t0xbj86DOzHrUDHJoATt0pOtL06ZpDQAuDitTSg32dsZ++f5CsvJxitbR2xbN/vn+QoAzbjmeX/AHzx+NR9B0p9zkXEo/2z/Oo6AHAZHNNxS5/OkyaAFGcUY54o9qTkUAHQcUoFBHSk6UALQOuRmjJJ5o5oAAfxoBo4pKAJEJAHPFXbe5ydpYc9B3qhnkU4EqQRwfWgCedUUkhsE9qhJwuMVIZA0e0qC3rULc8CgBUwcljimN1zzRmhcZ56UAOB4xyaUOxOM4FN657UZ4waAJ3ffGAvbrTQcjAPNRk9lzQgyevNADzjGGBDUpBBXIAHtTCSSdxzilDHGMUAOJP8PH1oUfOAAc9wO9AUnqOlOWYqcqBj9aAJXLOo2rgjtTdx+6x2+vtTZJ8r9386iGcZPSgCSM7XIzx604bXyV5YetQNzilyMYHFADlYAn19fSnh9sZKjk/xVCccYGfWnhsAjtQAwMOw5pCcEHvRnBOKTqeaAJUYbvmXj2pwfax8o4FQg+lLuAI4+tAErOCc8GmhiAajLDdkDHtStyRjNADvMJXDZ4qRn2qpBDH+VQhs5DCk5H0oAXcScsaPXGdtNJA6Um4/hQBIGz1pmeelNJoxzQAre1JQKMUAL+NJj0pcZ6Uc0AGK09Kx9nbJx8x/kKzFGR0rV0tW+ztg8bj39hQBnXP+vl7/ADn+dR9BmtifTovtMg3SffPcf4U0adD03SdcdR/hQBk9vej61r/2bD5gXdJjHqP8KR9OhDAbpPzH+FAGVx6803vWuumwlc7pPzH+FNOnRBQd0n5j/CgDL3HHWjmtIafF/ef8x/hTlsImIBaT8x/hQBl8UDv6VrNp0KjhpPzH+FH9mw/L80nPuP8ACgDJ/CjPPWtf+zIQ+N0mPqP8KadOiBb5n49x/hQBlZHpQfWtf+zYf70n5j/CmLp0Jyd0nHuP8KAM7JK9KaVwOK1k0yFlyWkz9R/hRHpsJUktJ+Y/woAyO1Ic1qfYIv7z/mP8KlGmQmPcWkz9R/hQBj9KCTWt/ZsIAO6TpnqP8KaunRZHzSdcdR/hQBl8mlAOO9aw02Eg5aTr6j/CnjTIQuQ8v5j/AAoAxqXPPPNaTafEHxuf8x/hUq6bDn70nT1H+FAGSWJFIOvStiLTIWzlpOnqP8KQaZCATuk/Mf4UAY5OT/jTiQQOfwrV/syHbndJ19R/hTRpsOSN0n5j/CgDKzg8UA8e1asunQpjDSfmP8KZ9gi/vP8AmP8ACgDNznilHGc8Vqf2fEdxLPx7j/Cmpp8RPLSfmP8ACgDMJ5pOta/9mw/3pPzH+FRfYIgcbn/Mf4UAZ2B0BBo71p/2fEFJ3SZz6j/CgafESAWf8x/hQBl9OtLkY71qnTYcgbpPzH+FNTToSeWk/Mf4UAZh4FJ2rVfToRj5pPzH+FImnQtnLPx7j/CgDLz7UZIPatddMhOMtJ+Y/wAKjbTog+Nz/mP8KAMyitVtNhB4aT8x/hTRp8XPzP8AmP8ACgDMznFIK1Tp8SkgM/5j/Cnf2bD5ZbdJn6j/AAoAyu1IfTtWn9giP8T/AJj/AApW0+IAHc/PuP8ACgDLBrU0td1ux/2v6CkFhESPmf8AMf4Vq6bp8YhcCSQDf6j0HtQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee demonstrates intermediate signal of the distal patellar tendon with discontinuity of some fibers (arrow) consistent with a partial thickness tear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21345=[""].join("\n");
var outline_f20_54_21345=null;
var title_f20_54_21346="Morgan lens removal";
var content_f20_54_21346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morgan&reg; lens removal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pH should be rechecked to confirm that a neutral pH has been maintained initially at five minutes and again at thirty minutes after the completion of irrigation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: MorTan, Inc. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21346=[""].join("\n");
var outline_f20_54_21346=null;
var title_f20_54_21347="Comminuted Salter-Harris IV distal femoral fracture";
var content_f20_54_21347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Comminuted Salter-Harris IV distal femoral fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 426px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGqAkcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3v4m+PtM+HehW+q6zb31xbz3S2ipZojOHKO+TuZRjCHv6V5p/w1D4O/6A/iT/AL8W/wD8eo/bK/5JppH/AGGY/wD0nnry34G/Cbw1448Cat4h8R6nqtkLG8lhY2skSxrEkMchYho2Ofnbv0A4oA9VX9p3wg3TR/Eh/wC2Nv8A/Hqev7S/hNumi+JD/wBsbf8A+P1w3ws+FPw0+I+mXt5oGq+MIRaTCGWG7ktUkGVyrYWNhtPOOf4TxXgtg5aCJmOSUBJ98UAfXUP7RnhqZwsWheJGJ4H7q2H/ALXrYPxo08KpPhfxJhuR/wAef/yRXydo5xcIPUgV6/LgW0Hb5RigD1A/GzTV6+GPEgx7Wf8A8kU5fjRp7Hjwv4kOf+vP/wCSK8kXaZCcZznJNWICQQAOT+lAHrEXxgtJTiPwr4kJ+tl/8kVTufjnpNtK0c/hrxIrr1GLQ/8AtxXH6YACWB59q4fxE2dSuWwPvUAexD4+aIQf+Kd8Sf8AfFr/APH6sw/G/S5lLReGfEjAcdLT/wCSK8AhwpPPX0rp9BQPb8jrkE0Aesj426aZfL/4RjxLv9MWn/yRV6L4rxSjKeEvEhH+9Zf/ACTXi8sLJOCSeuBXZaaw+zrkYOOCO9AHat8WIVOD4S8S5+tl/wDJNM/4W7bZx/winiTP1sv/AJJrirhiMgZzVcjlSfqKAO+Pxctwcf8ACJ+Jc/Wy/wDkmlHxatz08J+JPzsv/kmvPUPl8DJJYsTnpUzMOMdKAO9/4WzB/wBCl4l/Oy/+SaB8WYSMjwl4kx9bL/5Jrgt7bsckZ4zUgdSpHbHegDuf+Fsw/wDQpeJPzsv/AJJoPxZgAJPhPxJgf7Vl/wDJNcKXIUAD8qHbdx68GgDqbr456TaSbLjw14kRh222h/lcVWb9oHQF6+H/ABIP+AWv/wAfryDxcpW6Bz1Fcncuvyknn0oA+hz+0P4dHXQPEn/fu1/+P00/tFeGwf8AkA+JP+/dt/8AH6+bpGAHsarTSgbuf6UAfTB/aO8MjroXiT/v1bf/AB+o2/aT8LL10TxJ/wB+rb/4/XzBNIADj+dZ8knz84x2oA+rG/aY8Jr10XxJ/wB+bf8A+P00/tN+EP8AoDeJP+/Nv/8AHq+SZnwSKhLDH0oA+u/+GnPCH/QG8Sf9+bf/AOPUf8NOeEP+gN4k/wC/Fv8A/Hq+Q8nb1wR39aUH1PagD67/AOGnPCH/AEBvEn/fm3/+PUf8NOeEP+gN4k/782//AMer5D3HBoDUAfXn/DTnhD/oDeJP+/Fv/wDHqX/hpzwh/wBAbxJ/35t//j1fIW4HuCKchAOaAP0C0bx9perfDabxtb298mlxW1zdNDIiCfbAXDjAYrk+W2Pm9ORXmX/DUngz/oEeJf8AwHg/+PUvw+5/ZA1E/wDUI1j/ANGXNeAfATwFpnxE8a3ej61c31vbQ6fJdq1m6K5ZZIlAJZWGMOe3pQB79/w1J4L/AOgR4k/8B4P/AI9Qf2pPBg66R4k/78Qf/Hq808OfD34Za5d6NFEfH9rb6xcy2lldXElj5cksf31IQM6/UqBXmnxd8L2Xgz4jaz4f0ya5ns7Mw+W90ytId8MchyVVR1c9umKAPpf/AIaj8Gcf8SjxLz/0wg/+PUf8NR+DP+gR4k/78Qf/AB6vjft9acPbFAH2N/w1H4Mzj+yPEmf+uFv/APHqX/hqLwb/ANAjxJ/34t//AI9Xxz9eP60rEY5JoA+xP+GovBmcf2R4k/78W/8A8epR+1D4OPTSPEn/AH4t/wD49Xx0Ac+lSJweKAPsVf2nPCDfd0bxIf8Atjb/APx6nf8ADTHhP/oC+Jf+/Nv/APHq+RYid3Y/SrUeS/HFAH1oP2kvCxxjQ/EvP/TG2/8Aj9PX9o3wy3TQvEn/AH6tv/j9fK8XT+lXYzzjOAKAPqKH9oPQJjiPw94lY/8AXO1/+P1qQfGSyuIvMh8LeJGT1/0Mf+3FfN/h23LqXO7OQOvGK9Ps4hDpmMEMwHXigD0A/GWxD7T4W8Shv+3P/wCSKD8ZbEDJ8LeJcf8Abn/8kV5bc7iu5CPU+oqVW3KAM5x1HQ0AelN8atOXr4Y8SflZ/wDyRTT8bdMAyfDHiXH0tP8A5Iryq7UHBzwev/1qqggMuASO/tQB6/8A8Ls03IH/AAjHiTn2s/8A5Ip4+NFgTgeFvEp/Cz/+SK8lRiXXGCR1Panozbs7uT1HagD1ofGSyIyPC3iQ/wDgH/8AJFVNT+OukaZF5t94a8SRJ67bRv5XBrz9GCMFXrgE56Vx/wATX/0HHOcjj1oA9Zb9pjwmv3tF8SD/ALY2/wD8fqM/tPeDx/zBvEn/AH4t/wD49XylOeSCcnt9aouQTxQB9d/8NPeD/wDoDeJf+/Fv/wDHqP8Ahp7wf/0B/En/AH4t/wD49XyERkcHBo59KAPr3/hp/wAH/wDQH8Sf9+Lf/wCPUf8ADT/g/wD6A/iT/vxb/wDx6vkLnntTVbsaAPr8ftPeDz00fxJ/34t//j1L/wANO+EP+gN4k/78W/8A8er5C4A4pOvSgD6+/wCGnfCH/QG8S/8Afi3/APj1J/w094P/AOgN4l/78W//AMer5FBAHH5UwnB/+tQB9e/8NO+EP+gN4l/78W//AMepf+GnfCH/AEBvEn/fi3/+PV8ghs9TT6AP0S8CeKbLxp4Vstf0uG5hs7syBI7lVWQbJGjOQrMOqHoTxiiuO/Zk/wCSJeHv9+7/APSqaigDlf2zP+SZaRnp/bMf/pPPXHfA3QdZ8Ufs7eKdD8OXFpa3d/rDwSTXLMFWEw2/mY2qSSVyMe55Fdh+2b/yTHSf+wzH/wCk89fGxVS2Sqn6igD7v8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXxTpufs8I7bF/lWbDHETgxJ/3yK1bTZwo4AGKAN/RctdxEjksM/nXskpAs4CxGSgwa8c0JQb6AY53Dr9a9muFXyIFB4Kj6CgCmAeSOfpVqDnaOcfkKgKENgYHqasW+ScM3fH0oA29LCkkc7cE5rhPEIH9q3I6fMcV3+m43fL0CmvPfEag6lcNkkbjQBno2GIHK9D/jXVeGlBs+Pug9K5SNf3ZbBHoRXZeGR5li27gnJwKAFu4xIDIF5HfHIxXQaRJ/oqkt0XvWXLGGXDcA+lXNJfYgjOeOmaALF1yS2eKhLfLn9D3qW66AsOv6VUOG4J4oAcxzjkDvk0qsWIGBxyD0FI3yrwOcdzUSMecKBzyT0oAlBIIJP61IpxGWYDJ4AzURIwAAMjuOaQE5Axxj8jQBMPmDbfTH4UDGOOpqJTtLAkdOeKVXyvBx7ZoA5HxpEQInyMc9K4e4xkHH616H4tTzbJ2xwB27V5xPySAenFAFaVsjiq8vAPGfapZAy8FgDVaU/NgnFAFSY4OKpSnB4X9auzgdR+dUHOdzdRQBFITgEGq5PI4qRyRxUJGc460AOzz7elIDntQopei+lAAc0LySKKB1GOtAC45xjmgDB6YpM8c0o46daAPrj4e/8mfaj/2CNX/9Dua8w/Y3GPipqXGP+JNN/wCj4K9P+Hv/ACZ/qP8A2CNX/wDRlzXxw4Vj84BHuKAPsDwb8GNe0eTw4sqeH7CfTNVbULjV7CaRru7iLE/ZyDCnyEEA5dhx07V4d+0x/wAlx8UdOtt/6Sw15aI17ov5VIigcKAtAAhAYc0uQKQL8uTzS8dQKAAcnFOOcdeKYcZGelL17mgBy1JERu5NQknA/lUsQyRkZoAvxDJ+nrVtAM59BjFVbfJ7H05q2hXPI56YoAs2/UegNaEI3Yxn86zoTjpWtpKebdwx9mYA5oA73w9aAQwgHDEjoa7e5k/0eKM5Jxz7Vz2lRgTRK3AQDANbUzksQmNvSgCldkhjs2jI7VFBLlFVsYz+NPvXypC4yKzvNaOeIjAB7E9qAJrrcJFAOR9OlRMxXaxP8OOKmaUCUscbugqnPKnm7QenXvQBOrYQBeBin2zEk7RkjgiofMXYWGMY6npUtlnrxkt2NAF+IFmHzBfpzXGfE5ykKITkg88YrtY+JVBAFcJ8TM5UE5JOOaAPM7lvkPcjpVNj83IyatzjIqmeSRnpQADjoKMHvSr0PJpCaAEfoOv1oQDuPajse9NGc4HQ0APPSjJJxSKopXH5elAArgnpwKXOeKRR7UpNAAo4yM05eRx19abnpjjvTkyTnNAH3D+zL/yRLw9/v3f/AKVzUUfsy/8AJEvD3+/d/wDpXNRQByv7ZnPwy0j/ALDMf/pPPXxwB68V9j/tmZ/4VnpGP+gzF/6Tz18dIOfSgCaD73b6mtG3J6HGPWs6Pjuc1o2oJGSBnH5UAdBoI/02H5ifmH869qmwLaEgcY4FeLaAn+mw5/vDH517ZMv7uJMDG3NAFGMlWJ9atQoDJkccYxTAu3aWGOe3TNWIF3A54yaANfTM5x1ypOK4DXUJ1C4bbn5jXommphDh8jaa871s/wDEwnyT94+1AGXHlVYA5HYda7fwoqraAnIz09q4aNiX2nuc/jXoHhdQLNcjPXFAEk0ZBJ5OT3pYm2SLnlTkcjvVm5BxlT9apSbTjk5z60AaUvzqM4KjrVWSMDlTj0qS3dpIsE8jj0NRy7ifp60AIceWQxB+YY96jVThjjvTgnDZPB5pu0BiuMg8igBTnbngDuKfknPHyAZ+tMTJI3AelLtxuyeM/SgByuN2cf40xskEnGR1xSL95hkDHvSZAJJOQPU0AZ3iFBLpzD2xXllxlWIyO4NesX+GtWRQOma8q1Ndl3KDwVPNAGfMSSABwPWqkhyxzz61anOS3PBNVJTgHHWgCrPw3P1qlIBuP1zVuTuaqOQF46+lAFZz8xJpuRSu2TmmE8DtQA456/jSA8ZNBORQuCAPagBwwRnNIwIzQcevANITnHagBRyB6U5eOaamcfN+dSL7jPtQB9bfD7/kz/Ucf9AjV/8A0Zc18btX2R8Pv+TP9R7f8SjWP/RlzXxuwJ6HNACqcde9Gcjijpzjmg8dOhoAdjI46UDgDrg80iZNL7jrQA0jd+FOA2jNAAyetB5NACHBIqaHr1qEDjNTwnGBQBeiBRhnGOtWuCcnFV4SD9e3PFWMZxnkdhQBZhX5eK6fwjbCfVUJU7Yhu4PU1y0PRQSeDyR613vgmMi2ubg8cYGB1xQB1VpIUdudo69a0I5A+Cc8+9Y9gJArO2B8uVB960LfBY5PPr/SgB8+GyF+XnvWLdF0fcFy+euO9bc6ERtkcH07VjXK5bAyACME96AJIpTIoJHNRSAphv733qWykwMHOefpSTITnb94dOKAJoiCgHB28H1q5BtQcAdcgZrNgyW3ckZ57fWrsT7QM5zQBpWmTIByRjP0rz74nOTdDPQtxiu/tyfMTJA7nvn3Nec/EnP2zaTkAk9aAOAmPBA69qp/NyferEo4qr3oAeDgc9aT+H60gwB0zQMHjr7UAJ0B7UmM55xxT8c8nA9KaOueBQAoOKkxkZPemdDnBAp2cjGcUADMQvAzTM+tPKjtzSAZ5XtQAjH6fjTlPGaNv5mk2lSf5UAfcn7Mv/JEvD3+/d/+lU1FJ+zJ/wAkR8Pf713/AOlU1FAHLftl/wDJM9I/7DMf/pPPXx0renPuK+xf2zBn4Z6R/wBhmP8A9J56+Ol46cH09aAJY+uTkelaNrjPBGazo2zntV+2IyMc98UAdNoOTf2+P76/zr26dc29uVJGUFeI+Hf+P+2xjl1/nXuE6jyYMHGExigCqB8wz0zVmN8sMDgfrUIHyndk46GpLUHAyrdaAN/TdpVwCPukAY6CvM9aAGozgZI3ngdq9N0sApJnpt7V5jrCsNRuGXOCxx24oAz42Akwp/SvQPDIYWIGOSO1edxlt5yQT6jp+Feh+G9y2CAdCKANGTawYfdB6g9qzWwrjcAfr1rQcDn1Pb0qjdqfp9etADYJDuALbgRtxVqbHynd1rMU7GzuOPU1e3bkXjBFADgflwfzIpof5jjoB1706XoctnPIphAzk4LdNpoAVXI27iB35pGO/n72ajLMHw44zQXJAKr/AA5J6UAOJIcgjjpxULyDBUHPPcUMdxAH1JqEtg4Hb9RQAXDBomzxjvmvNPEMe3UH6kMck16JNw3AzXF+LotkqsOvOTQByUzKRjkVWm/iI6VYkABw3Sq8oJOSfagClKcA+9VJT83A5NW51OPb3qs/Q4GeetAFU96aRkAEGnyDA445pv559aAFPTpxQn0oJyMHpQPagA4Leh9qByetLxwcH8aTPr0oAaTgepqRTxnHWmY+bkU8HtjNAH1t8Pv+TP8AUf8AsEav/wCjLmvjkdTX2N8Pf+TP9R/7BGr/APoy5r45YYY+lABz2waKT+KlTgc9KAAHHtQRke1Gc9KOhFACj7uQfwpR1+tIevNAHHvQA5cdO1Sxjk44BqJRxU8OMZzzQBcgABGePf0q31IIz6c1BEoIFWsYHzE0ASxfX9K9J8PRm20RScZf5ua88tVDuiDnOK9JVDHaxRJ1VQOevSgCe1mLxYzhQxBBPWtKM7VDBRge/Ss6xD7SvBxwc9K00GFGBgZxk96AHuNyDHoec9axbjIuDu5HX6Vsz5VFK9sg4NYt+MEkEk46GgCKNw3BJBBOMVMDjl2yV6ZqhASeGHfqO9Tg5RgPmz0z1oAuxj94q8lWFWWZQwGOlUVydnXjgirO9NwIPv8AQUAaFkzDO8gelcB4/wAG+bPPvXdWxGU25POK4D4hsBfttbB6cUAcHOMDaOoqqRzVu55Y89Kq4zn+dACdutOOAcikwpz2GaU49aAAgkU2lDZFJjPJOKAHDp0pSOT3FIAQOKUdeoIoABx2OKXjOKCcjgcUh4HHWgBx6/Q0oOT0ppo5Htx1oA+4v2Zf+SJeHv8Afu//AErmoo/Zl/5Il4e/37v/ANK5qKAOV/bM/wCSZaR3/wCJzF/6Tz18cg4b27V9jftljPwz0gf9RmL/ANJ56+OB70ATxsuRx+FXrU4OOnP51QjXJz74rQt1G8A/WgDp/DvGpW4PaRf517jc5EEWCSCteHeGj/xNbcHrvXn8a9zmUiGPjjYMUAUR8vyj6g+lTwvjJGcdTmoCOcKRtByTnpVm3B3cHJxww6UAdBpO5oZWUDOzjPp3rzHWv+P6fjqx5HavT9PAjguGYbV2ctXluqPuu5SP9WWP40AZy8sTwPpXoWhcaXF0HGM154UJkABxx2r0nRk8vT4M9CAaALIJz0Hr+PrVacE4z9M1d2DPPNVplGWyOMYoAyL35SrdRnJGasW83mR7VG3v160y9jGwjv2x3qpYviZcZJJ4JoA1mY7RjHHv1qHPIIJNTzIMAHJ71GmOeBjtQA3g8knJODTd3bPHc0rgYJxwRTF+6OCAaAEdtpx26dKqSnDNjGD61ZkO1QcZ9+1VpdpAITn1oAg8xlOMHkYAzWB4oQTW27+IdTW1KQrH1Hvmsu+QyWrgk8ZIoA8/mwpIPT1FU5Gw33vzFX7pCjsD+RqhJj0z60AVZzwScke9VJD8oyvHark54PvVJ+g9KAIHPXvTTyeOKGYZ9vU00npyM0ABJ4XrS5Pek2tkdMfzoJ5I7CgBce3NKD370gY8YpWHfkmgA9Oopy53Y5P40zBBOe3vUinGDjmgD61+Hv8AyZ/qP/YI1f8A9GXNfHLcV9jfD3/kz7Uf+wRq/wD6Mua+Om5FADM+tO7UmOPbpS/SgBATnBpfp2pRjjjg96Q57igA5JyTSxjPGcUAdfSjp0NADxgHBJ/KrMHP061Vz83SrVvyB39qAL8Z5Xnt6VYjCk4bGP1qvEhGPSrGcden0oA2fDVv5+rRjHyg7yB2xXfb/McnAUbtorl/BsKiOaU/eI2qTXVRAdFQk54A6UAXbR8vjHXjp3q+q5XLfKo7HuaradYuZZJpTsXj5V7VeRdrMByOnzUAVbkCNSHwABmsW8AkILkbjyOa370HL4QAkd65nVeHCggGgCvDEAQVAIPOd1W1X5mwvFV4xtkBxlfTPFTBzwEIyeTQBOrHKk5BFWFTCscAt/P8KpqwkmLKg6VbVgw42g4OcUAW7AMyKx6buc1wfxCRRqDEZz2HavQbJcKuCo4BArz74iHGpHIxxQBwE4+Zv5VACB1qxMMuxAqt1xlhxQA8n5eBg0HlecZxSL1x1FKcCgBCBye1IByCOlOYknnmmgHpQA6lUYoIIHrTQ3NADz0xSf4Yo7UEg9QKAEI9KeOgFIeRk4BpR1FAH3D+zL/yRLw9/v3f/pVNRR+zN/yRPw9/v3f/AKVzUUAcr+2V/wAkz0j/ALDMf/pPPXx10J9q+xf2y/8Akmekf9hmL/0nnr45AORQBYTAHAIbvzV63OWBz+NZqMc/zrQt+cGgDqvDIH9p23f51/HmvcrtQFhIJUhRXh/hQf8AEztgMk71/nXuF6cbAOgUUAUgoYndgEdgP5VZtgQcdPXvUD55bPPb2qWzJDbz82Mk5oA3bRDIjD/lmiFyO7HtXmOof8fMgbP3jxjvXqliM2dwx6bMZz2ryfUWLTFsnG4n8c0AUUw0o3DjOK9LtGK2cIUdFFed2sTTXSIoJJYcelenWMKpEFdcuBycUARRSSO3A4Pt0p80bFOMY75NSNJ5RIUAA81C+4kMxyD2oAzdQKIpAO5h/KsyOQB1J4HpWrqanoBwenGM1khNsn1oA22w8A4+9zx3+lRkEsAcii2G9RyCAMZ9KlKnGQefegCuwwAQASOM5prcr3A7ZNSyAFvlxj+lRYJLBuKAEkwFycDnp61UmVugIx1qy+Nu04ODnNVZ2UEKxGTyAKAKUzYx71UujtUgn5W6CrcuWIYDGOlVLoEqo4x6CgDidZQLcvgcH1HWsWYdOPzrpvESAEOPWuclBYfLwKAKEwG7pn61VkGQSD14FXJhjcCeaqy/pmgCqRkHioTg8YqaTGTgkH6VESRQA7GBSYA6Cm9R15p2eAO9ACDqaXtTcjOKdntQAn8/SnL2pMU4jAFAH1t8Pf8Akz/Uf+wRq/8A6Mua+NyfQH69q+yPh7/yZ9qP/YI1f/0Zc18ckdxxQAmeAO1H8JxRz6AmgdKAFHQUrc49aQAnpxSYOe/pQApb5fpTgBnIHamKMnmney0AS4APH4e9W4AB2P4VSiOAeOa0LcEkZ4570AW4hxgcdualGdwUNk00bsDgY7Vb05S93GDyetAHeeFbcrZDIGFXJ966SyxvU4CAjj3NZnhuIlXBGFK8mtiZiGTK52jIAFAF62GGL53HGMds+tSCMlGHPTP603TF3KV6DHerkyqNpwBgYBxQBmXvJJAA461zuouCxGMkcDiukvSoDEty1czdJmSQkkgHjIoAhjKnblR07etPwBgbRnvxzTI/lkVRww65qVJRlv7p5BPegBsTYBbcRzyfpV1ME/dG7rxVFVZTnDZPXHvWhCdj47dBmgC5bOVReMAj0rz/AOI+RfqTyxGT9K7+EnA7gAkA88VwvxFAa4ibplTQB55IxZjyD9KgLAHpVmYYYnGSetV+/TFAAp64xn1FBz3796VetHegBWGQRnmmjj+lKeei9O9L3xu5oAORximgHcTTlpevTFACZ64oPGKXvg9aG6AUAAORzSj2/WkAAGKXnHHNAH3F+zL/AMkS8Pf793/6VzUUfsyf8kR8Pf713/6VTUUAcr+2X/yTPSP+wzF/6Tz18ddDgV9jftkjPw10ceutRf8AoievjjkNj3oAlXO75cA1dtiTgjOfWqUZXGc8/Sr8Jw3y+1AHV+Ev+QlackfvB0r3K7JHlbgM7BmvD/B5H9q2u0/NvHNe43+MxZI4UE0AUHI4IOOcZNWLfc2duAMVXk+6vp1qS2OX2Agc55FAHS2RJ0y6OOic4rya8ysj5Py5NesWrKuj3I7lCcivK3jea7KYB3N27D3oA0/DFmN/nsqkds/zrsYpWCll55yaw7JRCqpGMBRggVsQcRBdwHr7CgCV2JBznHp6imdV6hT0APYU5gHAUYyMYPt60j8DjrntQBn3wywJO72FZmCC3RvT3rSvcAgNgkmqRVmfOBx3oAs2m9Yx69CCeKuo/mITxwOtUbdWELdMe9WoCclc/nQAjrtPOcVCxAxngd6sTf6wkdD6dqryqQp4AJ7UAQSquc4/+tVeVck5xyPyqy42g55I7CqlwOMMCeenagCnL1ZSckniqtxxntgY+lWZwAVJz071Uul3Drk4zzQBi6tEZYCCAc9K46UMCRjkcV213kgAcHsK5PVI9k7Ed/SgDKkGMnIzVSYk9RnPcVeZQT0wKqTKQQT39KAM+XPrUIBPbnrVqReT2Paq7LnjIz7UAIDyKXv0ppHPtUgx680AJgDJ70hPtS/hS9DQA3OadtBIxz9aQDg4FOUYGTxQB9bfD3j9j/Uf+wRq/wD6Mua+Ojg96+xfh9/yZ/qP/YI1f/0Zc18dYHANACYOTxRTh97Hakz8+DQA5efw96TPJGOKTGePxpcZOaADoaASD9aB93nknnNA5oAljBOR2rQt1xzxz+OKpwAHNaUCAqPQUATD7vNa/h9A9wXI4HA4rJwT+mDXWeGLIvLGpHyAbm59KAO60mDyLCMsMNIoOB/WrL7246nnpRaZe33MAVHOfapbbc7Lz8p/WgDS0rHlj5dxPPPBH1q1OMpyB8pyKjsPkfHPsamuSfMkU4+vYCgDHvyxb5k2455rDvYxuHAAJ5OeK3r9cuGwSfUms6aLdkNxtNAGR5S7nDA/UHOaFXaXL+n0q+kIkG5VXp2pkkexGLDIHH/16AKa7FKjgnvz1rRWNWUBedp/pVQQbn3AEkcVpwRfIm4kk+n9aAHCEHknjBGR2FcV8Q4sQWr465zXowhPkZxx61xPj+1zpkTjs+OeKAPJrgbZORVcrya0r23aMgkfe6Gs5hhsUAIoOQT+lLikzg0buaAFOccU0Hb2px5700EHP5UAOPC0ikg5pR644NBOKAHE57U3J6E9aP4c0bSTz1oAcFAPU0qjnOTim8d859aASPr7UAfcX7Mv/JEvD3+/d/8ApXNRR+zN/wAkT8P/AO/d/wDpXNRQByv7ZfHwz0jH/QZj/wDSeevjjJ/Ovsf9sz/kmekf9hmP/wBJ56+OQMDk80ASRdatwA9c4qnGRznpVyFugPSgDsPBhP8Aa1r/AL4r3HUWG9d2ANo/lXhngrjVbU5/5aD+de2X7AMN390Y96AK7FcgM3B6Y5qxE2GKsuMdcVn7/mwwOAfpirlqxd8ZCqT0bqaAOjtpEXRbznqnFcJpsOInmYDcxPWvQrC1Emi3WM7dvOO1ca6KJNoO3HIHrQBJZnEQJXg8delbMEfK55zWNA4Chc9O1a1rKxZRuyCKAJcDPJwCR07UvyuRu3cnPNIylegzUch+YD1xmgDP1MhZCMgYNV48SFfm59KfffM5DH5c/nTEUDnAz37UAaEKjy9wK80zIVtwGO2KSByQwIGPTFP2dzwSOmMZoAUjehIJFRSDH+JqaPOzavWmuGA+YHp1oAqFRjHeqsvBI/hzirLSbWyzAN0x7VBMAQcdO4oAozgtk5FUZk3qQM57YGa0JAvAAB9aqyA4DA8+3SgDFuowOdp9+eawNWjLJxnA9q6a5yFOT04FYt0pYFZMEd6AOSkXBIxVWYkGtG6iEbt1HNZ8/I4oApydT61WIGSTVmY5OMYxUJ4FAEWBjJ70A896ceaRenTmgBT0PrTef8af0HODSE5B96AETjr9eKkXk8dKYAMc80o4bj8qAPrf4fcfsgaj/wBgjWP/AEZc18ct3PYd6+xvh9/yZ/qP/YI1j/0Zc18cE+tABnnvSj0pMk/hxTwRjn72MgUAJg+tBHPPehT05+tBPIoAUYxx0pMdz1oBz2pynJ5BFAFi3I4BrSiGMjpxWfaqSxOPlHPFaKrtQA9TxQBYt1MkyLnODya7/R4vs1plceZJ8x/2Vrj9DszNcRhgSpOTjn8K7+wsLqYOwgkMYO1sKePQUAa9hOwtS23J28Cr+lK0hUyAf3h3wKdZ6NfeXJ+5lBjGHAU966XS/Dd8p4t24TdyuM0AU7dSWAUA8noKdeJ1Lcjj73FdHa+G74tHuUrkZPPT2qWfwleTMoZ49rdQT92gDhXj3EFVJBHToKr3FqRtO0knua9Gt/BUyoBLLGdvoKsSeDI5EBa4bjjhaAPKPKK/LtIYdMd6Gt8jbjr6+navWV8GWSoBJJK36VKnhDSlY5haTn+JqAPI4LYhhntzzV+0tQXJCk55NetReG9NiKstpHx681Kmm2sWQttEv/AaAPOEs3NuFC4yOOM1k6v4WvtdtjaQDYxIO6ToMd69iMKKoAjQADjiopVI+VVU+1AHzZ8Q/hpJoWhNqNrem5WJgJ0ZduB6r+NeOzqVcjpX2T8SLVbjwbq0ez/lgzZC+hB/pXyLqds0UjHseQaAM5QV60rCkB9TRnPvigBp4HtTQRu46+9P6D2pox9KAJB29aQH8yaaelKeOnGaAHUuPXpTRke9KTxzyaAA849KUdaUYK+9IM9/woA+4f2Zf+SJeHv9+7/9K5qKP2Zf+SJeHv8Afu//AErmooA5X9sv/kmekf8AYai/9J56+OSfUjNfY37Zhx8MtI/7DMX/AKTz18b8YPOM96AJB39asWvXmqygDg81agIzjtQB2Pgfd/bFrxkeYOM17fqI2kZz90V4b4GbGu2gB2/OK9q1GY+aV47YoApYJyBkEnrir2mgllU85NVA3zZYDFa+hRfN5jcjovHFAHZW0axeHbrIwAM155J99iuCGHcV6PKSnh65LdMfnXmjvlWyTgdO1AEsfIzjABq7bSfvQWbacZwKpwKzSbQcj2rVgsncgkkHFAFlXEgG1u3pVWbAcgtg49K1LXTnVDnrnvUr2IG7cecUAcreqTtO38KbHHKRyNwJxgV0lzbQ7Dk/pSRRgKuxRjsaAMu3tpEBJHBp7IUG44yPWtMqRyRnHtVeVecgZ+vagCjBIvJ3DPvTZCpU5YgdyKdKhDbtu3175FRz7VXlvegCqyKT1DHt7VWb5CxByB69TUkjAYKnpVcuWLL0PX60ARSAbCBjIqnN+fPFTyuMOMjGMVSYkrtB5H8WOtAFS5cAMoAGD371kXJBbnB9q0pctuHfHJrMuAeeetAGFqUePnA5HUCsW4OGJFb93kHk1g3iMrk9jz0oAz5WyScZ9qifjCnrnvUrZJz0qF+nWgBv1pB3pf5UHJ/oKABQM8Dr3pWHvS445pSQE9s0ANAx9KUDJ9qTC8cU9etAH1n8Pv8Akz/Uf+wRq/8A6Mua+OH696+yPh9/yaBqX/YI1j/0Zc18buM5PpQAbhjgUuBtJOOaYvSlycZ7GgB2R2o60gyPrTlPc9qAEBxT1yTx1ppOW445p4Y7iMUAX7NcFWOMVo20JldOoxVC2U4zz7810uj2p2iVlIAPQ9zQB3Hw0s4V8Q2Ec6ry4Y7unsK+mLaziQMEghQE7mAUDn1NfLOi3M1tercxt+8jcOpYcZHFepaV401uQRiRdzI+9vl5K+/tQB7BHCFJwq4B5xU6rtByRx3NeYtrmsygxgShmbz1bHKr/hU4u9Rk3vJ5mLkCTaM4/D0oA9JLIpOWBxyeegqF7m3UuDMmQN2Mjp61xEH2+VmdkmPmLtPB59qZ/ZWqTXiSCCUqBgnHb0+lAHaNqlkBzKDx2HNU5NesYwQ3mFs8BVrOj0K+KDfH+uKJPDF3Iw5jA7BmOQaAJ5fE1sr4FvKQPpg1SuPFm04htQRn+Jqn/wCESlyu+4i6YwoJqQeEImwXnJx1AFAGf/wktwwUosSg9QQTSS61ey5O5FHYKK3k8L2QC7mkYemamXQLNflZXxnPDUAcpcX93LGMTMDj86z459Te8jFtNI0pbhc/54rvf7HsVTH2fIHqc0sVjb2zkxRJGcYyBzQB5F8UL/xPDoc0FzbWsdjN8jXEDEsB6Efw5r5+1iHMYbGMDGe1fYPjmyju/C2pQyj5GhZgPpyK+S9UTNp83YZoA4twQ3TOKUDPJHSnSjEp470h6fSgBMZJFG0Y6UUhJH4UAGVzgn6UpPHagZyOBSsPp+AoAMkDrRjJ96CMdqUE5oAFI4wMmlDZA9R2pg4z608Kc88fWgD7h/Zk5+CXh7/fu/8A0qmoo/Zl/wCSJeHv9+7/APSuaigDlv2yhn4aaQB/0Gov/SeevjcgY+6K+x/2y/8Akmmkf9hmP/0nnr465oAX+VTRHHPvzUC9QO1TR9D9aAOr8HE/23a9jvGM17LfTfvmHUjjNeMeDOdateSfnHWvX7kg3bj+EGgCe2DSOqk8nnJ9K6fTgMIi8isKyQiAcfMRuz6CtvTsABs9uKAOrvUaTw1cYz0x9K4VbBlwrksBXo06mPw1MT95hkVxO0K5LZx6UAFlaIp6Hnn8a14TgAYAz69qpW3UfXp6Ve3Bz06YAzQBYRyVCqxGOpNMYjuDnrnPWhCCMENTZDg8ZII60AR3SK6sCpIqtFHtTccjnAFXQw8vp159arNxJgE88UANZRnqeuKhZVKYOQSetTsxypz+ApjH5fTB9KAKckIK4J5J/Sqc1uSrYPv07Vek4wWbDDpVZ3Utjdj1oAx5k+Yg5I96ryJgfQ9K0LhgJto5BHpVO43DPQjHbtQBQkXIAOc9eKqSKQQeo9KvNy3IAI65qrcALz1HUGgDMmXqOxrLvFJGB161ryYJJ5FZdznJPP5d6AMa5Xgjbn3rIvIgwIPUVuXGcDco61mTqNxIBwO9AHPSKQTntUJUY5rQvIhvyPvdKovlsYHFAEOD6cUlPYH2/OmqMHmgBw9TRjg+9GR0HNIT1oABwKcvJzimH64p64H8QNAH1p8Pv+TP9R/7BGsf+jLmvjhjyR619j/D7/k0DUv+wRrH/oy5r44xycmgBByRTuh4Gf6Uhx3HWg8nmgBRSEZ6U4frQcgEkUAJjHHNSQJuamZ9etSwAswHqelAHq/wr+HEni60+3C/ht7eKYRsjKWY+uK96sfhf4egtntvs87JIyuSz8jHYH0rxr4G3tjp+twxXf2sSTkBDE/yAgH769xXvul+LFvba0ltdOu2WacwMBH90D+LntQBdXwdou64zp8ZFwF8wY4O3pj0rWt9IsI2YpaxAsgQnHJUdqyE8QX0qM0Gj3XyXPkbcAbl/v8A0q4+oauWvBFpp/dyARk4+Zf8aANhLSFQp8pQQMfd7elTRRqAMKNueBjp/wDWrDefXWa4VLaNV2ho2J5z3WoZrLXp5VLz+WrJkquBtb0oA6dV2Ahj7YxSDAXaxAwc8muWh0nWWAM8pLZH8dWDo96+VdwD3y+cUAdC7ptYmVAR6VA15bpwZU681n/2FO0QHmpgDmg6BIXGZl29MYoAunUrNCT5mT2wKgOqWpYlVkz7CoxoI3D99jHtmlTQwjkmckn2oAH1iAHiOT8eKpvrjK+EiHPqa0BoiA/PIxHsOlRnRLcsuWY9+ooAzH1ycghYo81nHxDPFNmZEdB1A6/nXSnRbYAHL/TPU1VuPD9lKPmWTJ6jNAHFeNPEMl14furbQrSee/mXyyoXO1T1r558RWFxaSPbXkEkEq8MjjBX0r68tdMtrCJktYwoJyWPJzXiX7RNtGk2nTRIPMdXViO4BGM0AfOl8hSUgcc1XyDV3UVO9s+tUlXr60AGKQjJpTk8Dr60mCTzQAClBFOVQRSbcHHAoAB05HNKBgD3pSvWk9MmgBPXHFAzmlx14GaBwPSgD7h/Zl/5In4e/wB+7/8ASuaij9mX/kiXh7/fu/8A0qmooA5X9sv/AJJnpH/YZi/9J56+OjxX2N+2V/yTTSP+wzH/AOk89fG/3uPTrQA8AdR+NPTqTnAPWo1HapAQBwAaAOl8GORrVsvT5q9lgTzLs5JKA8t6mvGPBJA1q3yOAa9qsyJGIbcAp6CgDXtkLN8wwpre0q3DSKMEZ7elZMEbhU2cgj610+ixktGQ3IPOeaAOo1O2ZfDkmATkDGK4aS0YE7QTjnAHevU7shtBYSAAMBwK5G9jUvsQH8B0oA56CJ1ySDyR8oqcx7UPDAe/WtGKEKW2g8+tTvD8uHAzQBmRKzAZ6H1qN+GwG/H1rXNoDHjBOeeKz7qzdWJAYjtnigCtuJyeFPaoyR5gJG7qc9M0shccMvXgE1FI5UDAXjv1oAaSFUenv2pjOQDhvzqJ5Tu+UHPfNQsxZiG4x6UANnZiCSC2RVeQll2rnnrjtVmXB4xwRnOagkPy8ZOOgFAFC4BDAk8g4GaqyMxc8Z5/SrN18zAH64NVmVm69Ac8UAQzL83UexNULhc9j8taE/CBuuOapzKfbnmgChL13f3u1ZV0CGIBP0rVk6kn8BWfdBQ57CgDLnXkt3rMuQN3P1IFak4zms64TBznPtQBkXe3ccDrWZMB/CMdq2LhBycDI71mzrg4I/KgCgeDim5x1p74B5GT2qMHI57mgACkn1FLnBxSjC5FIwwfrQAYH4mlxnp600nNOQHs2PagD61+H3/Jn+o/9gjV/wD0Zc18dvkHrz+VfYnw+/5M/wBR/wCwRq//AKMua+OScfSgBDyP/r04A9utHBPHelHB5/CgAB/P1oJJPXI9aWk7cUAJ24q7p0TPKDj5apYOa19Pbbtz29qAPSPhjcvp/izTbiGGSd42P7uIZZuOgr6x0S4a90+GaS1ks2IyYpMZXJ9q+M9GuZoZla3do3HIZTgivQrXxdr0t2JH1OTLRiBh2wBjOPX3oA+nhk/MBgDj605GGQSwwfcc18+2niLUY4oPMvJGaFSisSeQf/11rWGr3SxRD7RL+7JKc5xnrQB7Z50YI/eLgHA5p6zQqHLyKGHBy1eRW97OEKl3wW3Fc96vW1077iWOW6g96APThfWoXHnp+BpReW4GRMmD1rgbRvnXeB9B2rZDEr8uPlHBoA6QX9vnBlUginC9tyoKsfpiudt8GMANg4/KrkYOQSfbOaANQ30CsQzN+C0xL+BiSpJA6jbzWWw5OWPJ4OKcFJYcUAaDX0RAIV+vSopL1DIWEbhsYyTVdIm28gDkniowhLjdkL3wKAJjqJwuYiMDnnvVWfWdin91/wCPUSIvzDufWqF3DhMqBj1HUUALD4gtndkuf3LZwCentzXj/wAdb+21S5sra1dZfs4bfIOmSen4V12tqXkdBnOM15x4rg2jexBLEYFAHjmrQFHYfzrI2nPWuq12EMrHjPNcvJjOOhoARgcU3A7jr6U7jB56imnGBzQA5CAc0hOWI7UvTg0ZHQUAOBwOaaGGcdTSdM0oHHTpyKAHAZox2PSjoOKM+tAH3B+zN/yRPw9/v3f/AKVzUUfsy/8AJEvD3+/d/wDpVNRQByv7Zf8AyTPSP+w1F/6Inr45frX2N+2X/wAkz0j/ALDUX/pPPXxznj1oAX0Ip0fYmkWnLx0PFAHSeBhu123B7nP0r2u3dBcMDnGema8Y8BY/t+HPTFevhiJWIxwSAT3/AAoA6jT2by0ZTyM8NwK6rRGy6vsKtj864OxYjG0kcdM5rsdGeUFAVJUjBxQB6Fqf/IBDMNrcYFc7KQeN3PQ1d1W7ZfD6hjkjgY69a5T7bIJAoxtHqO9AHQQIpQ469/apHgU55zx0zWXaXxKncu0mr/2gH5gOo6UASxp8nBwPeqrqCSDnjpk1a3/u85HPGKozMUYg9fU0AVriEMgAHINYt5GYjtAO0cit5pNygZ5zzVG6gEmBtJPoDQBhuCSGViT6CoJNwcltxY9MVcu4mTGxSCOMVTeQqVyPwPNADyAR84P0AqPAIyMj6nr7U4yK568euaheQJnbn0zmgCGVA0hPfsOtQNHhcg96WaUFstkdqYrcYJ6GgCEjI+baOfwqvcQKRwSD1HNW3KnAAqGX7oyR6UAY1wm0HgZHp2NZdyu4jI/Otq5hyRjH1rKnjY57+tAGTMNpPBIqjKOueBWpMMdFyAaoTqc8dKAMa4XlsZIz1qhOuASODWvKh7djVGVMD5ue1AGNMuM4PSqrDke1XrtVXgc81TbqR0oAb1Joz6Ug69aXr04oASnoOfem8ZBODThjgDPXvQB9a/D7/kz/AFH/ALBGr/8Aoy5r45IOTzX2P8Pv+TP9R/7BGsf+jLmvjigAU+valBwuSKbu4xSAjH1oAfuyCDyTQMUnTkUoOBzQAoJJwBW/pkKlR1rBiwHyTXQaTIpcBh16HNAHRWMBQ7lwxxx2OK6XS0VHjYqQQeD1/CuesJmXAjIY9MMMEV1WkOoVcKfMJ6GgDoLP51GAeevFbenk+YTjIIwT7VU0+DJCFSvHeugsbIKMcZx/OgBYY5BGoyeeT7Ves87xz8p9algtmBwQx4yO1WktSGUgkjqRQBYiDYG0jOO9aluzhdu7HHFU7WLHPU1peVsOQBnrQA62zgjjPbNXoWzEN2M96pphSGU9uc1PvYiPlVHegCfjILFiPSpgCcEdOv1qskg+YDkepp6zqH2DHTgigC5Ht4GMZ9KZIuM5J/Ko0nTgHaWJ6GhrpVGCuGBxnHNACNGAnOeuRVSeAMpBBqzLNhcAZY881VkmwjA5J9qAOU1qIJKSo5wQPevI/Fu5NplbLE4AHavYdfzsZgccce1eQeLNhmZdoDZyR/jQB51q6E28m0Ddya42UHzGyBj1ru9VAAY4Oc1xN6Asx2j5TQBX69MUzksOMYp5I9KM/lQAo+lJg5JoBOKOTQAZ608keppmKX6UAAJ9cUo5PPNIKBy2RzQB9xfsy/8AJEvD3+/d/wDpXNRR+zL/AMkS8Pf793/6VTUUAcr+2X/yTTSOM/8AE5i/9J56+OQMdOa+xv2y/wDkmekf9hmP/wBJ56+OOaAH88nFGOlA6d+aU9aAOo8AsF12E5GB+lepSSMLhz8x5OPpXk/gqQrrMZQ4GOtelpOswP7wgjOc/WgDodLuN5CseP8APWux0i6ZZY8NgdK8702bDjaeOmK7HR3LFdxGeMgUAdn4mvHi0OEkgoTya5ZdUwwOBycYra8UtjQIRnuOetcQr7ZFA9e9AHc2d6zoDtUd+lasVwrKTt6dPeuS0+RdhUkknnit23PJViTzQBdMgkUlQcg9qhkJH3ice9NQYOc5bOTTpgzKGYYxxjOc0AQ7gDyOfY0zcuT8uT6UrMMZ7DqajdiRk9B6UARXZDnDAjtkDrWZcRRsO6k/qKtTXIx3/lVCWXjLHgdPpQBRuQLc4A4PpVUSBmbGfU5qzcbQwwwYZ64qq5Q5DgDnFAEUgXcpzgipF2rnBXJ96biNgD26UyVoxyAeDigBfmBycYPWoZEIQkcZPSljmjRTk4JyORggVDJexqhAOc9sUAQSIcEj5iDzVSaNCuScGie/znZj+lZNzdMWOTxQA65K4OCOO1YtwVV+tTTThcnuax7u5Y8ZFAEtxIOfasS8mIkIByB6064lb5gTxVGU5IJJoAjmfdj6VXz82cgVIx96jJyeOKAF3ZPamkZJGaM0HqDQAbcHFOX+uaU8rkUi9aAPrb4ff8mgaj/2CNY/9GXNfG5NfZHw+/5M/wBR/wCwRq//AKMua+Nz0460AAOCKUDntjtSEe1GPWgBcc8frS4GOetL1OR+dIRmgB0Y+Y8E5ra07arAnAA9axgvzY4xWnZSEbOfzHagDrtOxIV/egLiup05hD/q3ByRkkfyrjNOZuMEA9gRXR2k7xqpOWJ9KAPQtFuwd3mycYxtBya6m1ukTADkE9c15/pVwiuA0ZeUdeTXTW9xERllP3c8HvnpQB2FvLFIqYYnHAxVkyBQNiZHQ981ydlcqeYvk5PynvWt5xeAO7EKB/D0FAG7BMy5CjHHatCJi2CTk45JrnbaU42qeCM1rwMQqknI7Y60AWwWL/KCR6VMN4bIGSOeaZGjEk5qSQHLdgB2HegBjzgkgqSRxnpTZJNpbBB46011LD5sfWkZMq4GB+FAEiODht2PXmni4JGCeV74qk4YKBxtzjI9acrZ42j1zmgC5JPhQV5PtVG8vSv3VKjBplxv+Xy1Yjv6VXa1u5Yw0cTSe200AYeqXsk8W1QXZgcZ7V5frEMpuJjID5nJGT1Fe0Q6DqE1wifZfKjJ5c8Y96t6t4F0a7tXieFlnIJ88E7gfr6e1AHzBq0fyEnjd1rhtWRknxtwtek+MNPk0zUbqymK+bDIQxHcdj/KvOdacGYKOQO9AGY2SKACev5UpOKASTx0oAUEkdeKO7U0Zzj0px+770AGeKVPzHem07qMDigAPoKTHNL0HHWlHQUAfcP7MnHwS8Pf793/AOlU1FH7M3/JE/D/APv3f/pXNRQByv7Zf/JNNI/7DUX/AKTz18dE8g19i/tl/wDJM9I/7DMX/pPPXxz3oAkB49qMZpuOOKcOlAG74PfZqqsO1d/azfvSDgg8da868NNs1EEDA2n867KznPm9eA3I9qAOps2IZWyBg5wO9ddok3zIWbJz6VxFk+W7bB1966bRJi06BshccZPWgDr/ABc+7SIPmy5PauOLAsoBcMf5V0niyYDSLcHIJI6HmuUDMFUqwBB65oA3rKRlbG4+3qa6Kxn+XCkgA9M1ydrMVPJA4rbsZvM2lj847mgDoYWDE4OPUYq0TuiG0DJP6Vlwzrj/AGsc4NalvzCpZ8n1HegCvKpGemfpVSeUpG2B0q5cSDbgsBz19azLiYEFDjg460AZ09wGfYQwPbNUbpiFCjI/GrV0qbuprOnUbVbOaAIXAzxk4POKegJwrc4PQ9qOPXmo/OjQY3/MaAGuoCnb1HGKryuFQ84P6CpJ5wy8/MAOnSs6WTzCdxyp42+nvQAx5GOSD09e9UJNxLDcAatMpIIzz/Kqs549O31oAz7hyFI/Os+UPu6nntV6fG3PH0qlJ0BHTp1oAoyP1GfrxWVdAh+eSa0LjiQgA5+tZd05ZyemKAKUpBz6iq0jc7R1NTSZJOT+VRHBwTgCgCu+Md80wjGPpUvABz1qPBOcdKAE7daBgUnbGfwpV+lADlBIJDEUq5wDmkJwQMEU5T29PWgD6z+H3/Jn+o/9gjV//RlzXxy4ANfY/wAPv+TP9R/7BGr/APoy5r43c8HjI9aAFIyBikFIDxilU80AL3p4pg6ZNOB55xQA+IgSjPTpWlZcydBjHGazYx8wyMnOcVt2FjcXDRCCF5fNbagUZ3n0FAGvprsxAwQOma6O0YyKFIxz1Hbmq/hnwnrWpG0ay0+aSOd2jjfGFZl6jJ6Y969D8PfDLXbg2sssHkRylyd3/LMjj5h70AZtiHASQ5JI+9nrW/buAuRnaRjJFbtl8MdVaGEmWGKTJ8xWPKgHj8627P4bXQVvtN5Go/2VJoA5KFkG3grg1s2ziWBgvTHIz1rrrbwBZIV8+5lk74X5Qa2LTwrpMK/6t37Hc1AHn1rKy7Qdzc461u2TSsAPmPfj1rt7fSNOgP7qzjx7jOKtBY4xhYkUHgBV/nQBy1tDdPyIZDn1HNacVjdlRvTaD6mtreQ5JOMfyqOS7t42IMqA9etAGaNJlkxudcd8VMmjp5hLSn6AYqSbVbSI8y5z2UVC2vWyYwGJ7kjFAEiaLaAq22QnBHLnGD7f1qwum2kfSEfjzWY3iBc/uYf++mxio5daucApsXPfGaAN9IoY1Hloo7dOlIWCg4AB75rl5tVuyrZlxx/DxXP3+pXB+VpZCSf72KAO/ku41OHlVf8AePWobluuOfoa8snuhK5dmLgc5yTWV4g8SatZaPILS8eJW+VSeSB+NAHBfF6aK58YamYGDKGCFh3IAzXkOqDEzkY5NdTq12cOQ+52OeRzz61yV6SSST1oAq47elJzngUhHGc04EjpQAY5oxnpS+hNHOc9qAEIx0o6f570rnI7DFHoaAFPJ9qD24OB3pAcHGce9P6jAJIoA+3/ANmX/kiXh7/fu/8A0rmoo/Zl/wCSJeHv9+7/APSqaigDlv2yiR8NNIx/0GY//SeevjfJH1r7H/bM/wCSZaR/2GY//SeevjvGRyBQADPpSg8+vtS8njvSDp1oA0tEKreqcnpXRWdwBLn1ODXL6awW5XPpWjbSlZM5JwT3oA7uwnC4+bK/nXT6LNmUAHnmuA06XoAcjrzXWaNLh43yQQ3SgDsfFVwf7PtcjoME9a5hZztVd3uAa1/F8oXT7bBBDEVyqTAbfmGM9BQB0lpK2MsRn19a3bKZQAFbr1yK5C1vF9QRjn2rWhuSAMn7ozigDqYbtUJDdfT29a1La8H2dsE4Hqa4c3jJkggnrzV211L7+cgY/WgDdvL7aME8d6zJ9RDHHQD3rnNX14QggLk/WuYm1u4kY4k2+47UAd+16rMQcY+tV7i8jIwrZx2964RdTnLjc5fHr1qzb37Nnc34E0AdQbwuDg/N3+lVwy+YMjjuazI7naxzxzVyKY7TkcdeDQBdl5VccqOlUnJdjuAznHFSfaFKY43dqrtKASRg4GQPSgBzZVTyMetUZmYL1yPapi+fm7iqtzIS4HA3GgCnO+SQATzVaXHb8qndlIOOp5zVSU4hPfJoAz72UCU4xmseZsZrQuuhIHOc8GsuQjdhs0AV5CCSRwPaoGYEAjkZqSTq2OfQ1CeMUAMZhnAFMGQO9KRg+9Jj3oAQdeaXn2xSd8GlPPWgBU60AnPtSqOPelUY9DQB9afD7/kz/Uf+wRq//oy5r44br719kfD7/k0DUf8AsEax/wCjLmvjYg5oAOjUAdcil4xxRu6DnIoAATjinLt60hbnufqaM59vpQB79+z9oPhzXNND3umvNqdhcee00mQuf4QPUAdvWvoPSdL02wiVbSwt4lWUygLGBhz1YehNfIPgT4ra14R042UMNvdWiqTEjrho2PQ7h1+ldla/tBasbaGN9LtDcLnzHDHa3oQOxoA+poFVV/dqqgEtgADrU/mEbuRzg565r5PPxr8UXOwJLBGFyCFjzuB+vpUY+I3iW5WPztVlG0FflAGQfXFAH1m1xEFYs6gAbuvb1rEm8Y6KhYC7DlTghVJxXzXba7fyyL5t3O+1Sq5cnAP9K1LHUB5is23gZOOxoA90ufHWnxLuhSRwBjOOtVU8c+YMpaBMn5dzZNeWx32YeGCk9ycCrVreojJzuyOMCgD0h/FF+0h/1aZ6DGTis+71+7DESTyH/dOB+lcw99mNm3AYHBB7Vm3mvRI+wuFHPA9KAOte/eSYSNM+8DZ949PWp1v1ADPyBzkV5pJ4i8tmMbFgOvaov+EqZWG1Rn69PwoA9QN/l9u5iSc461L9tDjHJPevLF8SOzqFIPrz0rRsdbZ5BuYj2J4NAHosV1uZQQVB71cSQCPeoJB7n/CuMsdVV2VTIFPpWwt5gAkkZHHf8aANlidm7BDEdqxtVlDAZbAX071Ya6IiwCTkYJrJu5RGME5xzQBl3l0I9zMQB35rnvEt2J9M2QjO3nmptYvAjsq4HckiuYuJ98RZnzuPQnFAHD6s4knYk8ZzXP3YJbHX0FbF+cSyc8bjisO5Lbsd6AIFBzgkUdG9RTyRjgEHPOTTGPrQA7JxjAo+bjjim9/8aVjhueeKAEcfMODj1oPSlX0PAoxgnHSgAB4p6HIHTFMJ9aOeooA+4/2Zf+SJ+Hv9+7/9K5qKP2Zf+SJeHv8Afu//AEqmooA5b9sr/kmmkf8AYZj/APSeevjrJzX2J+2V/wAk00j/ALDMf/pPPXx0tADhkc5xQpOcCj+IUDkUATWp2y5z0qaKQ7sZ781UTAkzT4yffP0oA6jTLggKQwx0x611+hXOxlyTj0IrzzT7jy22knkV1+j3IBTZzQB1/i+4/wBHtgAQTg4rmoJWyG7deav+LJiTag8DaKw4W2nqT24FAG3bNjHJx3rUS5IHXr61z8EjZ64XoKvRy89yMflQBpGfqSTk+lJ9saNMk9+az7i8jiRt5IxytZF9qTTMVQ7Yu3vQBNqM7TTsSSD1xnNUGIA2jOWpiu3IIxnvQXAGQaAJkbaTz1qQMQQTwT+lVs9DkH69qdvODk5PagDRiumBBkbI9a07a43KW35DdMdaxYIlkQljgf1pEd43K4IINAHSAgKDzuxTSzKN2Oox9Kx4NQkjPzjeAcY71ejvYZTyTluoNAEgfAIJ47VWlHy/Mc/0odxuxgeo5qCWQHJyQaAGSn5sjgVXuMeWSMkU95AynqT6jvVSWXII6etAGdctgN1ArLuCQRgjHert5KXJGMgGs2Y7jx60AROe4/EVA+WPAqaXnOBjHXmoCBj1NAA3AGevtRyc5+mab6U4+vSgBpAGfUUHOaDy1L97HtQAgYjtTlOeg/GjBIwTSjnrQB9a/D7/AJNA1H/sE6x/6Mua+N36mvsf4ff8mf6j/wBgjV//AEZc18cnrQA1c4JNKQCAc5J7DtSD7wNGeelAC9Bz1pSvGf0oxzyeaOhx1oAVB29akRtvT1zTP0oyM4zn8KANawmJcEng1tWbkOCpxmubsG6ccg/lW3Z5IJYd+xoA6SGUsq5yMHpWxZSZkUgnA64HWueteXAJwPWtuwXOQTQBupK4RS/Kj8cmrFnceWWB9M4z1qirgRkc9c57fSpM8AAAHpwKAL1zeOq/um2qeB34+lZGo4jy1y27Iyqf41YubmKziUs2XIGFFc3cXTzTMzNuZhyevFAD57hpWy5+UDCjGMU0SkMDnHHpUJyxHK59MU4jA5xQBIZHLEqevp6VoWV+0TBZBvGOOORWaG2j27VbtUEndSuOATzQB1mm6jFIB8wyOMNwRXSRXOEGxtwH6V5o8LopZThRyR3z7VJDqt7bspWVh0yDyKAPTzdyBGDHg+lUr26I53n0IauQj8V3SLiW3hkHqcjNQT+JxKmHtguPQ5zQBPrVyWmZi+B1rmr+bK8c44z60ajq4ckiJQT0yxrFnvHkUjhc9MUAZ2ov+9k7ZNY8pO7rWpcMGJH3j6msy4XaQT3/AEoAhbk00DNOIpPegA5wPlwPWlOeMUuegxQMH73FACcY9h2pRyKQ8Hg0q9cUAKRgD3FIOSKUnIx6UDg0AfcP7M3/ACRLw9/v3f8A6VzUUfszf8kT8Pf793/6VzUUAcr+2V/yTTSP+wzF/wCk89fHeRX2J+2X/wAk00j/ALDUX/oievjrvx2oAUgn1zRnHWk3dO9B45NADwM9aN2CME4pme9NyDzmgCzFJ82C2BW/pVyVdTvZcd81zaGtrS0JkXmgDf8AEuqXDPBuKltnT2rLt764dsgA4/WpdfQb4cY3Y4qlDu7UAa0d5cEg5AB9qsrd3DHAkxjgYFZsOcDrxVuFcqc/UYoAmyzqDkkk45NLDCGJBJIzUkaHAU/dNTxRAYAbB9qAEFruXr+tSNZsi5/hq1DFgHcCT61ZWVFXbkY9xQBimA9V59qiKkdiM+tdMLeCU/KQpI69qjm09ET5MOfUGgDGt5HRT8vHvT5MyAsG5NSTREDJXnoRQiEcY6npQBTBwCScmnGYhDjg+oq1cWwkXegHH4VUMEg4KcfWgBBcvx83I70x7uRRkcn3pHhkHTg+tNeMgDzCfegBsl27D0I9KqSSPnJJz0qdkGc9R7VXlTnuMe1AFWQ4zznNVpOfSrlxGqxK6nc38SntVCU/xds9KAIZDhufpUBPenydc1HjgDmgAB4JozkGjnGM8UijHvQAuRyaM8dOtManL0oAXGQaenT2pqjsacAc8dPWgD62+H3H7H+o/wDYI1j/ANGXNfHTIcc9Oma+xfh9/wAmgal/2CNY/wDRlzXxyeD7Z4oAZg560p70oHB4z70Z4IPWgApdvejjNKcY60AIQQRQAOtGcGgGgCWFjG+c8Gt/TptxXk4Nc5ncalgmZD8rsMe9AHf2XJA+U9+DWzDIqg525+tee291KRhpHA+tX7cyTOPvH0J6UAd1NeQgfPIoUD7uc1Ul1sxIY7Pc2R99zk/gO1YVvCDw745xxWjDAg6Bc/XNADMyyyAku7k8k96u21jPNKqQj5z09qmtYyScAnA7VtWURihIwQ8nCnvigCo+jsqgt8wA4cdCe9VJtOeNuQBuPeuktBMkhODggAbunHtWwsFtcgCaNR7UAcCum3BPKqo6k54oWBo2JyDjivQTp1rIixxyKABkAjpWVd6Gw5jcEHnhePxoA5/yjNbDdkY6nNZ1zE8ONynB/iPSulS1nt3IaBihOCQMinPaKQ2ANpxkMM0Acc7HHtUBDbjgE54rrzowz/q1bPTAxTP7FVA25tuOgzQBxkltM+RtPPOSOlMi09mzuIGeM45rs5bBIzkAnPc/zrPngIwdo56GgDmJ9NCr1P51j31qqD5S3pzXWXiiNfmGTiuc1HL5wcdqAMBwQxFNqa4jw+eM9DUAB6HtQA73pM5pfbv7UEetAAV6ZFOK4PSm5z1H5UpPfFABjFKAc8Up5HvSqef06UAfb/7Mn/JEfD3+/d/+lU1FH7Mv/JEvD3+/d/8ApXNRQByv7ZYz8M9IH/UZi/8ASeevjlehr7G/bL/5JnpH/YZi/wDSeevjmgA6EUp54NAoz24zQAnak/l9KdtNIo7UACnGCOlbGmShGHespVAFWLVtjr/SgDotZkR5olODhR07UlrGjKcdfQ1lanN/pC7egHfrTbW6dT9aAOnigWtCG1UEHGV6muft71yOH/OtO31BgBluRQBsxWgORg1MYIYsE5ZuuKyF1FsYPTtjtUv2wkZIHPTigDQNyTkbQF9qhkcDpjd2B71UW4GBgDNTLPE20ZHBoAnWRgAQc+5qxbz4P3c+1QeVnJQ/LSlsDgYIFAFl5QzkBR75qLbCwztIJ7VUZy+ccil3gKB+tAGhGqBQOfamTQqxJXI4ql57A8HAp5uGVgXOAaABrYkc1WktycjHNWvtPUDHNRy3AzgY5FAFOS3IPNVJIuuByB1A61beUZPeqkh5OOB3oAqXChh1rKufvE46HHWtOcn8D0qjef6s4A64oAzZMlvxxTWHOD29KVyckU3PPPWgBMChBwRmg9xSrjGRQAHGOaB60v8AD0pOMAigBetKvA/GkUA808AZ56UAfWvw+/5NA1L/ALBGsf8Aoy5r45Y+1fY3w+/5NA1L/sEax/6Mua+OXAyaAGA5p20lRjGKTHNKBx1oAKUD9aYM59aeeBQAuBmmnGe9Obn8ab/KgA6dCR+FT28DSt6CoR1qW3ba+c0Ab9pZKmMozZH8RrZhtS4wvboM4wKxrCWLCbmYdua6Ox8gkZdtuMEigC5a6ecZMqDJxxmteLS4BjzLhw3oqdfxqG1ntQv7sFsDOD61pQalDs2pGqNu6kcUAWra1t4GJSIk9ix6VOqqZd0nzep/lVA6nCGJIYnHJHQUv9qoFYbCVJzg0AX7lz50W3G088cYpY3McpIU5IJYg/lgVTae2mdGywbb9zHSpQUJ3plsfeJPXigC5HNJuLhjk4OCe1Wkv9rOHXp27msW6nIlXPQDgUyN0+zuQzEgdPSgDbl1OFSzCPpjqaR9VibGUXGOAOCfeublLOPmJXI6etKCTCBjJ6EigDpDqiGIMgZTg5BAqncX8YBZW4OCNw5rGyVVgTzzioRvUFpGZlPIAPC0Aacl/uBOBxnGO9Ys9zvwANw9BTpXOwsRt5wT61TmwcgdM0AQ3YEgIwenHPQ1zl7GUchlPHH1rfuOGwRzWPqJ+ViASB09M0Ac9eLtA44NVMc8cVbviCEwOcZIqqQc8igBp4HWgDnrn9aOg6YpQPUDHtQA4ZBPNID0p23I+WkwPpQAp4PFOBwcCmYwBjP40Zxj1oA+4v2Zefgn4e/37v8A9K5qKP2Zf+SJeHv9+7/9K5qKAOV/bMGfhlpA/wCozF/6Inr46x7fjX2L+2WM/DPSP+wzH/6Tz18dYIxkUAKOaDwRwD9aXHfNI3tQApz1ApO/vSAc8U4decUALn0p8H+sWmE5OaWNtrqTwBQBZviTPz6YNRxDDDFFwxaQkGmR8dTzQBp27Kh5bA+laEEndcYrJhOMY5rQtzkcDGDQBoJLj+H65qRCTkkNn29KjjG4DGcZ59TVtQDjqMe9ACIwAyAQPcZp6cYxwT61NHGAMDqOetSiIGRRgHI6elABFIYyMHIFTNIZME9Oc0vkgfw4/HNSRRZKjKbTQBCpAA9KXBIJAOM+nWryRqFwVGMU8IFXGVAHQYoAzfJdzjHyj0prxOF6ZI96vOzZ+VUFV28zdynHtQBXZWAO/wCU+tQOXB6Ee471cdyoG4N+NVZSGPDYPpQBXY7iAQee9QMQGzz75qWU7ODnFVHODnsaAIZTnOQR6VRvjuXjjFWpjk9apXTH2PtQBQbOTx2pFyetLKTnnikXpxQAp4OT0pB9aCegzzQMY56UAO29qMY4oBwRTg3zHpj3oABhaOSRS8Y9qUdeelAH1p8Pv+TP9R/7BGr/APoy5r44Y/MR1r7H+H3/ACaBqX/YI1j/ANGXNfG7n5unWgAHJ9KXjq3P0pAxz3pWAyeDnFACY44pccAE0fw49KeDxigBB06ZpuKdgnGBmg5/LtQAhyPxozxSkZOTmgDB56duKALVrMVdQSR9a3tPnZwQW5HP1rmVODmtWwl2kZzg9KAOptZcHpz9auQSll9CpznNY9rkoGwFXPetOzAOQQWUnpigC+JjImApJ6cd6edyuMgYPI5/nSQhy3AKoOgHSrMUBKhpGCg91GaAGxSEEOCcgdRzmrdu5ySJD8vp6ULaxDOZmO3727ip40gK7d4Yjqw60AQOzY3N9QQKsWyFgAVwHGPpVhVjhGVk4B4BGQKXzIg27KfN1B6UATRQQIAhVpWzg4HANWGVo2wkIHbpxUa3kKiNUACj8TSNfpvO5VKDkHNAFmTd5Q32qEE/fQ5xVO7svNIMMeD3APWpGvQ7YAyOMDoT702a4Qlt0Gccbs9aAMK5heKZo5FIx7cGqUvUgAj1A7VuSlXRhBO4Q/wOM7azbiNgPu546r3oAyrn+Js9B3rFuG3IVOTznmt24TepypBHc1i3R2Ft3ZegoA5+/HzZ7Z4qmevPIq5qDbnUDoRVQ9Pf0oAbtH4U7oeOc0Y46Uv8/rQA5QAORSt24pu47SDQeeKAEyef50oySMjFNPGOOad17Z/GgD7h/Zl/5In4e/37v/0rmoo/Zl/5Il4e/wB+7/8ASqaigDlv2yjj4Z6Qf+ozH/6T3FfHQPavsT9sv/kmekf9hqL/ANJ56+OQelADzjAoHOMU3OeB2pVyAe1AC4x0oOOR3pT60mAT/hQAdhQASRSPnPal5HrQA5jluaBxSNndTsD3oAsRSADnmtC3lIPA61mxYzyPpV2GdQcccUAaqM7A8kVYVm7A9Kz47gDOSAD0qXzTwFOPYUAaKNlRzkCrSSEDjqayonBOOcZ4q3FJg8+uKANJHy3096lU5IOePrVGKRTuG7k8kVIWGOCQfSgC41xtGFz3FJ5xIHJzVLKqB+PANKJQcDoaANBZNq/MRml8/O0frVQuoX72T7UwyEZ+tAFuSTk5UY9KrTIhxxg+tRPKehJJNRSy4xkg0AQurqCM7lz1qtLyeVINWXnBQr/WqM02PvLnPv0oAgn+UehNULn0qzNOQM5z6e1UGkySxzQBCeSSaMelNY+goVuPegB2O/ekxmgEn0+lOzwfagBBzwcinbcepAozQc4oAUHHTpTlNRqCO+aX0/OgD63+H3P7IGo/9gjWP/RlzXxsevNfZHw+/wCTP9R/7BGr/wDoy5r46YZoAaBz6mgHkFhk0YGTtJzSLgkZP1oAeOcUpwPvU0dAOlHbsRQA9DyNvSkYruJH50i0duQKAH89hR1yOv0pmTTkPUgnn0oAMjPtV/T87gf7vfGcVnc44qzbO2QA20dzQB01sdq7nwPdj/StW3l+UFVY+5GBXOWs8cRyCXfs79q0EuXPJYk+5oA6BLkqoLNkj07Uz+0G2kpkPjr6VkJMxwzcZ4wKmjYqDzmgDVW5wqk59+etOjumXID4VutZocDg8fWl3hsDqBz1oA1nlaSPG45+tLHMyKFbBxWcZcqCvA+tAlycZ/GgDWW4KnIOCec08XG4MP4Tms2Mll+YZ9xUw+715A4zQBdMxUcncSeBntR9oZVxvIJ6c9KrB8rnH4013+Q5H40AWGuDtwQARzkd6j8/5SDk5qiHw4Ck9KkdsKcnjpk0AOuZwMAjP9K5/VHZwWx8nOATyPetW4dVGQQ3WsK8m2LIefT6UAY9wGaTdkYHGKrscmnyHMhDc9+tN469hQAoGR9KDx2pe+O1B4z7UANz9cHilFGRxmjIzQAuAx6c0Aeuc5oQkcj+VLnv6c4oA+4P2Zf+SJeHv9+7/wDSuaij9mU5+Cfh4n+/d/8ApXNRQByv7Zf/ACTPSP8AsNRf+iJ6+OG56dK+xv2zf+SZaR/2GYv/AERPXx0p5z0NACA8DbTgT3pG+97U8Y/SgBoPJ5p3vTRg5x9KUcZGc80ALSZOBj+dH8qMHr2oAXB/CjJ6gfrQp4waMZ5oAcGP4VNGxyOtQE4YAVIjYPGQD1oA0IWyOvP1q1E/A9azY34xg9KtocFQDwRQBoKwGACT7iplcgjg1RjfHbHarCN2zknigC9Eecng45qfzOe2fUmqSvlf/r1IrkjrjigCwzDoDnr7UqPgjgfWoC4wMdfc05G9x+VAFsHCZ7elNLZ5BwfSmB+CRz7VGX7A49zQArvjgnNV55AvUUhfBGD9arTuWyRxj1oASWQKxqrLJnIyaJWyD2qB22rwMGgBspzkVE3ygetKzbhk9faoTnPUcepoAa2ckMKRSAOmT7UM25jwBQvrQA7dtFNOc8UMfc0KcjAFADx0oGR70tIe54x9KAADjBoX7wFG7OMUq+oPSgD63+H/APyaBqX/AGCNY/8ARlzXxxk8g4r7H+H3P7IGon/qEax/6Mua+OGGTx260ANPJ680rewpOpzThz2oAReeaXrxSjAFIOtAC/wikPSgkgnml6jpzQA0fdPrin0057Ype2aAF/lSqQDxSEkdTRigC9BJuK9cD3rTgl+RQOSD2rEhwG5/nWnbsBjPIFAGrG+eOobpVmI8DJwD6Gs6BjnGSQR+VWRJuGD6du9AF5uQD3z+VNDfKBnk+lQ5yM84p67QOeKAJpHG0ccdKQHgEj6YqB3GAM//AK6PMPAHTFAGnCScYHGPzqwsgz2wKqW7fuwC2KnGAP8AGgCff0zxSueCD+NRhvkGSSD6UFhs46igCIqPMPJwT6USuoz83y981Gxw2eaSUqwOAW54xQBBK2QcdMZrnbuRgzKOVA6e9bt0u2FiPmJ7Vj3EDgZxyRQBkMeeTzSHkirEts+Sf5VAFwcUALn8KDwQevsTRjP0pO/FADgAeOBSMKGx1BGaaT0oAfnA4pBkjHIzSE9qVTzQB9xfsy/8kS8Pf793/wClc1FH7Mpz8EvDx/27v/0qmooA5X9sz/kmekf9hmP/ANJ56+OO9fY/7Zf/ACTPSP8AsMx/+k89fHOecUAOABxmjHU54pAeeaXPuRQAinGOKeoGeQMUZ9uOwowDyOKAEOc8dKUAA8NRx3z+FLnHYZoAQjpSfLzSg8UnVgfSgAHJHen45AFMGO2aVTg0AXI8Yx69Pepoug+lVomyoB7VZhPFAFpCMYP4VLEwU/yqtuPyjOfYVOvuOTQBaB4XBzx+lAJDEA8UxT+dPTuc8UASZGc0IzfTNIeWxSLuI/lQBYEjkdx6U192CRgDPWm7vugD60SNnI7UARSN8p54z1NV5mAyOvvmnStk8Y/Gq7uPTNAETvgZx+GarlizAk/lSzOC2Mcj2pqcLnpQAjn0ppJzUj8jrzULBTQA09zQucc0nGSP1pyc4zQAEUDB5NK3THFC5B5oAP4vbvTiMHHpSEehzRk9cigBFA7VIoPUAfWkHI6nH0pVBHuKAPrX4f8A/JoGpf8AYJ1j/wBGXNfG78Ma+yPh9/yZ/qP/AGCNX/8ARlzXxsxG3mgATHOacOpqOnqPl44JoAU9elHUdMUE45pfXvmgBDgAUdsUEjcRkZoGM0AFLxtppPNOPP0oAOuAaTBFFHb3oAchwauW0p3DB68GqQGRycVNC2HXigDZgcg+vtV3rhkGAO9ZMDknkgY61oqRuJIHNAFrpg5wfWmlxn7w59qYAe33cE0sYGwcDJ96AJd+T1py4D4B/M0wHJzxnOcUADp3IPNAF+3kBjG3txzVnzMDGcZ9qpWpOzNWN+QvTAPAoAmST5NqnoPSlMg49+meaYmQvYE01x8qc5oAJmxk44pyuiocdxVeQA8Z79u9KrjnOM4zigCpfXGZVVgCqjnHFZ80yY6btvTNIz+ZMzk9W4qrKdzHcPyoAhuJSxOBxVVzz2/Cp5sgYz9M1A4PbFACg849qM+vSm80EnB4oAeWz0GaafoTQuATg9qcThfSgBOevFKOtA/lThyD2oA+4f2Zf+SJeHv9+7/9KpqKP2Zv+SJ+Hv8Afu//AErmooA5X9sv/kmekf8AYZj/APSeevjcivsj9sv/AJJppH/Yai/9ET18dYBPfNACAkcYpexNJkg8mlU56UAKDSrTcZPJpSMdKAF6mlyB7imd6caAFwMU3p14pSfTpRxQAd8ZzS4wRxSH73v3pcmgCVM849asRkhcVVjPAqwvzdOhoAsowB5Hap0YEY6elVAWXBx2xU0Up7nvQBdQ7jxxT8sp4OajRvu9sdac5zzjFADy3r09DUinpluhzVZQcgnn0xUy5x60ATFwCCOpqOVg2fl60rHCY4qIsdwVSaAIpCcYzxnNVZzgEg4FSzHPXoap3LYUKO5yfpQBAzHOW/SnBiwxk565pjEHg9qUHnpQAMeTxR0FKcHNMI6UAJ949OacDjAPSkPGcUZP1oAM7Txz+NANIOM8DJ5pR2x1oAUH1xTuMYxzTMEHJ69KXeM98UAPTI9MU8ccjrnFRqcnFOBKn2NAH1t8Pv8Akz/Uf+wRq/8A6Mua+NmH8Jr7I+H3/Jn+o/8AYI1f/wBGXNfHEn3uKAAAZFDcHOeKOcUhGaAFpRk4Ao+gI+tHfoPxoAaRk80o+UHk078qQ47UAGTgHrn1pc8U1iTz/Sheg/nQAv8ADSg4FJ2pQM0AODZWgOQetN5HFKRmgC7bsWxk9etaEbkcnr7VmWT4Jzir8DFgAOCKANCDJHJ605Rk8cdzmmQ9iOP61JyGGcYyBxQApBbk8ilIYBQDnHSmSMPUg57CpYQfTAIPXvQBat+AOpIHNTA5wO5GcVFAdq7RjOPrUrjAG4AdsigB2cbSueuM0RnK7gOcmkjOQc/dp6scgAnH9KAI3GAT15qjey+TGz7cBm2j+taRY5YHjPasXW32LDE2eBkj1yaAK6AI5PzepFQyDB4780+L54VIHJ64pspz7H60AVZBuGevNRSjaFHc1afnkDHaq1zhSuey5+tAERx0xzSFc8dKQElucZ7U4sMkd6AEA5+lOIy2O1A55FKRg0AGMAdacoJ5pqn5v0pQAf60AfcX7Mv/ACRLw9/v3f8A6VTUUn7Mn/JEfD3+9d/+lU1FAHLftl/8kz0j/sMx/wDpPPXxtj0NfZP7Zf8AyTPSP+wzF/6Tz18c4G36UANxwM04DnOaTaOvNO5PWgB2Mmkzxg0A57UP1yRyRQAuQKYR704DOKXPYCgA5waaQDz6U6g4x70AA6H1pD0GBS/Q0oGe9ADkOM4ANWIj8wxjP1qGEc4PpU6kZ4oAkySQBwaeh5AAwP1qFWHRvWpl+9yKALkOQT2GKl54yRUMLZXB5P1p+4k8fdoAk+6+MYp27A4ORn8ahBBPI56c07dgAenpQBN9SKZIRxnk+wpS2709qhkfgjv6etAEMhyV6YI71RnYNIdpyB+lWnPy5xVEndkfrQAn8QNIQR1JxmnDmkPSgABOOTxS5GePSjGPekOOCCKAGk9cdM0ZzijGM+9A6UAKD2NOz9B6UzGDQAeOc0APJHrSEfNkUmeeKUHkYAoAUDin9gaTv70o64IBoA+tvh7/AMmf6j/2CNX/APRlzXxy2D0NfY3w9/5M+1H/ALBGr/8Aoy5r44fr0oAQHn6UDtSDkmnKOevHrQAo6cHr2o6kkf8A6qGAx70DoTxxQAnQ+1J3I70vPUCjqeRn6UAHQc8D0NLn8qQ9gfSlxxQAbvyoHUEc0KOKXOAB7UAAGSfXrS56cU0Ae9KOtAEkDBW+vFaNqOcNkVlA4wfeteHaQGUgdPxoAvo3QjOfepd3IxgioUJKBcA85p6FQoyPpQBKPm56YqVMEYPPGM1GpJI3dR19KcrEsMDOMnAPFAF6IYUDPPTjsKVwxIyfamW7AKcAnAp33iTxQA5CAAMnr2qVRyOOQe9RIuU9xT0zu569aAHouXJVR1rn9cfdqEin+HiuntEJmUfjXH38m68mPq5oAW0bEbDjOelLIucHuKhs3IlIAyGHNTS9PunmgCN+5PpVS8GJeR2FWiOuOmKrX3M3HYCgCA9/XIpO/NKOelJ1OelADiPl6GlXJpCQO/NOB465oABxQDkj+VBPzYAxml/iGe1AH3F+zL/yRLw9/v3f/pVNRR+zL/yRLw9/v3f/AKVTUUAcp+2b/wAky0n/ALDMX/oievjkcGvsf9sz/kmekf8AYZj/APSeevjfBPXigBw57gU7ApoxxntTg3WgAI4oHJOaaaXtigBScUZ456CgcClIFACDvS9qac4pw6UAGM0mOBzS52jNJn9aAJ4SN2akbI6bQO2Kro3zD61YLe9AAD04wanj68ncfWquRvyDzU8bdaALcL5PByamXJBGee4qnG6kDHLVYiPyEnrjIoAkOCc9KUZBxTSDnqOtKp3HHoaAH7hjio2J4z29qkUAElcFqjk6cUAV7g4Tj1x9aog4PJ5q1eMAVHcVUP3h6ZzQAZ28jnNBJxj060ZOelIpORxQBIPmHJpOgx2po+vNO7e4FADOOaUkHqaBxQD6cigAPJH0p2Mj3pq9cmnEj2oATH50uMfWlB9KWgBpPIpw55FGPl7E/wAqcoGBnNAH1r8Pf+TPtR/7BGr/APoy5r44fpg9a+yPh9/yZ/qOP+gRq/8A6Mua+OCOaAIx7fzpSxxigjuaVRhsdfWgBT056UZ9OtISc5xTeeeOtADjx/WhmPVTil6ik20AGRnmngDHpTCvUgjOelOxng5wKAEyd2eKXPrSHAzQOlAC/TpR0YUo9vX86CDngdfTtQAmfk5rTsJD5IJGAPXvWYQeeKv6WQWkQjoN31oA0omJDAYxng4p27oBhiD0B6UxcDPTB6YqTBZskbSewoAsROGT/a5IOacnHUDJqBAWB54BqaNfmBx9B60AXIGAXJ54qwBxwQTUERO5MEfT0qf7wLd85oAdjLAA8+1SAd1//XTEYo+SOPXFOxuHy8e1AFu0PyyPyNiE/nXByuWkZiOprvIP+QffseoQBTivPmBY9O1AD7dgsy8HnvVuYDB7jNZ8fEg7c1qTL8nKdcUAV2bHy9sVX1Af6SfoKtAfOMgDPaoNVGb045GwZoAqnqKD6ZzSAFuopSKAEX0xkU9fWmrnNOGcUAKeQc0dBQOenSlH6d6APuL9mX/kiXh7/fu//Suaij9mX/kiXh7/AH7v/wBKpqKAOU/bN/5JjpP/AGGYv/RE9fHAPPTivsf9swZ+GWkD/qNRf+iJ6+OgPQUAJz64pc0YBx60pGDQAHHGKSgZI5pQKAF6delKTxQq/NnHWjuaAExnFKOBQc5FG3mgBCcZpoOCKcFBJJPNIAM0ALn5varHJwewqvgYzzmpwAFBVjk+tAABg9PepYyOc1EOoyc1JGR1B69sUATxL8+4dR29aspwAT071XiwWyM1KnPfNAEuT3pABgkggdMUh4Ax2/lS8Ed6AFDEYwOKCTj3HNIWGPmP0zS8dQenTigCjdsDJzwKrn86mm/1hqIgY70AC9M4o6nI6UgB4PYU/gUAJg//AF6Q5B69afjrzQV/SgCMnd0PSlAx0oYbc4H40qHIx3oAXkYHHFHU+nFLgbRz1pSDnFADdg9aXIB9c0qjkg5/ClCjnnrQAd+P0pcH3pOO2cj9acuD9f5UAfWvw+/5M/1H/sEav/6Mua+NznPWvsj4f/8AJoGpf9gjWP8A0Zc18ckHNADByelA9adjv+VKFoAbxQMelPI5AxSADNACH0pRjk9v50YGc5ox3FACZHY0d+KcAM9qUr3B4oAZ1OT1o4B4zTiMg4o24NADRzTu3HPtQRzg9qUAepFADQepwRVqwbbdIPXg1WC+mcetSwYSeNz2PJoA241xvGOD0zQFbjOcAd6cCcA5bnpQqnByaAHqDsOOQD61PGRjk8VCFXd7d6nUgk7cEZzj60AW4lyEwcehNWWGG68ntUMGAvP4f4VOM7Q3cc9KAFU5X5vwqbqN3foOKbENw6Y4qXaRjPUUAS3WY/DF2w78HHtXnbbgBxx716Tq42+D52UgB3Of615tj1GPxoAAO4HtWqx3RKccFRWWByeta0WPsyeuMcUAVsc5BwO9R60MXSf9cwRU5BL9qj1lczxMeuygDPOQOKQg7uOlOUE/ShRjODQAADOT0pf4TR0+lOAAHBoAacg8Hj0pw6dximjinZJwB1oA+4f2Zf8AkiXh7/fu/wD0qmoo/Zl/5Il4e/37v/0qmooAf+0D4C1X4ieD7HStDnsYbmDUEu2a8d0QoIpUIBVWOcuO3rXgR/Zg8cH/AJiXhv8A8CZ//jNfZVFAHxqP2YPG4/5iPhv/AMCp/wD4zR/wy/43/wCgj4b/APAqf/4zX2VRQB8bf8MweN8Y/tHw3/4FT/8Axmg/sw+N/wDoI+G//Aqf/wCM19k0UAfG4/Zh8bj/AJiPhvPr9qn/APjNIf2YfG5Of7R8N5/6+p//AIzX2TRQB8b/APDMPjj/AKCPhsf9vU//AMZoP7MPjfn/AImPhvJ/6ep//jNfZFFAHxuP2YfG4/5iPhv/AMCp/wD4zSf8MweN/wDoI+G//Aqf/wCM19k0UAfG/wDwzD43/wCgj4b/APAqf/4zTh+zJ4324OoeGz/29T//ABmvsaigD45/4Zk8cZ/5CHhv/wACp/8A4zTh+zN43H/L/wCGv/Aqf/4zX2JRQB8fD9mnxxx/p/hvA7fa5/8A4zUg/Zu8bgY+2+Gv/Auf/wCMV9e0UAfIf/DN/jjve+Gv/Auf/wCMUf8ADN3jjP8Ax++G/wDwLn/+MV9eUUAfIR/Zt8cY/wCP7w3/AOBc/wD8Yp8f7OHjhFx9t8Nn/t8n/wDjFfXVFAHx4/7M/jhmJ+3+Gxz/AM/U/wD8Zpp/Zl8b8/8AEw8N/wDgVP8A/Ga+xaKAPjofsy+NwMf2h4b/APAqf/4zS/8ADM3jjj/iYeG//Aqf/wCM19iUUAfHZ/Zm8cHrqHhv/wACp/8A4zTj+zR42KgfbvDX/gXP/wDGa+wqKAPjv/hmXxvz/p/hr/wKn/8AjNA/Zl8bj/mIeG//AAKn/wDjNfYlFAHx3/wzP4473/hrH/X1P/8AGaP+GZvHGR/xMPDf/gXP/wDGa+xKKAPjz/hmfxvnP2/w3/4Fz/8Axij/AIZn8b5z9v8ADf8A4Fz/APxivsOigD48P7M/jf8A5/8Aw3/4Fz//ABigfsz+Nxj/AE/w3/4Fz/8AxivsOigDzLwt4C1XSvgPdeCrqexbVprG/thLHI5gDztKUO4qGwPMGfl7Hg14G37MHjcn/kI+G/8AwKn/APjNfZNFAHxr/wAMv+N/+gj4b/8AAqf/AOM0f8Mv+N8f8hHw3/4FT/8AxmvsqigD41H7L/jfJP8AaPhvn/p6n/8AjNA/Zg8bj/mI+Gv/AAKn/wDjNfZVFAHxr/wy/wCOM/8AIS8N49PtU/8A8ZpT+zB42x/yEPDX/gVP/wDGa+yaKAPjU/sv+N/+gl4b/wDAqf8A+M0o/Zg8b/8AQR8N/wDgVP8A/Ga+yaKAPjY/sweN8Y/tHw3/AOBU/wD8ZpP+GX/HGMf2l4b/APAqf/4zX2VRQB8bf8Mw+OP+gj4b5/6ep/8A4zR/wzD447aj4b/8Cp//AIzX2TRQB8bf8MweOP8AoI+G/wDwKn/+M0q/sw+Nwf8AkI+G/wDwKn/+M19kUUAfJC/s6eNhGqfavDRwMZ+2T/8Axig/s6eN8gi78NAD/p8n/wDjFfW9FAHySP2dfHAP/H34a/8AAyf/AOMU8fs8eNwMfavDX/gbP/8AGK+s6KAPlOP4AeN1zm48NHIx/wAfs/8A8YqUfAXxv/z28Nf+B0//AMj19T0UAfLQ+BHjjvN4bP8A2/T/APyPTv8AhRXjf/nr4aP/AG/T/wDyPX1HRQB8x3vwQ8bXOivYbvDalm3eZ/aE5/T7P/WuZP7NHjjtf+G//Aqf/wCM19hUUAfHh/Zm8cE/8hDw3/4FT/8AxmrcX7OfjdIVj+2eGzjoftk//wAYr64ooA+RB+zf43Bz9t8N/wDgZP8A/GKS8/Zv8b3GzF74bQqMH/TJzn/yBX15RQB8d/8ADMvjf/oIeG8f9fU//wAZoH7MvjcHP2/w1/4FT/8AxmvsSigD48/4Zn8b/wDP/wCG/wDwKn/+M0f8Mz+N+1/4b/8AAuf/AOMV9h0UAfHn/DM/jjH/ACEPDf8A4FT/APxmj/hmfxvtx9v8Nex+1T5/9E19h0UAcZ8HvC994M+HWlaDq0ttLe2pnMj2zM0Z3zSSDBZVPRx2HOaK7OigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Comminuted Salter-Harris IV fracture of the distal femur in a 14-year-old boy involved in a motor vehicle collision.",
"    <br/>",
"    (B) Appearance six months after open reduction and internal fixation using cannulated screws in the metaphysis and epiphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Price CT, Herrera-Soto J. Extra-articular injuries of the knee. In: Rockwood and Wilkins' Fractures in Children, 7th edition, Beaty JH, Kasser JR. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21347=[""].join("\n");
var outline_f20_54_21347=null;
var title_f20_54_21348="Anal rectal anatomy lateral view";
var content_f20_54_21348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F54523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F54523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Anal rectal anatomy, lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 476px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration depicts the lateral view of the antomy of the anus and rectum. Note the superficial and deep external sphincter muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21348=[""].join("\n");
var outline_f20_54_21348=null;
var title_f20_54_21349="Giant bilateral bullae PA";
var content_f20_54_21349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82207&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a giant bilateral bullae in young smoker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows large bilateral collections of gas devoid of any vascular structures with a sharp edge concave laterally, which is a differentiating feature from pneumothorax. The functioning lung is retracted to the bases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21349=[""].join("\n");
var outline_f20_54_21349=null;
var title_f20_54_21350="Structure of the insulin receptor extra-cellular domain";
var content_f20_54_21350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82549&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Structure of the insulin receptor extra-cellular domain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The receptor domains in all panels are colored as follows: L1 domain, magenta; cysteine rich domain, yellow; L2 domain, green; FnIII-1 domain, red; FnIII-2 domain, cyan; FnIII-3 domain, purple.",
"    <br>",
"     (A) Domain structure of the receptor monomer: The extra-cellular receptor monomer is depicted in ribbon representation to show secondary structural elements. The Insert Domain which is not visualized in the crystal structure is designated by the locations of its N- and C-termini.",
"     <br>",
"      (B) Receptor dimer: This illustrates the inverted V conformation. The monomer in front is shown in tube representation and that in the rear in surface representation. The position of the major inter &alpha;-cystine (Cys 524-Cys 524) is shown.",
"      <br>",
"       (C) Insulin binding sites: Side view of dimer rotated 90 degrees counter-clockwise around the vertical axis from the view in B. Receptor monomers are shown in ribbon representation and the heavy black lines designate the approximate locations of the insulin binding sites. The cell membrane would be located at the bottom of each panel.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Courtesy of Dr. Jonathan Whittaker, based on the coordinates of PDB structure 2DTG.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21350=[""].join("\n");
var outline_f20_54_21350=null;
var title_f20_54_21351="Pheochromocytoma in genetic disorders";
var content_f20_54_21351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pheochromocytoma in genetic disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21351/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21351/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/54/21351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma is a rare neoplasm, probably occurring in less than 0.2 percent of patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Pheochromocytoma in genetic disorders will be reviewed here. The diagnosis and treatment of pheochromocytoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=see_link\">",
"     \"Treatment of pheochromocytoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHEOCHROMOCYTOMA IN GENETIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most catecholamine-secreting tumors are sporadic. However, some patients (15 to 20 percent) have the disease as part of a familial disorder; in these patients, the catecholamine-secreting tumors are more likely to be bilateral adrenal pheochromocytomas or paragangliomas.",
"    <br/>",
"   </p>",
"   <p>",
"    Hereditary catecholamine-secreting tumors typically present at a younger age than sporadic neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ]. Sporadic pheochromocytoma is usually diagnosed on the basis of symptoms or an incidental discovery on computed imaging, whereas syndromic pheochromocytoma is frequently diagnosed earlier in the course of disease because of biochemical surveillance or genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Familial pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several familial disorders associated with pheochromocytoma, all of which have autosomal dominant inheritance: von Hippel-Lindau (VHL) syndrome, MEN2 and, less commonly, neurofibromatosis type 1.",
"   </p>",
"   <p>",
"    The approximate frequency of pheochromocytoma in these disorders is 10 to 20 percent in VHL syndrome, 50 percent in MEN2, and 0.1 to 5.7 percent with neurofibromatosis type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071222\">",
"    <span class=\"h3\">",
"     VHL syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VHL phenotype includes pheochromocytoma (frequently bilateral), paraganglioma (mediastinal, abdominal, pelvic), hemangioblastoma (involving the cerebellum, spinal cord, or brain stem), retinal angioma, clear cell renal cell carcinoma, pancreatic neuroendocrine tumors, endolymphatic sac tumors of the middle ear, serous cystadenomas of the pancreas, and papillary cystadenomas of the epididymis and broad ligament.",
"    <br/>",
"   </p>",
"   <p>",
"    The VHL tumor suppressor gene, located on chromosome 3p25-26, encodes a protein that regulates hypoxia-induced proteins. More than 300 germline VHL mutations have been identified that lead to loss of function of the VHL protein.",
"   </p>",
"   <p>",
"    Patients with VHL syndrome may be divided into two groups: type I and type II. Patients from kindreds with type I syndrome do not develop pheochromocytoma, whereas patients with kindreds with type II syndrome are at high risk for developing pheochromocytoma. In addition, kindreds with type II VHL syndrome are subdivided into type IIA (low risk for renal cell carcinoma), type IIB (high risk for renal cell carcinoma), and type IIC (pheochromocytomas only). Genotype-phenotype correlations have been documented for this disorder and specific mutations are associated with particular patterns of tumor formation. In up to 98 percent of cases, pheochromocytoma is associated with missense mutations (rather than truncating or null mutations) in the VHL gene. Certain missense mutations appear to be associated with the type IIC presentation of VHL (pheochromocytomas only). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108070739\">",
"    <span class=\"h3\">",
"     MEN2",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN 2A is characterized by medullary thyroid cancer (MTC) in all patients, pheochromocytoma in 50 percent, primary hyperparathyroidism in 20 percent, and cutaneous lichen amyloidosis in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    Most mutations in MEN 2A kindreds (93 to 98 percent) involved one of six cysteine residues in the cysteine-rich region of the RET protein&rsquo;s extracellular domain encoded in RET exons 10 (codons 609, 611, 618, and 620) or 11 (codons 630 or 634). Eighty-five percent of individuals with MEN 2A have a mutation in codon 634, particularly p.Cys634Arg. Aganglionic megacolon (Hirschsprung&rsquo;s disease) can occur in families with mutations of codons 618 and 620 in exon 10. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MEN type 2B represents approximately 5 percent of all MEN2 cases and the phenotype is characterized by MTC in all patients, pheochromocytoma in 50 percent, mucocutaneous neuromas (typically involving the tongue, lips, and eyelids) in most patients, skeletal deformities (eg, kyphoscoliosis or lordosis), joint laxity, myelinated corneal nerves, and intestinal ganglioneuromas (hyperganglionic megacolon).",
"    <br/>",
"    <br/>",
"    MEN 2B-associated tumors are caused by mutations in the RET protein&rsquo;s intracellular domain. A single methionine to threonine missense mutation in exon 16 (p.Met918Thr) is responsible for more than 95 percent of MEN 2B cases. Another mutation, alanine to phenylalanine at codon 883 in exon 15, has been found in 4 percent of MEN 2B kindreds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Phenotype of MEN2 versus VHL syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and biochemical characteristics of pheochromocytomas in MEN2 versus the VHL syndrome were investigated in a study of 19 and 30 patients with these disorders, respectively; the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN2 patients were more symptomatic with a higher incidence of hypertension (primarily paroxysmal).",
"     </li>",
"     <li>",
"      MEN2 patients all had elevated serum concentrations of metanephrine (the epinephrine metabolite), while all VHL patients had elevated serum normetanephrine concentrations (the norepinephrine metabolite).",
"     </li>",
"     <li>",
"      Compared to MEN2 tumors, VHL tumors had lower total tissue contents of catecholamines and expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis. They also had much lower expression of phenylethanolamine N-methyltransferase (PNMT, the enzyme that converts norepinephrine to epinephrine) and tissue stores of epinephrine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the difference in clinical phenotype (MEN2 patients are more symptomatic) can be explained by the differences in biochemical phenotype (MEN2 patients, due to the higher PNMT and TH expression, have an adrenergic phenotype with higher rates of catecholamine biosynthesis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108070768\">",
"    <span class=\"h3\">",
"     Neurofibromatosis type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also an association with neurofibromatosis type 1 (NF1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/5\">",
"     5",
"    </a>",
"    ], an autosomal dominant disorder characterized by neurofibromas, multiple cafe au lait spots, axillary and inguinal freckling, iris hamartomas (Lisch nodules), bony abnormalities, central nervous system gliomas, pheochromocytoma and paraganglioma, macrocephaly, and cognitive deficits. The expression of these features is variable. Approximately 2 percent of patients with NF1 develop catecholamine-secreting tumors. In these patients, the catecholamine-secreting tumor is usually a solitary benign adrenal pheochromocytoma, occasionally bilateral adrenal pheochromocytoma, and rarely a peri adrenal abdominal paraganglioma.",
"   </p>",
"   <p>",
"    Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made based upon clinical phenotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108070829\">",
"    <span class=\"h3\">",
"     Other mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;More genetic causes of pheochromocytoma and paraganglioma are yet to be discovered. For example, in 2010, loss of function mutations in the",
"    <span class=\"nowrap\">",
"     FP/TMEM127",
"    </span>",
"    gene were identified in patients with familial and sporadic pheochromocytoma, but not paraganglioma. TMEM127 is a negative regulator of mammalian target of rapamycin (mTOR) effector proteins. In a study of 990 individuals with pheochromocytoma or paraganglioma, germline mutations in",
"    <span class=\"nowrap\">",
"     FP/TMEM127",
"    </span>",
"    were identified in 20 individuals with adrenal tumors, five of whom had a family history of pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/12\">",
"     12",
"    </a>",
"    ]. Among 547 patients who presented with sporadic pheochromocytoma (unilateral adrenal tumor with negative family history), 11 (2 percent) had",
"    <span class=\"nowrap\">",
"     FP/TMEM127",
"    </span>",
"    mutations.",
"   </p>",
"   <p>",
"    In 2011, loss of function mutations in the MAX gene were identified in patients with familial pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/13\">",
"     13",
"    </a>",
"    ]. In an initial study of three individuals with familial pheochromocytoma (who did not have mutations in any of the nine previously described susceptibility genes), MAX germline mutations were found. MAX is a component of the MYC-MAX-MXD1 transcription factors that regulate cell proliferation, differentiation, and apoptosis. In an extension of this study, MAX mutations were found in 5 of 59 patients (8.5 percent) with suspected familial pheochromocytoma (based on age of onset &lt;30 years, bilateral pheochromocytoma, or positive family history) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial paraganglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial paraganglioma is an autosomal dominant disorder characterized by paragangliomas that are located most often in the head and neck but also in the thorax, abdomen, pelvis, and urinary bladder.",
"   </p>",
"   <p>",
"    The occurrence of catecholamine hypersecretion in a patient with familial paraganglioma depends upon tumor location; approximately 5 percent of head and neck paragangliomas and more than 50 percent of abdominal paragangliomas produce hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"     \"Paragangliomas of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most cases of familial paraganglioma are caused by mutations in the succinate dehydrogenase (SDH; succinate:ubiquinone oxidoreductase) subunit genes (SDHB, SDHC, SDHD, SDHAF2, SDHA), which compose portions of mitochondrial complex II [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. Mitochondrial complex II is a tumor suppressor gene involved in the electron transport chain and the tricarboxylic-acid (TCA) cycle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most germline mutations in SDHD, SDHAF2, and SDHC have been identified in multi-generational families with biochemically silent head and neck paragangliomas [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .) In patients with SDHD and SDHAF2 mutations, penetrance depends on the mutation's parent of origin [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/18,19,22\">",
"       18,19,22",
"      </a>",
"      ]. Hence, the disease is not manifested when the mutation is inherited from the mother but is highly penetrant when inherited from the father. This phenomenon is known as maternal imprinting.",
"     </li>",
"     <li>",
"      The SDH gene mutation detection rate for individuals with familial paraganglioma is currently unknown.",
"     </li>",
"     <li>",
"      SDHB mutations have been associated with families that have abdominal, pelvic, and thoracic catecholamine-secreting familial paraganglioma.",
"     </li>",
"     <li>",
"      SDHB mutation carriers develop disease early (mean age at diagnosis was 34 years, with a range of 10 to 62 years in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/24\">",
"       24",
"      </a>",
"      ], and are more likely to develop malignant paragangliomas and additional neoplasms (eg, renal cell carcinoma) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SDHD, SDHC, SDHAF2, and SDHB germline mutation screening are commercially available and staged testing (eg, starting with SDHD, SDHC, and SDHAF2 mutation analysis in patients with head and neck paragangliomas and SDHB and SDHC mutation analysis in patients with paragangliomas below the neck) should be considered in all patients with paraganglioma [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sporadic pheochromocytoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107339676\">",
"    <span class=\"h3\">",
"     Frequency of genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the frequency of the above genetic abnormalities in patients with sporadic and nonsyndromic pheochromocytoma. Data have been conflicting, with frequency estimates ranging from 13 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3,25,26\">",
"     3,25,26",
"    </a>",
"    ]. In one series of 271 patients with apparent sporadic pheochromocytoma from population-based registries in Germany and Poland who were tested for germline mutations in the four genes described above that have been associated with pheochromocytoma (VHL, RET, SDHD, and SDHB [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ]), the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mutation was identified in 66 (24 percent) &mdash; 30 VHL (11 percent of patients overall), 13 RET (4.8 percent), 12 SDHB (4.4 percent), and 11 SDHD (4 percent). All but four of the patients had no signs or symptoms of the diseases associated with the specific mutation. Possible explanations for sporadic and frequently localized disease in these patients include spontaneous mutation, decreased penetrance, maternal imprinting, and gene-gene or gene-environment interactions.",
"     </li>",
"     <li>",
"      Although all had a negative family history at entry, the family history became positive at last follow-up in 12 of 30 with a VHL mutation, 6 of 13 with a RET mutation, and none of 23 with a SDH complex mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the relatively high frequency of mutations noted in this report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ], other studies have reported a lower frequency. As an example, in a subsequent study based upon a larger group of patients with apparently sporadic pheochromocytoma (n = 545), the frequency of mutations was considerably lower (12.7 percent; 69 of 545 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other series have also reported a lower frequency of VHL, RET, and SDHD mutations when compared with the study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 11 of 337 had a VHL mutation (3.3 percent) in three studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/25,27,28\">",
"       25,27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Only 1 of 414 patients (0.2 percent) had a RET mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/25,27-30\">",
"       25,27-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one series, only 2 of 102 (2 percent) of patients with apparently sporadic pheochromocytoma had a SDHD mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These markedly discrepant findings could be due in part to differences in the populations studied and perhaps to ascertainment bias toward inherited disease in registry-based cases. For example, although the overall frequency of a genetic mutation in one series was 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ], only 31 of the 66 patients with a gene mutation (11.4 percent of the study population) had a unilateral adrenal tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ]. The remaining patients had multifocal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extraadrenal tumors and, therefore, should not have been categorized at baseline as having &ldquo;apparently sporadic pheochromocytoma&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071132\">",
"    <span class=\"h4\">",
"     Implications for genetic screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the above data, it appears that the yield of routine genetic testing in patients with apparently sporadic adrenal pheochromocytoma (defined by unilateral disease, a negative family history, and no syndromic signs of symptoms) is very low, particularly for MEN2. Nevertheless, clinicians should have an increased index of suspicion for a hereditary syndrome.",
"   </p>",
"   <p>",
"    All patients should be monitored for findings of a genetic syndrome, some of which can be detected on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/6,32\">",
"     6,32",
"    </a>",
"    ], including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retinal angiomas in VHL syndrome",
"     </li>",
"     <li>",
"      A thyroid mass in MEN2",
"     </li>",
"     <li>",
"      Cafe au lait spots, axillary and inguinal freckling, and subcutaneous neurofibromas in neurofibromatosis type 1",
"     </li>",
"     <li>",
"      A neck mass in paraganglioma syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation and monitoring of first-degree relatives is also important, since each of these disorders is transmitted as an autosomal dominant trait.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETIC SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing should be considered if a patient has one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraganglioma",
"     </li>",
"     <li>",
"      Bilateral adrenal pheochromocytoma",
"     </li>",
"     <li>",
"      Unilateral adrenal pheochromocytoma and a family history of",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"     </li>",
"     <li>",
"      Unilateral adrenal pheochromocytoma onset at a young age (eg, &lt;45 years), or",
"     </li>",
"     <li>",
"      Other clinical findings suggestive of one of the previously discussed syndromic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An asymptomatic person at risk for disease on the basis of family history of",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    should have genetic testing only if an affected family member has a known mutation.",
"   </p>",
"   <p>",
"    Genetic testing can be complex; testing one family member has implications for related individuals. Genetic counseling is recommended to help families understand the implications of genetic test results, to coordinate testing of at-risk individuals, and to help families work through the psychosocial issues that may arise before, during, or after the testing process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107340331\">",
"    <span class=\"h2\">",
"     Suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the considerable cost of genetic testing, using a stepwise approach based on each patient's clinical scenario is prudent. The clinician may obtain a list of clinically approved molecular genetic diagnostic laboratories at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     GeneTests",
"    </a>",
"    ; genetic screening for mutations in RET, VHL, NF-1, TMEM127, SDHD, SDHC, SDHB, and SDHAF2 is currently available. The First International Symposium on Pheochromocytoma concluded that it is not cost effective to test for every disease-causing gene in every case, and suggested that the secretion profile, patient age, focality of primary tumor, and prior history be included in a genetic testing algorithm [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A sequential genetic testing algorithm, based upon these findings, and incorporating metaanalysis data and tailored for cost efficacy has been proposed, and is outlined in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef86406 \" href=\"UTD.htm?8/63/9214\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the field of genetic testing is rapidly evolving, and at many clinical laboratories sequential genetic testing is no longer done, as it is less expensive to order an analysis of all SDHx mutations as a package. Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made based upon clinical phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071162\">",
"    <span class=\"h3\">",
"     Bilateral adrenal pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient presents with bilateral adrenal pheochromocytoma, but without a history of MTC or goiter, tests for mutations in the following genes should be ordered sequentially: VHL, RET, SDHD, SDHB, TMEM127. The biochemical phenotype (eg, adrenergic [MEN 2] or noradrenergic [VHL]) can also be used to guide genetic testing. If a mutation is identified at any point in the testing algorithm, no further testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071177\">",
"    <span class=\"h3\">",
"     Young age at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21351/abstract/35\">",
"     35",
"    </a>",
"    ] of age or less presents with apparent sporadic unilateral adrenal pheochromocytoma, tests for mutations in the following genes should be ordered sequentially: VHL, RET, SDHB, SDHD, TMEM127. If a mutation is identified at any point in the testing algorithm, no further testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071190\">",
"    <span class=\"h3\">",
"     Abdominal paraganglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient has a catecholamine-secreting abdominal paraganglioma, tests for mutations in the following genes should be ordered sequentially: SDHB, SDHD, VHL. If a mutation is identified at any point in the testing algorithm, no further testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071197\">",
"    <span class=\"h3\">",
"     Skull-base or neck paraganglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient has a skull-base or neck paraganglioma, tests for mutations in the following genes should be ordered sequentially: SDHD, SDHC, SDHAF2, SDHB. In some clinical laboratories it may be less expensive to order an analysis of all SDH mutations as a package. If kindred show a typical maternal imprinting inheritance pattern, then SDHD and SDHAF2 should be ordered. If a mutation is identified at any point in the testing algorithm, no further testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82948689\">",
"    <span class=\"h3\">",
"     Known mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional evaluation for patients with an identified mutation or syndrome (VHL syndrome, MEN2, neurofibromatosis type 1) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108071204\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Most catecholamine-secreting tumors are sporadic. However, some patients (15 to 20 percent) have the disease as part of a familial disorder; in these patients the catecholamine-secreting tumors are more likely to be bilateral adrenal pheochromocytomas or paragangliomas.",
"   </p>",
"   <p>",
"    There are several familial disorders associated with pheochromocytoma, all of which have autosomal dominant inheritance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Von Hippel-Lindau syndrome, associated with mutations in the VHL tumor suppressor gene (see",
"      <a class=\"local\" href=\"#H108071222\">",
"       'VHL syndrome'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 2, which is associated with mutations in the RET-proto-oncogene (see",
"      <a class=\"local\" href=\"#H108070739\">",
"       'MEN2'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Pheochromocytoma is also seen, albeit rarely, with neurofibromatosis type 1, due to mutations in the NF1 gene (see",
"      <a class=\"local\" href=\"#H108070768\">",
"       'Neurofibromatosis type 1'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The approximate frequency of pheochromocytoma in these disorders is 10 to 20 percent in VHL syndrome, 50 percent in MEN2, and 0.1 to 5.7 percent with neurofibromatosis type 1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases of familial paraganglioma are caused by mutations in the succinate dehydrogenase (SDH; succinate:ubiquinone oxidoreductase) subunit genes (SDHB, SDHC, SDHD, SDHAF2, SDHA). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Familial paraganglioma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Genetic testing should be considered if a patient has one or more of the following (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Genetic screening'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraganglioma",
"     </li>",
"     <li>",
"      Bilateral adrenal pheochromocytoma",
"     </li>",
"     <li>",
"      Unilateral adrenal pheochromocytoma and a family history of",
"      <span class=\"nowrap\">",
"       pheochromocytoma/paraganglioma",
"      </span>",
"     </li>",
"     <li>",
"      Unilateral adrenal pheochromocytoma onset at a young age (eg, &lt;45 years), or",
"     </li>",
"     <li>",
"      Other clinical findings suggestive of one of the previously discussed syndromic disorders (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Genetic screening'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An asymptomatic person at risk for disease on the basis of family history of",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    should have genetic testing only if an affected family member has a known mutation.",
"   </p>",
"   <p>",
"    The specific genetic tests ordered should be based upon the patient presentation (see",
"    <a class=\"local\" href=\"#H107340331\">",
"     'Suggested approach'",
"    </a>",
"    above).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/1\">",
"      Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore) 1991; 70:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/2\">",
"      Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/3\">",
"      Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/4\">",
"      Pawlu C, Bausch B, Reisch N, Neumann HP. Genetic testing for pheochromocytoma-associated syndromes. Ann Endocrinol (Paris) 2005; 66:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/5\">",
"      Walther MM, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/6\">",
"      Dluhy RG. Pheochromocytoma--death of an axiom. N Engl J Med 2002; 346:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/7\">",
"      Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/8\">",
"      Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/9\">",
"      Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/10\">",
"      Neumann HP, Vortmeyer A, Schmidt D, et al. Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med 2007; 357:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/11\">",
"      Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/12\">",
"      Yao L, Schiavi F, Cascon A, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 2010; 304:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/13\">",
"      Comino-M&eacute;ndez I, Gracia-Azn&aacute;rez FJ, Schiavi F, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/14\">",
"      Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86:5210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/15\">",
"      Niemann S, M&uuml;ller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000; 26:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/16\">",
"      Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001; 69:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/17\">",
"      Lee SC, Chionh SB, Chong SM, Taschner PE. Hereditary paraganglioma due to the SDHD M1I mutation in a second Chinese family: a founder effect? Laryngoscope 2003; 113:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/18\">",
"      Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/19\">",
"      Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/20\">",
"      Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/21\">",
"      Young WF Jr, Abboud AL. Editorial: paraganglioma--all in the family. J Clin Endocrinol Metab 2006; 91:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/22\">",
"      Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/23\">",
"      Schiavi F, Boedeker CC, Bausch B, et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/24\">",
"      Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) 2008; 69:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/25\">",
"      Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63:5615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/26\">",
"      Gimenez-Roqueplo AP, Lehnert H, Mannelli M, et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 2006; 65:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/27\">",
"      Brauch H, Hoeppner W, J&auml;hnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997; 82:4101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/28\">",
"      Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005; 23:8812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/29\">",
"      Bar M, Friedman E, Jakobovitz O, et al. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clin Endocrinol (Oxf) 1997; 47:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/30\">",
"      Arnold A. RET mutation screening in sporadic pheochromocytoma. J Clin Endocrinol Metab 1996; 81:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/31\">",
"      Dannenberg H, van Nederveen FH, Abbou M, et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. J Clin Oncol 2005; 23:1894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/32\">",
"      Jim&eacute;nez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 2006; 91:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/33\">",
"      Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010; 39:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/34\">",
"      Welander J, S&ouml;derkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18:R253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21351/abstract/35\">",
"      Erlic Z, Rybicki L, Peczkowska M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res 2009; 15:6378.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 133 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-89.32.226.102-CE97BA6EE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21351=[""].join("\n");
var outline_f20_54_21351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H108071204\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHEOCHROMOCYTOMA IN GENETIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Familial pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108071222\">",
"      - VHL syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108070739\">",
"      - MEN2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Phenotype of MEN2 versus VHL syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108070768\">",
"      - Neurofibromatosis type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108070829\">",
"      - Other mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sporadic pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H107339676\">",
"      - Frequency of genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108071132\">",
"      Implications for genetic screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETIC SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107340331\">",
"      Suggested approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108071162\">",
"      - Bilateral adrenal pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108071177\">",
"      - Young age at presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108071190\">",
"      - Abdominal paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108071197\">",
"      - Skull-base or neck paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82948689\">",
"      - Known mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108071204\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/133\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/133|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/63/9214\" title=\"algorithm 1\">",
"      Proposed genetic testing algorithm for pts with PCC or PGL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_54_21352="Hydrocortisone (topical): Drug information";
var content_f20_54_21352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=see_link\">",
"    see \"Hydrocortisone (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=see_link\">",
"    see \"Hydrocortisone (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8116177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ala-Cort;",
"     </li>",
"     <li>",
"      Ala-Scalp;",
"     </li>",
"     <li>",
"      Anu-med HC;",
"     </li>",
"     <li>",
"      Anucort-HC&trade;;",
"     </li>",
"     <li>",
"      Anusol-HC&reg;;",
"     </li>",
"     <li>",
"      Aquanil HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Beta-HC&reg; [OTC];",
"     </li>",
"     <li>",
"      Caldecort&reg; [OTC];",
"     </li>",
"     <li>",
"      Colocort&reg;;",
"     </li>",
"     <li>",
"      Cortaid&reg; Advanced [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Intensive Therapy [OTC];",
"     </li>",
"     <li>",
"      Cortaid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      CortiCool&reg; [OTC];",
"     </li>",
"     <li>",
"      Cortifoam&reg;;",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Healing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Hydratensive Soothing [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Intensive Healing Eczema [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Cooling Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Easy Relief [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength Intensive Healing Formula [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Cortizone-10&reg; Plus Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Dermarest&reg; Eczema Medicated [OTC];",
"     </li>",
"     <li>",
"      Hemril&reg; -30;",
"     </li>",
"     <li>",
"      Hydrocortisone Plus [OTC];",
"     </li>",
"     <li>",
"      HydroSKIN&reg; [OTC];",
"     </li>",
"     <li>",
"      Locoid Lipocream&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Pandel&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; HC;",
"     </li>",
"     <li>",
"      Preparation H&reg; Hydrocortisone [OTC];",
"     </li>",
"     <li>",
"      Procto-Pak&trade;;",
"     </li>",
"     <li>",
"      Proctocort&reg;;",
"     </li>",
"     <li>",
"      ProctoCream&reg;-HC;",
"     </li>",
"     <li>",
"      Proctosol-HC&reg;;",
"     </li>",
"     <li>",
"      Proctozone-HC 2.5%&trade;;",
"     </li>",
"     <li>",
"      Recort [OTC];",
"     </li>",
"     <li>",
"      Scalpana [OTC];",
"     </li>",
"     <li>",
"      Texacort&trade;;",
"     </li>",
"     <li>",
"      U-Cort&reg;;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8116178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aquacort&reg;;",
"     </li>",
"     <li>",
"      Cortamed&reg;;",
"     </li>",
"     <li>",
"      Cortenema&reg;;",
"     </li>",
"     <li>",
"      Cortifoam&trade;;",
"     </li>",
"     <li>",
"      Emo-Cort&reg;;",
"     </li>",
"     <li>",
"      Hycort&trade;;",
"     </li>",
"     <li>",
"      Hyderm;",
"     </li>",
"     <li>",
"      HydroVal&reg;;",
"     </li>",
"     <li>",
"      Locoid&reg;;",
"     </li>",
"     <li>",
"      Prevex&reg; HC;",
"     </li>",
"     <li>",
"      Sarna&reg; HC;",
"     </li>",
"     <li>",
"      Westcort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8116184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Rectal;",
"     </li>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8116329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatosis:",
"     </b>",
"     Topical: Apply thin film to affected area 2-4 times/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocortisone probutate (Pandel&reg;): Topical: Apply thin film to affected area 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocortisone valerate (Westcort&reg;): Topical: Apply thin film to affected area 2-3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      External anal and genital itching:",
"     </b>",
"     Topical (OTC labeling): Apply to clean dry skin up to 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hemorrhoids:",
"     </b>",
"     Rectal: One suppository (30 mg) twice daily for 2 weeks. For severe cases of proctitis, 1 suppository 3 times/day or 2 suppositories twice daily may be needed. For factitial proctitis, duration of treatment may be up to 6-8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ulcerative colitis:",
"     </b>",
"     Rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foam: One applicatorful (80 mg) 1-2 times/day for 2-3 weeks, and then every other day thereafter; use lowest dose to maintain clinical response; taper dose to discontinue long-term therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: One enema (100 mg) every night for 21 days or until remission (clinical improvement may precede improvement of mucosal integrity); 2-3 months of therapy may be required; taper dose to discontinue long-term therapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8116328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=see_link\">",
"      see \"Hydrocortisone (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atopic dermatitis:",
"     </b>",
"     Topical: Children &ge;3 months: Hydrocortisone butyrate (Locoid Lipocream&reg;): Apply thin film to affected area twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dermatosis:",
"     </b>",
"     Topical: Apply thin film to affected area 2-4 times/day. Products labeled for OTC use (self-medication) should not be used in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      External anal and genital itching:",
"     </b>",
"     Topical: Children &ge;12 years: (OTC labeling): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8116330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8116386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, rectal, as acetate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortifoam&reg;: 10% (15 g) [90 mg/applicator]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetate: 1% (28.4 g, 454 g); 2% (43 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U-Cort&reg;: 1% (28 g) [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as acetate [strength expressed as base]: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as base: 0.5% (28.4 g, 30 g); 1% (1 g, 1.5 g, 15 g, 28.4 g, 30 g, 114 g, 454 g); 2.5% (20 g, 28 g, 28.35 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ala-Cort: 1% (28.4 g, 85.2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anusol-HC&reg;: 2.5% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caldecort&reg;: 1% (28.4 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Advanced: 1% (42 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (37 g, 56 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Maximum Strength: 1% (14 g, 28 g, 37 g, 56 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength: 1% (15 g, 28 g, 56 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Intensive Healing Formula: 1% (28 g, 56 g) [contains aloe, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Plus Maximum Strength: 1% (28 g, 56 g) [contains aloe, vitamin A, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydrocortisone Plus: 1% (28.4 g) [contains aloe, vitamin A, vitamin D, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HydroSKIN&reg;: 1% (28 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preparation H&reg; Hydrocortisone: 1% (26 g) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procto-Pak&trade;: 1% (28.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctocort&reg;: 1% (28.35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProctoCream&reg;-HC: 2.5% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctosol-HC&reg;: 2.5% (28.35 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctozone-HC 2.5%&trade;: 2.5% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recort: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as butyrate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid Lipocream&reg;: 0.1% (15 g [DSC], 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as probutate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pandel&reg;: 0.1% (15 g, 45 g, 80 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as valerate: 0.2% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CortiCool&reg;: 1% (0.9 g, 42.5 g) [contains ethanol 20%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Cooling Relief: 1% (28 g) [contains aloe, ethanol 15%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength Easy Relief: 1% (36 mL) [contains aloe, ethanol 45%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scalpana: 1% (85.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as base: 1% (114 g, 118 mL); 2.5% (59 mL, 60 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ala-Scalp: 2% (29.6 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aquanil HC&reg;: 1% (120 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Beta-HC&reg;: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (98 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Hydratensive Healing: 1% (113 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Hydratensive Soothing: 1% (113 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Intensive Healing Eczema: 1% (99 g) [contains aloe, vitamin A, vitamin C, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermarest&reg; Eczema Medicated: 1% (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HydroSKIN&reg;: 1% (118 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as base [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediaderm&trade; HC: 2% (29.6 mL) [contains benzalkonium chloride, isopropyl alcohol; packaged with protective emollient]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as butyrate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as acetate [strength expressed as base]: 1% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as base: 0.5% (30 g); 1% (25 g, 30 g, 110 g, 430 g, 454 g); 2.5% (20 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Maximum Strength: 1% (28 g, 37 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortizone-10&reg; Maximum Strength: 1% (28 g, 56 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as butyrate: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (15 g, 45 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as valerate: 0.2% (15 g, 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Westcort&reg;: 0.2% (15 g [DSC], 45 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as acetate [micronized]: USP: 100% (10 g, 25 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Texacort&trade;: 2.5% (30 mL) [contains ethanol 48.8%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as base [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortaid&reg; Intensive Therapy: 1% (59 mL) [contains ethanol 45%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as butyrate: 0.1% (20 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Locoid&reg;: 0.1% (20 mL, 60 mL) [contains isopropyl alcohol 50%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal, as acetate: 25 mg (12s); 30 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anu-med HC: 25 mg (12s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anucort-HC&trade;: 25 mg (12s, 24s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anusol-HC&reg;: 25 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemril&reg; -30: 30 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proctocort&reg;: 30 mg (12s, 24s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, rectal, as base: 100 mg/60 mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colocort&reg;: 100 mg/60 mL (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cortenema&reg;: 100 mg/60 mL (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8116182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam (acetate), cream (probutate),  gel (base),  liquid (base), lotion (base), lotion (butyrate), solution (base)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8116359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     Topical cream, lotion, ointment: Apply a thin film to clean, dry skin and rub in gently.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Rectal foam: Shake vigorously for 5-10 seconds prior to use. Do not remove cap during use. Hold container upright to fill applicator. Gently insert applicator tip into anus. Only use applicator provided by manufacturer; do not insert any part of the aerosol container in the anus. Clean applicator after each use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Rectal suppository: Remove foil from rectal suppository and insert pointed end first. Avoid handling unwrapped suppository for too long.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Rectal suspension: Shake bottle well. Remove protective sheath from applicator tip. Lie on left side with left leg extended and right leg flexed forward. Gently insert lubricated applicator tip into rectum, pointed slightly toward navel. Grasp bottle firmly and squeeze slowly to instill the medication. After administering, withdraw and discard the used unit. Remain in position for at least 30 minutes. Retain the enema all night if possible.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8116252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of inflammation of corticosteroid-responsive dermatoses (low and medium potency topical corticosteroid); adjunctive treatment of ulcerative colitis; mild-to-moderate atopic dermatitis; inflamed hemorrhoids, postirradiation (factitial) proctitis, and other inflammatory conditions of anorectum and pruritus ani",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8116165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydrochlorothiazide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Anusol&reg; may be confused with Anusol-HC&reg;, Aplisol&reg;, Aquasol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cortizone&reg; may be confused with cortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydrochlorothiazide)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hytone&reg; may be confused with Vytone&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Proctocort&reg; may be confused with ProctoCream&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nutracort [multiple international markets] may be confused with Nitrocor brand name of nitroglycerin [Italy, Russia, and Venezuela]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8116263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined. Local adverse events presented. Adverse events similar to those observed with systemic absorption are also observed, especially following rectal use. Refer to the Hydrocortisone (Systemic) monograph for details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream, ointment:",
"     </b>",
"     Acneiform eruptions, burning, dryness, folliculitis, hypertrichosis, hypopigmentation, irritation, itching, maceration of skin, miliaria, perioral dermatitis, secondary infection, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema:",
"     </b>",
"     Burning, pain, rectal bleeding",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppositories:",
"     </b>",
"     Allergic contact dermatitis, burning, dryness, folliculitis, hypopigmentation, itching, secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8116259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Rectal enema: Systemic fungal infections; ileocolostomy during the immediate or early postoperative period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Cortifoam&reg; is also contraindicated with obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses, extensive fistulas and sinus tracts (other enemas are labeled to be used with caution).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8116260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high-dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic events: Prolonged use of corticosteroids may produce cataracts or glaucoma and may enhance the establishment of secondary ocular infections Use caution with ocular herpes simplex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use caution with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: With severe ulcerative colitis, it may be hazardous to delay surgery while waiting for response to treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects associated with systemic absorption, topical corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Avoid use of topical preparations with occlusive dressings or on weeping or exudative lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rectal enema: Damage to the rectal wall may occur from improper or careless insertion of the enema tip.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Contact healthcare provider if condition worsens, symptoms persist for &gt;7 days, or rectal bleeding occurs. Consult with healthcare provider prior to use if needed for diaper rash.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8116282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8116283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8116254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8116255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8116257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8116258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemically administered corticosteroids are excreted in breast milk and endogenous hydrocortisone is also found in human milk. It is not known if systemic absorption following topical administration results in detectable quantities in human milk. Use with caution while breast-feeding; do not apply to nipples (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8116388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Anusol-HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (30 g): $118.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortaid Advanced 12 Hour External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (42 g): $5.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortaid Maximum Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (14 g): $2.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortizone-10 Intensive Healing External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortizone-10 Plus External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Cortizone-10/Aloe External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $4.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Demarest Dricort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $2.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Gynecort 10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $3.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydrocortisone Acetate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.4 g): $0.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydrocortisone Butyrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $25.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydrocortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30 g): $2.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.4 g): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (30 g): $11.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Hydrocortisone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (45 g): $32.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (HydroSKIN External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $2.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lanacort 10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 g): $2.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Locoid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $65.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Locoid Lipocream External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (45 g): $283.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Medi-Cortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $2.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Monistat Soothing Care External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $3.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Pandel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (45 g): $240.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Preparation H Hydrocortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (26 g): $6.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Procto-Pak Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.4 g): $48.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Proctocort Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.35 g): $140.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Proctocream HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (30 g): $78.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Proctosol HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (28.35 g): $24.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Proctozone-HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (30 g): $24.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (U-Cort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-10% (28.35 g): $35.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Colocort Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/60 mL (60 mL): $12.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Cortenema Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/60 mL (60 mL): $12.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Hydrocortisone Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/60 mL (60 mL): $11.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Cortifoam Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (15 g): $324.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Itch-X External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (88.7 mL): $6.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (CortAlo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (43 g): $39.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Corticool External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (42.53 g): $4.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Cortizone-10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (First-Hydrocortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (60 g): $90.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Instacort 10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $4.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (MG217 Psoriasis Anit-Itch External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (56 g): $4.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (NuZon External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (43 g): $49.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Pediaderm HC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1): $212.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Cortizone-10/Aloe External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (36 mL): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Ala Scalp External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (29.6 mL): $38.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Anti-Itch Intensive Healing External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (99 g): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Aquanil HC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (120 mL): $14.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Cortizone-10 Eczema External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (99 g): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Cortizone-10 Hydratensive External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (113 g): $7.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Hydrocortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (118 mL): $8.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (59 mL): $52.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Itch-X External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (88.7 mL): $6.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Locoid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (59 mL): $274.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (NuCort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 g): $125.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Sarnol-HC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (59 mL): $9.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (TheraCort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (118 mL): $4.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Cortizone-10 External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28 g): $4.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Hydrocortisone Butyrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $25.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Hydrocortisone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30 g): $2.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (28.4 g): $6.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (28.35 g): $11.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Hydrocortisone Valerate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (45 g): $180.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Locoid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 g): $62.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Westcort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (45 g): $156.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cortaid Intensive Therapy External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (59 mL): $5.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hydrocortisone Butyrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 mL): $14.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Locoid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 mL): $248.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Scalpicin Maximum Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (44 mL): $6.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Texacort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (30 mL): $150.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Anusol-HC Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $132.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Hemril-30 Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (12): $86.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Hydrocortisone Acetate Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (12): $10.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (12): $45.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Proctocort Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (12): $156.46",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13386378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum glucose, electrolytes; blood pressure, weight, presence of infection; monitor IOP with therapy &gt;6 weeks; bone mineral density, growth in children",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfacort (AR);",
"     </li>",
"     <li>",
"      Alfason (DE);",
"     </li>",
"     <li>",
"      Biocort (ZA);",
"     </li>",
"     <li>",
"      Colifoam (AU, GR);",
"     </li>",
"     <li>",
"      Cort Dome (CO, EC);",
"     </li>",
"     <li>",
"      Cortaid Cream (AU);",
"     </li>",
"     <li>",
"      Cortema (TW);",
"     </li>",
"     <li>",
"      Cortifoam (IL);",
"     </li>",
"     <li>",
"      Cortril (TW);",
"     </li>",
"     <li>",
"      Delster (HK);",
"     </li>",
"     <li>",
"      DHAcort (HK, MY);",
"     </li>",
"     <li>",
"      Dilucort (ZA);",
"     </li>",
"     <li>",
"      Eczacort (PH);",
"     </li>",
"     <li>",
"      Efcortelan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Hidrotisona (AR);",
"     </li>",
"     <li>",
"      Hovicor (PH);",
"     </li>",
"     <li>",
"      Hyde (KP);",
"     </li>",
"     <li>",
"      Hydrocort (SG);",
"     </li>",
"     <li>",
"      Hydroderm (SG);",
"     </li>",
"     <li>",
"      Hydrokortison (EE);",
"     </li>",
"     <li>",
"      Hydrotopic (PH);",
"     </li>",
"     <li>",
"      Hysone (PK);",
"     </li>",
"     <li>",
"      Hytisone (TH);",
"     </li>",
"     <li>",
"      Lacticare HC (PH, TW);",
"     </li>",
"     <li>",
"      Lanacort (IL);",
"     </li>",
"     <li>",
"      Laticort (BG, HN, PL);",
"     </li>",
"     <li>",
"      Lexacorton (ID);",
"     </li>",
"     <li>",
"      Locoid (AE, BE, BH, BR, CH, CL, CN, CY, CZ, DK, EG, FI, FR, GB, HN, IE, IQ, IR, JO, KW, LB, LY, NL, NO, NZ, OM, PE, PT, QA, RU, SA, SE, SY, TR, YE);",
"     </li>",
"     <li>",
"      Locoid Lipo (IN);",
"     </li>",
"     <li>",
"      Locoidon (AT, IT, PE);",
"     </li>",
"     <li>",
"      Medrocil (AR);",
"     </li>",
"     <li>",
"      Mylocort (ZA);",
"     </li>",
"     <li>",
"      Nutracort (CO, CR, DO, GT, NI, PA, SV, VE);",
"     </li>",
"     <li>",
"      Pandel (CN, PE, PY, UY);",
"     </li>",
"     <li>",
"      Sigmacort (AU, HK);",
"     </li>",
"     <li>",
"      Siquent Hycor Eye Ointment (AU);",
"     </li>",
"     <li>",
"      Unicort (CO);",
"     </li>",
"     <li>",
"      Youzhouer (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8116313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8116319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact  vs abraded skin),  formulation, and the use of occlusive dressings. Rectal absorption is more substantial than most topical preparations; therefore, systemic effects are more common.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/54/21352/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9146 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21352=[""].join("\n");
var outline_f20_54_21352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116177\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116184\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116329\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116328\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116330\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116386\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116182\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116359\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116252\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116165\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116263\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116259\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116260\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116282\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116283\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116254\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116255\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116257\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116258\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116388\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386378\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961980\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116313\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8116319\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/48/8969?source=related_link\">",
"      Hydrocortisone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/36/35398?source=related_link\">",
"      Hydrocortisone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/46/22249?source=related_link\">",
"      Hydrocortisone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/25/19861?source=related_link\">",
"      Hydrocortisone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/33/7702?source=related_link\">",
"      Hydrocortisone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_54_21353="Ingested foreign bodies and food impactions in adults";
var content_f20_54_21353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ingested foreign bodies and food impactions in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21353/contributors\">",
"     George Triadafilopoulos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21353/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21353/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/54/21353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accidental foreign body or large food bolus ingestion occurs primarily in children and in edentulous or mentally impaired elderly subjects. Food (typically meat) bolus impaction above a pre-existing esophageal stricture or ring is by far the most common cause of esophageal body obstruction in adults; by comparison, the majority of foreign bodies in children (76 percent in one large series) are coins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/1\">",
"     1",
"    </a>",
"    ]. Other causes include intentional ingestion in psychiatric patients or prison inmates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/2\">",
"     2",
"    </a>",
"    ] and, rarely, foreign body impaction as a complication of pill ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common foreign body ingestions include [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fish and chicken bones",
"     </li>",
"     <li>",
"      Medication packaging",
"     </li>",
"     <li>",
"      Dentures",
"     </li>",
"     <li>",
"      Coins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More than 80 percent of ingested foreign bodies pass without the need for intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, in the setting of intentional ingestions, endoscopic intervention is required in up to 76 percent of patients, and surgical intervention is required in up to 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Complications of foreign body ingestion or food impaction include ulcer formation, lacerations, perforation, intestinal obstruction, aortoesophageal fistula formation, tracheoesophageal fistula formation, and bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/10-14\">",
"     10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When foreign bodies become impacted, they often do so at sites of physiologic or pathologic luminal narrowing. The esophagus has three areas of physiologic narrowing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The upper esophageal sphincter",
"     </li>",
"     <li>",
"      The level of the aortic arch",
"     </li>",
"     <li>",
"      The diaphragmatic hiatus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Structural or functional esophageal abnormalities that increase the risk of foreign",
"    <span class=\"nowrap\">",
"     body/food",
"    </span>",
"    impaction in the esophagus include diverticula, webs, rings, strictures, achalasia, and tumors (",
"    <a class=\"graphic graphic_table graphicRef66623 \" href=\"UTD.htm?35/9/35995\">",
"     table 1",
"    </a>",
"    ). In a large series from China, underlying conditions in impactions included esophageal carcinoma (33 percent), stricture (23.9 percent), diverticulum (15.9 percent), postgastrectomy (11.4 percent), hiatal hernia (10.2 percent), and achalasia (5.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/15\">",
"     15",
"    </a>",
"    ]. Esophageal food impaction is also a common presentation of eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the approach to adults with ingested foreign bodies and food impactions. The approach to foreign body ingestion in children and the conditions that predispose to foreign body or food bolus impaction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=see_link\">",
"     \"Esophageal webs and rings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=see_link\">",
"     \"Zenker's diverticulum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2011, the American Society for Gastrointestinal Endoscopy published guidelines on the management of ingested foreign bodies and food impactions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/17\">",
"     17",
"    </a>",
"    ]. The discussion that follows is consistent with those guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimpaired adults and older children can typically identify foreign body ingestion and may point to a specific area of discomfort, though the area often does not correspond with the site of impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/18\">",
"     18",
"    </a>",
"    ]. However, children, mentally impaired adults, and patients with psychiatric illness may not give a history of foreign body ingestion. In these cases, foreign body impaction may be suspected from the associated symptoms. While symptoms typically develop soon (minutes to days) after ingestion, there have been cases in which foreign bodies were discovered decades later [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical clinical presentation is the acute onset of dysphagia or complete inability to swallow saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/17,23\">",
"     17,23",
"    </a>",
"    ]. The most common clinical features in a review of 103 patients with history of foreign body ingestion were dysphagia (92 percent) and neck tenderness (60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/24\">",
"     24",
"    </a>",
"    ]. An inability to swallow oral secretions is an important symptom since it indicates total obstruction. Other symptoms that can occur include choking, refusal to eat,",
"    <span class=\"nowrap\">",
"     hypersalivation/drooling,",
"    </span>",
"    retrosternal fullness, regurgitation of undigested food, wheezing, blood stained saliva, respiratory distress, and occasionally odynophagia. The latter may indicate spasm but may also suggest laceration or perforation. Some patients will present with signs of a small bowel obstruction such as abdominal pain and distension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=see_link\">",
"     \"Small bowel obstruction: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms in patients with a perforation will depend upon the site of the perforation. Perforation the oropharynx or proximal esophagus may cause neck swelling, tenderness, erythema, or crepitus. Perforation in the mid or distal esophagus may result in severe retrosternal chest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper abdominal pain, tachypnea, dyspnea, cyanosis, fever, and shock. Perforation of the stomach, small bowel, or colon may present with signs of peritonitis, such as abdominal pain, rebound, guarding, tachycardia, hypotension, and fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=see_link&amp;anchor=H21#H21\">",
"     \"Differential diagnosis of chest pain in adults\", section on 'Esophageal rupture, perforation, and foreign bodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H23#H23\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Peritonitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many foreign bodies can be detected with plain radiographs. However, some foreign bodies may not be seen on radiographs (such as fish bones). In patients with suspected foreign body ingestions and ongoing esophageal symptoms, endoscopic evaluation is required, even in the setting of negative radiographs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69214981\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain neck, chest, and abdominal radiographs may reveal a radiopaque foreign body or signs of esophageal perforation such as mediastinal, subdiaphragmatic, or subcutaneous air. Radiographic localization and identification of foreign bodies in the esophagus is important prior to any attempt at extraction to localize the foreign body since this will affect the endoscopic approach. In particular, identification of airway landmarks on posterior-anterior and lateral chest radiographs is important to differentiate between tracheobronchial and esophageal foreign bodies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Flat objects, such as coins, usually orient themselves in the coronal plane when lodged in the esophagus and are best seen on anteroposterior projections (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76887 \" href=\"UTD.htm?14/15/14578\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tracheal foreign bodies align in the sagittal plane and are best seen on a lateral projection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/25\">",
"       25",
"      </a>",
"      ] (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70775 \" href=\"UTD.htm?12/46/13026\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Disk batteries may be seen as a double shadow or a stack of coins, depending upon their position (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62847 \" href=\"UTD.htm?25/39/26239\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77690 \" href=\"UTD.htm?38/21/39263\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Not all foreign bodies will be seen on radiographs. Fish bones, chicken bones, wood, plastic, glass, thin metal objects, and food impactions are not readily seen on plain films, so failure to locate an object on radiographic examination does not preclude its presence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomographic scanning may be helpful if plain radiographs are negative, particularly in patients suspected of having ingested packets of narcotics or other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, examinations using oral contrast, such as a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow, should not be performed since contrast administration may impair subsequent endoscopic visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69214988\">",
"    <span class=\"h2\">",
"     Endoscopic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with persistent esophageal symptoms, an endoscopic evaluation should be performed, even if the radiographic examination is negative. In addition, in patients with suspected nonbony food impactions who do not have evidence of complications, endoscopy may be performed without first obtaining radiographic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management depends upon the type of object ingested, the location of the object, and the patient's clinical status. Conservative management is appropriate for the majority of patients since most objects will pass uneventfully [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients with negative radiographs who are asymptomatic can be followed expectantly. Other patients will likely require endoscopic or surgical intervention, though the specific approach varies with the type of ingestion and the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing of endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring endoscopy can be triaged into one of three groups: those requiring emergent endoscopy, those requiring urgent endoscopy, and those requiring nonurgent endoscopy (",
"    <a class=\"graphic graphic_table graphicRef68276 \" href=\"UTD.htm?38/10/39083\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under no circumstances should a foreign body be allowed to remain in the esophagus beyond 24 hours from presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/2,29-31\">",
"     2,29-31",
"    </a>",
"    ]. Endoscopy under general anesthesia and surgical consultation should be considered in patients in whom the duration of an esophageal foreign body impaction is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69216831\">",
"    <span class=\"h3\">",
"     Emergent endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent endoscopy is indicated in patient with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Esophageal obstruction (evidenced by an inability to handle oral secretions)",
"     </li>",
"     <li>",
"      Disk batteries in the esophagus",
"     </li>",
"     <li>",
"      Sharp-pointed objects in the esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69216838\">",
"    <span class=\"h3\">",
"     Urgent endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent endoscopy (within 24 hours) is indicated in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Esophageal foreign objects that are not sharp-pointed",
"     </li>",
"     <li>",
"      Esophageal food impaction without complete obstruction",
"     </li>",
"     <li>",
"      Sharp-pointed objected in the stomach or duodenum",
"     </li>",
"     <li>",
"      Objects &gt;6 cm in length at or above the proximal duodenum",
"     </li>",
"     <li>",
"      Magnets within endoscopic reach",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69216845\">",
"    <span class=\"h3\">",
"     Nonurgent endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonurgent endoscopy is indicated in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coins in the esophagus may be observed for 12 to 24 hours in asymptomatic patients",
"     </li>",
"     <li>",
"      Blunt objects in the stomach that are &gt;2.5 cm in diameter",
"     </li>",
"     <li>",
"      Disk batteries and cylindrical batteries that are in the stomach in patients without signs of GI injury may be observed for up to 48 hours (however, disk batteries that are larger than 20 mm are unlikely to pass and should be removed)",
"     </li>",
"     <li>",
"      Blunt objects that fail to pass the stomach in three to four weeks",
"     </li>",
"     <li>",
"      Blunt objects distal to the duodenum that remain in the same location for more than a week (deep small bowel enteroscopy or surgery may be required depending on the location of the object)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69216824\">",
"    <span class=\"h3\">",
"     Foreign bodies that have passed into the stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most foreign bodies that enter the stomach will pass in four to six days, and conservative management is appropriate for most blunt objects in asymptomatic patients. As noted above, exceptions include disk batteries, magnets, objects longer than 6 cm, and objects with a diameter &gt;2.5 cm. Patients who are being managed conservatively should have weekly radiographs to follow the progress of the object, and they should be instructed to follow-up immediately should abdominal pain, nausea, or vomiting develop. Patients should resume a normal diet and monitor their stools for evidence of the object. An abdominal radiograph one to two days after the patient notes the object in the stool can help confirm passage, provided that the object is radiopaque.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69215188\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway protection is important for all patients undergoing endoscopic foreign body removal. Oropharyngeal suction is required to avoid pulmonary aspiration. Patients with impactions in the upper esophagus may require endotracheal intubation to protect the airway. The use of an overtube should also be considered to prevent an object from accidentally being dropped into the patient's airway. In addition, a laryngoscope should be immediately available in the event of airway obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69215195\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Choice of endoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forward viewing flexible endoscope has become the instrument of choice in managing foreign bodies in most medical centers because it permits safe extraction of the object and inspection of the esophageal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. It can usually be performed under conscious sedation. However, patients with objects that are difficult to remove, who have ingested multiple objects, or with significant psychiatric illness may require endotracheal intubation and general anesthesia. Rigid endoscopy may be required to remove foreign bodies in the upper esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of large channel or double channel endoscopes may be advantageous over standard caliber endoscopes since they can facilitate clearance of food particles and other esophageal luminal contents proximal to the foreign body impaction. However, these larger endoscopes are harder to navigate around the foreign body in search of underlying distal esophageal pathology and may not be readily available at all centers. As a result, some endoscopists prefer the smaller, more flexible, standard esophagogastroduodenoscopes.",
"   </p>",
"   <p>",
"    Both flexible and rigid endoscopic approaches are successful in more than 90 percent of cases, but rigid endoscopy is associated with a higher perforation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. However, the overall incidence of esophageal perforation with these techniques is low. In a series of 192 adults and children requiring foreign body extraction using rigid or flexible esophagoscopy, no serious complications (mediastinitis, hemorrhage, perforation, or death) were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/33\">",
"     33",
"    </a>",
"    ]. In a second study, perforations occurred in 2 of 63 patients (3 percent) who underwent rigid endoscopy, and no perforations occurred in 76 patients who underwent flexible endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Endoscopic tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Devices that are commonly used for foreign body removal included rat-tooth and alligator forceps, polypectomy snares, baskets, and nets. The rat-tooth forceps and the snare are the most frequently used accessory devices [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/15\">",
"     15",
"    </a>",
"    ]. In general, the endoscopic tools used vary with the type of foreign body:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depending upon the bolus or foreign body shape, a polypectomy snare, tripod, or stone basket may be used",
"     </li>",
"     <li>",
"      Coins are best retrieved with a rat-tooth forceps, snare, or retrieval net",
"     </li>",
"     <li>",
"      Round objects such as disk or button batteries are best captured using a retrieval net [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overtubes may be used to protect the airway when removing objects that are difficult to grasp securely and to facilitate passage of the endoscope multiple times for piecemeal removal of a food bolus or to remove multiple objects. Overtubes can also be used to protect the esophageal mucosa when removing sharp objects. Another option for protecting the esophageal mucosa during removal of a sharp object from the stomach is a foreign body protector hood. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Sharp-pointed objects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Overtubes are backloaded over the endoscope before the procedure and then slowly advanced with the endoscope into the esophagus (short overtubes) or into the stomach (long overtubes). In some cases, application of the overtube over a meat bolus followed by rigorous suction through the endoscope may suction the bolus into the end of the overtube and facilitate removal.",
"   </p>",
"   <p>",
"    All endoscopic manipulations should be performed under maximal esophageal distention using air insufflation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56989054\">",
"    <span class=\"h2\">",
"     Management based upon the type of ingestion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Food bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A food bolus usually consists of meat lodged above a peptic stricture or ring (",
"    <a class=\"graphic graphic_picture graphicRef74740 \" href=\"UTD.htm?16/59/17343\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with total obstruction require immediate intervention. The American Society for Gastrointestinal Endoscopy guidelines suggest that food boluses that are not causing complete obstruction be removed within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/17\">",
"     17",
"    </a>",
"    ]. However, we attempt to remove such boluses within 12 hours in order to avoid pulmonary aspiration.",
"   </p>",
"   <p>",
"    The bolus can be removed using grasping devices (either en bloc or piecemeal, depending upon the consistency of the bolus), or it can be gently pushed into the stomach using the endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. However, excessive force must not be applied since it can result in perforation. If attempts to gently push the bolus into the stomach fail, then the bolus should be removed using a grasping device (preferably via an overtube). A friction-fit adaptor attached to the end of the endoscope can be helpful for aspirating pieces of the food bolus under direct vision [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29,38,39\">",
"     29,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopy can be deferred in patients in whom the food bolus impaction resolves spontaneously. However, endoscopy, esophageal biopsy, and in some cases esophageal motility should be performed at a later date because of the high likelihood of an underlying esophageal structural or motor abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29,40\">",
"     29,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an esophageal stricture or ring is identified after clearing a food bolus, dilation should be performed during the same session, provided there is no significant mucosal inflammation. However, before performing dilation, eosinophilic esophagitis (EoE) should also be considered since accumulating data suggest that up to one-half of patients presenting with food impaction have EoE [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/16,35,41\">",
"     16,35,41",
"    </a>",
"    ]. Dilation should be deferred or performed extremely cautiously if eosinophilic esophagitis is suspected because of the risk of severe chest pain, mucosal tearing, and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link&amp;anchor=H209738#H209738\">",
"     \"Treatment of eosinophilic esophagitis\", section on 'Esophageal dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (1.0 mg IV) can be attempted to relax the esophagus, which may promote passage of the food bolus. Studies of glucagon in this setting have had mixed results, with some studies suggesting a benefit while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. However, glucagon is relatively safe and is a reasonable option, provided its administration does not delay definitive endoscopic therapy.",
"   </p>",
"   <p>",
"    Under",
"    <strong>",
"     no circumstances",
"    </strong>",
"    should meat tenderizers (such as papain) be administered to patients with food impactions because serious esophageal damage may result [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Blunt objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blunt objects should be removed with equipment that is suited to the shape of the object. Coins, for example, are best removed with foreign body forceps (rat-tooth or alligator), a snare, or a retrieval net [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/2,29,30\">",
"     2,29,30",
"    </a>",
"    ]. Smooth and round objects are more easily removed with a retrieval net or basket [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/48\">",
"     48",
"    </a>",
"    ]. Objects that cannot be secured in the esophagus may be advanced into the stomach where they may be easier to grasp.",
"   </p>",
"   <p>",
"    Blunt objects that have already entered the stomach can usually be managed conservatively since most will pass within four to six days (although it may take as long as four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29,49-51\">",
"     29,49-51",
"    </a>",
"    ]. In adults, objects larger than 2.5 cm are less likely to pass the pylorus and should be removed endoscopically. Patients should consume a regular diet and observe their stools for passage of the object. Weekly radiographs are sufficient in asymptomatic patients. Endoscopic or surgical removal (depending upon the location of the object) should be considered if the object fails to pass out of the stomach within three to four weeks or if an object distal to the duodenum remains in the same location for more than one week. Surgery is also indicated in patients who develop symptoms suggestive of peritonitis, such as fever, vomiting, or abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Long objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long objects (longer than 6 to 10 cm) are unlikely to pass the duodenal sweep and should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/6,29,52\">",
"     6,29,52",
"    </a>",
"    ]. Examples include toothbrushes and spoons. The objects can be grasped with a snare or basket and drawn into a long overtube (ie, &gt;45 cm), after which the entire apparatus can be withdrawn in one motion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sharp-pointed objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of sharp pointed objects (such as chicken and fish bones, straightened paper clips, toothpicks, needles, bread-bag clips, and dental bridgework) in the esophagus represents a medical emergency because of the risk of perforation. While sharp-pointed objects that enter the stomach often pass uneventfully through the remainder of the gastrointestinal tract, complications have been described in up to 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, they should be removed endoscopically if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/2,3,53\">",
"     2,3,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For removal of sharp objects in the stomach, a protector hood should be placed at the tip of the endoscope, or a long overtube that spans the esophagogastric junction should be inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/54\">",
"     54",
"    </a>",
"    ]. The bell portion of the flexible endoscopic protector hood is inverted during insertion of the endoscope. The object is then grasped, and the scope is withdrawn. If only one end of the object is pointed, when possible, the object should be grasped so that the sharp end is trailing during removal (ie, pointing away from the endoscope). When the protector hood comes into contact with the esophagogastric junction during withdrawal, the hood is pushed forward, forming a bell that surrounds the tip of the endoscope and the object, protecting the esophageal and pharyngeal mucosa from any sharp edges.",
"   </p>",
"   <p>",
"    If endoscopic removal of a sharp-pointed object in the esophagus cannot be achieved safely, patients should be followed with daily radiographs; surgical removal should be considered for objects that do not advance within three consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ] or in patients who develop abdominal pain, vomiting, fevers, hematemesis, or melena. Sword swallowers run a higher risk of injury when they are distracted or adding embellishments to their performance. In these cases, the management of esophageal injury dominates over the foreign body removal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Disk batteries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disk batteries in the esophagus should be removed promptly. Contact of the flat esophageal wall with both poles of the battery conducts electricity that may rapidly result in liquefaction necrosis and perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. These batteries can be removed with a retrieval basket or net. An alternative technique involves inserting a balloon under direct visualization past the battery, after which it is inflated and then withdrawn to capture the battery between the balloon and the tip of the endoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ]. The balloon, battery, and endoscope can then be removed as one unit. With this type of retrieval method, there is a risk of the battery falling into the trachea, so an overtube",
"    <strong>",
"     must",
"    </strong>",
"    be used to protect the airway. If the battery is retrieved by securely capturing it within a retrieval net, an overtube is not required. A battery that cannot be removed from the esophagus can be gently advanced into the stomach where retrieval is sometimes easier.",
"   </p>",
"   <p>",
"    Most disk batteries that are in the stomach will subsequently pass through the remaining gastrointestinal tract without consequence. Patients who present with the disk battery in the stomach can be followed with a radiograph every three to four days; 85 percent pass within 72 hours once the battery is beyond the duodenal sweep [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/58\">",
"     58",
"    </a>",
"    ]. Endoscopic removal should be attempted in patients who develop signs or symptoms of gastrointestinal tract injury, those who have ingested batteries larger than 20 mm in diameter, and those in whom the battery remains in the stomach for longer than 48 hours. Emetics are not useful. Cathartics and acid suppression are of unproven benefit, although cathartics may expedite passage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Batteries less than 15 mm in diameter almost never lodge in the esophagus. In one study, while only 3 percent of button batteries were larger than 20 mm, they were responsible for the severe esophageal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/60\">",
"     60",
"    </a>",
"    ]. These data suggest that manufacturers could eliminate most complications related to button batteries by replacing large batteries with smaller ones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69215622\">",
"    <span class=\"h3\">",
"     Magnets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingested magnets may result in severe gastrointestinal injury because the attractive force between magnets or between a magnet and an ingested metal object can trap a portion of the bowel wall and cause necrosis. This can result in fistula formation, perforation, obstruction, volvulus, or peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/61\">",
"     61",
"    </a>",
"    ]. While patients who only report ingestion of one magnet may not be at risk, if additional undetected magnets or pieces of metal were ingested along with the magnet, damage could occur. As a result, all magnets within endoscopic reach should be removed if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Drug packets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug packets ingested by drug traffickers in an attempt to conceal their possession should not be removed endoscopically because of the risk of rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/62\">",
"     62",
"    </a>",
"    ]. The packets can often be seen radiographically; computed tomographic scanning can be helpful, although false negative results have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Surgery is indicated for patients in whom the packages fail to progress and those with signs of intestinal obstruction or suspected rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69215658\">",
"    <span class=\"h2\">",
"     Foreign bodies in the small bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep small bowel enteroscopy has been used as an alternative to surgery for the management of patients with foreign bodies in the small bowel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=see_link&amp;anchor=H388475172#H388475172\">",
"     \"Overview of deep small bowel enteroscopy\", section on 'Therapeutic applications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Management of foreign body-induced esophageal perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of esophageal perforations depends upon the clinical status of the patient, the degree of injury, and the time elapsed between the injury and its diagnosis. Although nonoperative intervention may be acceptable in highly-selected patients with contained perforations who are clinically stable, operative intervention is the most conservative and safest approach and is generally considered the treatment of choice, particularly for those seen more than 24 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/63\">",
"     63",
"    </a>",
"    ]. The surgical management of esophageal perforations is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=see_link\">",
"     \"Surgical management of esophageal perforation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other considerations include the nature of the foreign body, the location and the clinical manifestations of perforation, the possible underlying esophageal disease, the results of the various imaging techniques, and the patient's operative risks. In many instances of small iatrogenic perforations, nonoperative, conservative management may be chosen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link&amp;anchor=H6#H6\">",
"     \"Complications of endoscopic esophageal stricture dilation\", section on 'Medical management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of endoscopic esophageal stricture dilation\", section on 'Approach to medical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoclips may be effective for closing both acute and chronic esophageal perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/64\">",
"     64",
"    </a>",
"    ]. Self-expandable plastic endoluminal esophageal stent placement by a gastroenterologist familiar with their use may also be an effective method for the treatment of acute, iatrogenic perforations of the intrathoracic esophagus. These stents result in rapid leak occlusion, provide the opportunity for early oral nutrition, may significantly reduce hospital length of stay, are removable, and avoid the potential morbidity of operative repair [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of endoscopic esophageal stricture dilation\", section on 'Approach to medical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent esophageal foreign body impactions occur in 10 to 20 percent of cases. In a retrospective study of a prospectively collected database at a tertiary care center, the presence of a diaphragmatic hernia, disimpaction by piecemeal extraction, and acquisition of esophageal biopsies increased odds for recurrent foreign body impaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21353/abstract/66\">",
"     66",
"    </a>",
"    ]. Clinician follow-up after disimpaction decreased the odds of recurrence. When possible, underlying structural defects that predisposed to the impaction, such as strictures, should be treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link\">",
"     \"Management of benign esophageal strictures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=see_link\">",
"       \"Patient information: Swallowed objects (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accidental foreign body or large food bolus ingestion occurs mainly in children and in edentulous or mentally impaired adults. Food (typically meat) bolus impaction above a pre-existing esophageal stricture or ring is by far the most common cause of esophageal foreign body obstruction in adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most ingested foreign bodies pass readily, but some may be impacted behind a physiologic or pathologic luminal narrowing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical clinical presentation is the acute onset of dysphagia or complete inability to swallow saliva. An inability to swallow oral secretions is an important symptom since it indicates total obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic localization and identification of foreign bodies in the esophagus is important prior to attempts at extraction in many patients. However, failure to locate an object on radiographic examination does not preclude its presence. In patients with suspected nonbony food impactions who do not have evidence of complications, endoscopy may be performed without first obtaining radiographic imaging. In patients with persistent esophageal symptoms, an endoscopic evaluation should be performed, even if the radiographic examination is negative. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to management depends upon the type of object ingested, the location of the object, and the patient's clinical status. Conservative management is appropriate for the majority of patients since most objects will pass uneventfully. Patients with negative radiographs who are asymptomatic can be followed expectantly. Other patients will likely require endoscopic or surgical intervention, though the specific approach varies with the type of ingestion and the clinical setting (",
"      <a class=\"graphic graphic_table graphicRef68276 \" href=\"UTD.htm?38/10/39083\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent endoscopy is indicated for patients with (see",
"      <a class=\"local\" href=\"#H69216831\">",
"       'Emergent endoscopy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete esophageal obstruction (evidenced by an inability to handle oral secretions)",
"     </li>",
"     <li>",
"      Disk batteries in the esophagus",
"     </li>",
"     <li>",
"      Sharp-pointed objects in the esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgent endoscopy (within 24 hours) is indicated for patients with (see",
"      <a class=\"local\" href=\"#H69216838\">",
"       'Urgent endoscopy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophageal foreign objects that are not sharp-pointed",
"     </li>",
"     <li>",
"      Esophageal food impaction without complete obstruction",
"     </li>",
"     <li>",
"      Sharp-pointed objected in the stomach or duodenum",
"     </li>",
"     <li>",
"      Objects &gt;6 cm in length at or above the proximal duodenum",
"     </li>",
"     <li>",
"      Magnets within endoscopic reach",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonurgent endoscopy is indicated for patients with (see",
"      <a class=\"local\" href=\"#H69216845\">",
"       'Nonurgent endoscopy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Coins in the esophagus may be observed for 12 to 24 hours in asymptomatic patients",
"     </li>",
"     <li>",
"      Blunt objects in the stomach that are &gt;2.5 cm in diameter",
"     </li>",
"     <li>",
"      Disk batteries and cylindrical batteries that are in the stomach in patients without signs of gastrointestinal injury may be observed for up to 48 hours (however, disk batteries that are larger than 20 mm are unlikely to pass and should be removed)",
"     </li>",
"     <li>",
"      Blunt objects that fail to pass the stomach in three to four weeks",
"     </li>",
"     <li>",
"      Blunt objects distal to the duodenum that remain in the same location for more than a week (deep small bowel enteroscopy or surgery may be required depending on the location of the object)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most foreign bodies that enter the stomach will pass in four to six days, and conservative management is appropriate for most blunt objects in asymptomatic patients. As noted above, exceptions include disk batteries, magnets, objects longer than 6 cm, and objects with a diameter &gt;2.5 cm. (See",
"      <a class=\"local\" href=\"#H69216824\">",
"       'Foreign bodies that have passed into the stomach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/1\">",
"      Schunk JE, Harrison AM, Corneli HM, Nixon GW. Fluoroscopic foley catheter removal of esophageal foreign bodies in children: experience with 415 episodes. Pediatrics 1994; 94:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/2\">",
"      Webb WA. Management of foreign bodies of the upper gastrointestinal tract: update. Gastrointest Endosc 1995; 41:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/3\">",
"      Vizcarrondo FJ, Brady PG, Nord HJ. Foreign bodies of the upper gastrointestinal tract. Gastrointest Endosc 1983; 29:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/4\">",
"      Wisniewski RM, Stone DD, Fang JC. An esophageal foreign body impaction from a Tums E-X tablet. Gastrointest Endosc 1997; 45:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/5\">",
"      Wu WT, Chiu CT, Kuo CJ, et al. Endoscopic management of suspected esophageal foreign body in adults. Dis Esophagus 2011; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/6\">",
"      Pellerin D, Fortier-Beaulieu M, Guegen J. The fate of swallowed foreign bodies: Experience of 1250 instances of subdiaphragmatic foreign bodies in children. Program Pediatr Radiol 1969; 2:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/7\">",
"      Carp L. FOREIGN BODIES IN THE INTESTINE. Ann Surg 1927; 85:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/8\">",
"      Palta R, Sahota A, Bemarki A, et al. Foreign-body ingestion: characteristics and outcomes in a lower socioeconomic population with predominantly intentional ingestion. Gastrointest Endosc 2009; 69:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/9\">",
"      Weiland ST, Schurr MJ. Conservative management of ingested foreign bodies. J Gastrointest Surg 2002; 6:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/10\">",
"      Zhang X, Liu J, Li J, et al. Diagnosis and treatment of 32 cases with aortoesophageal fistula due to esophageal foreign body. Laryngoscope 2011; 121:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/11\">",
"      Ahn D, Heo SJ, Park JH, Sohn JH. Tracheoesophageal fistula with tracheal stenosis resulting from retained esophageal foreign body. Auris Nasus Larynx 2011; 38:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/12\">",
"      Sung SH, Jeon SW, Son HS, et al. Factors predictive of risk for complications in patients with oesophageal foreign bodies. Dig Liver Dis 2011; 43:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/13\">",
"      Tonkic A, Kulic D, Peric M, et al. Bacteremia caused by a swallowed toothpick impacted in the gastric mucosa. Case Rep Gastroenterol 2011; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/14\">",
"      Lam HC, Woo JK, van Hasselt CA. Management of ingested foreign bodies: a retrospective review of 5240 patients. J Laryngol Otol 2001; 115:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/15\">",
"      Li ZS, Sun ZX, Zou DW, et al. Endoscopic management of foreign bodies in the upper-GI tract: experience with 1088 cases in China. Gastrointest Endosc 2006; 64:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/16\">",
"      Desai TK, Stecevic V, Chang CH, et al. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005; 61:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/17\">",
"      ASGE Standards of Practice Committee, Ikenberry SO, Jue TL, et al. Management of ingested foreign bodies and food impactions. Gastrointest Endosc 2011; 73:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/18\">",
"      Connolly AA, Birchall M, Walsh-Waring GP, Moore-Gillon V. Ingested foreign bodies: patient-guided localization is a useful clinical tool. Clin Otolaryngol Allied Sci 1992; 17:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/19\">",
"      Adams DB. Endoscopic removal of entrapped coins from an intraluminal duodenal diverticulum 20 years after ingestion. Gastrointest Endosc 1986; 32:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/20\">",
"      Kirberg AE. Long-standing esophageal foreign body. Gastrointest Endosc 1986; 32:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/21\">",
"      Yamamoto M, Mizuno H, Sugawara Y. A chopstick is removed after 60 years in the duodenum. Gastrointest Endosc 1985; 31:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/22\">",
"      Tsui BC, Mossey J. Occult liver abscess following clinically unsuspected ingestion of foreign bodies. Can J Gastroenterol 1997; 11:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/23\">",
"      Nandi P, Ong GB. Foreign body in the oesophagus: review of 2394 cases. Br J Surg 1978; 65:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/24\">",
"      Khan MA, Hameed A, Choudhry AJ. Management of foreign bodies in the esophagus. J Coll Physicians Surg Pak 2004; 14:218.",
"     </a>",
"    </li>",
"    <li>",
"     Ghahremani GG. Foreign bodies of the alimentary tract. In: Textbook of Gastrointestinal Radiology, Gore RM, Levine MS, Laufer I (Eds), WB Saunders, Philadelphia 1994. p.2547.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/26\">",
"      Cranston PE, Pollack CV Jr, Harrison RB. CT of crack cocaine ingestion. J Comput Assist Tomogr 1992; 16:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/27\">",
"      Eng JG, Aks SE, Waldron R, et al. False-negative abdominal CT scan in a cocaine body stuffer. Am J Emerg Med 1999; 17:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/28\">",
"      Takada M, Kashiwagi R, Sakane M, et al. 3D-CT diagnosis for ingested foreign bodies. Am J Emerg Med 2000; 18:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/29\">",
"      Eisen GM, Baron TH, Dominitz JA, et al. Guideline for the management of ingested foreign bodies. Gastrointest Endosc 2002; 55:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/30\">",
"      Ginsberg GG. Management of ingested foreign objects and food bolus impactions. Gastrointest Endosc 1995; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/31\">",
"      Chaikhouni A, Kratz JM, Crawford FA. Foreign bodies of the esophagus. Am Surg 1985; 51:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/32\">",
"      Gmeiner D, von Rahden BH, Meco C, et al. Flexible versus rigid endoscopy for treatment of foreign body impaction in the esophagus. Surg Endosc 2007; 21:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/33\">",
"      Berggreen PJ, Harrison E, Sanowski RA, et al. Techniques and complications of esophageal foreign body extraction in children and adults. Gastrointest Endosc 1993; 39:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/34\">",
"      Neustater B, Barkin JS. Extraction of an esophageal food impaction with a Roth retrieval net. Gastrointest Endosc 1996; 43:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/35\">",
"      Kirchner GI, Zuber-Jerger I, Endlicher E, et al. Causes of bolus impaction in the esophagus. Surg Endosc 2011; 25:3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/36\">",
"      Vicari JJ, Johanson JF, Frakes JT. Outcomes of acute esophageal food impaction: success of the push technique. Gastrointest Endosc 2001; 53:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/37\">",
"      Longstreth GF, Longstreth KJ, Yao JF. Esophageal food impaction: epidemiology and therapy. A retrospective, observational study. Gastrointest Endosc 2001; 53:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/38\">",
"      Saeed ZA, Michaletz PA, Feiner SD, et al. A new endoscopic method for managing food impaction in the esophagus. Endoscopy 1990; 22:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/39\">",
"      Pezzi JS, Shiau YF. A method for removing meat impactions from the esophagus. Gastrointest Endosc 1994; 40:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/40\">",
"      Breumelhof R, Van Wijk HJ, Van Es CD, Smout AJ. Food impaction in nutcracker esophagus. Dig Dis Sci 1990; 35:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/41\">",
"      Kerlin P, Jones D, Remedios M, Campbell C. Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus. J Clin Gastroenterol 2007; 41:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/42\">",
"      Rajagopalan J, Triadafilopoulos G. Ring(s)-related esophageal meat bolus impaction: biopsy first, dilate later. Dis Esophagus 2009; 22:E14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/43\">",
"      Ferrucci JT Jr, Long JA Jr. Radiologic treatment of esophageal food impaction using intravenous glucagon. Radiology 1977; 125:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/44\">",
"      Trenkner SW, Maglinte DD, Lehman GA, et al. Esophageal food impaction: treatment with glucagon. Radiology 1983; 149:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/45\">",
"      Tibbling L, Bjorkhoel A, Jansson E, Stenkvist M. Effect of spasmolytic drugs on esophageal foreign bodies. Dysphagia 1995; 10:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/46\">",
"      Sodeman TC, Harewood GC, Baron TH. Assessment of the predictors of response to glucagon in the setting of acute esophageal food bolus impaction. Dysphagia 2004; 19:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/47\">",
"      Goldner F, Danley D. Enzymatic digestion of esophageal meat impaction. A study of Adolph's Meat Tenderizer. Dig Dis Sci 1985; 30:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/48\">",
"      Faigel DO, Stotland BR, Kochman ML, et al. Device choice and experience level in endoscopic foreign object retrieval: an in vivo study. Gastrointest Endosc 1997; 45:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/49\">",
"      Panieri E, Bass DH. The management of ingested foreign bodies in children--a review of 663 cases. Eur J Emerg Med 1995; 2:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/50\">",
"      Hachimi-Idrissi S, Corne L, Vandenplas Y. Management of ingested foreign bodies in childhood: our experience and review of the literature. Eur J Emerg Med 1998; 5:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/51\">",
"      Stringer MD, Capps SN. Rationalising the management of swallowed coins in children. BMJ 1991; 302:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/52\">",
"      Blaho KE, Merigian KS, Winbery SL, et al. Foreign body ingestions in the Emergency Department: case reports and review of treatment. J Emerg Med 1998; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/53\">",
"      Selivanov V, Sheldon GF, Cello JP, Crass RA. Management of foreign body ingestion. Ann Surg 1984; 199:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/54\">",
"      Bertoni G, Pacchione D, Sassatelli R, et al. A new protector device for safe endoscopic removal of sharp gastroesophageal foreign bodies in infants. J Pediatr Gastroenterol Nutr 1993; 16:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/55\">",
"      Witcombe B, Meyer D. Sword swallowing and its side effects. BMJ 2006; 333:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/56\">",
"      Litovitz T, Schmitz BF. Ingestion of cylindrical and button batteries: an analysis of 2382 cases. Pediatrics 1992; 89:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/57\">",
"      Gordon AC, Gough MH. Oesophageal perforation after button battery ingestion. Ann R Coll Surg Engl 1993; 75:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/58\">",
"      Litovitz TL. Battery ingestions: product accessibility and clinical course. Pediatrics 1985; 75:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/59\">",
"      Namasivayam S. Button battery ingestion: a solution to a management dilemma. Pediatr Surg Int 1999; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/60\">",
"      Yardeni D, Yardeni H, Coran AG, Golladay ES. Severe esophageal damage due to button battery ingestion: can it be prevented? Pediatr Surg Int 2004; 20:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Gastrointestinal injuries from magnet ingestion in children--United States, 2003-2006. MMWR Morb Mortal Wkly Rep 2006; 55:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/62\">",
"      Lancashire MJ, Legg PK, Lowe M, et al. Surgical aspects of international drug smuggling. Br Med J (Clin Res Ed) 1988; 296:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/63\">",
"      Bryant AS, Cerfolio RJ. Esophageal trauma. Thorac Surg Clin 2007; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/64\">",
"      Qadeer MA, Dumot JA, Vargo JJ, et al. Endoscopic clips for closing esophageal perforations: case report and pooled analysis. Gastrointest Endosc 2007; 66:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/65\">",
"      Freeman RK, Van Woerkom JM, Ascioti AJ. Esophageal stent placement for the treatment of iatrogenic intrathoracic esophageal perforation. Ann Thorac Surg 2007; 83:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21353/abstract/66\">",
"      Prasad GA, Reddy JG, Boyd-Enders FT, et al. Predictors of recurrent esophageal food impaction: a case-control study. J Clin Gastroenterol 2008; 42:771.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2271 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21353=[""].join("\n");
var outline_f20_54_21353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69214981\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69214988\">",
"      Endoscopic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing of endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69216831\">",
"      - Emergent endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69216838\">",
"      - Urgent endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69216845\">",
"      - Nonurgent endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69216824\">",
"      - Foreign bodies that have passed into the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69215188\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69215195\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Choice of endoscope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Endoscopic tools",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56989054\">",
"      Management based upon the type of ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Food bolus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Blunt objects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Long objects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sharp-pointed objects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Disk batteries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69215622\">",
"      - Magnets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Drug packets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69215658\">",
"      Foreign bodies in the small bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Management of foreign body-induced esophageal perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2271|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/15/14578\" title=\"diagnostic image 1\">",
"      Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/46/13026\" title=\"diagnostic image 2\">",
"      Radiopaque foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/39/26239\" title=\"diagnostic image 3\">",
"      Battery versus coin AP radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/21/39263\" title=\"diagnostic image 4\">",
"      Battery versus coin lateral radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2271|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/59/17343\" title=\"picture 1\">",
"      Meat bolus impaction Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2271|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/9/35995\" title=\"table 1\">",
"      Esophageal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/10/39083\" title=\"table 2\">",
"      Timing of endoscopy for ingested foreign bodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/57/10137?source=related_link\">",
"      Complications of endoscopic esophageal stricture dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26634?source=related_link\">",
"      Differential diagnosis of chest pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12838?source=related_link\">",
"      Esophageal webs and rings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24649?source=related_link\">",
"      Overview of deep small bowel enteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/24/14722?source=related_link\">",
"      Patient information: Swallowed objects (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/38/8807?source=related_link\">",
"      Small bowel obstruction: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/20/329?source=related_link\">",
"      Surgical management of esophageal perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29512?source=related_link\">",
"      Zenker's diverticulum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_54_21354="Steroid-resistant idiopathic nephrotic syndrome in children";
var content_f20_54_21354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Steroid-resistant idiopathic nephrotic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/54/21354/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/54/21354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H174704350\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children who present with idiopathic nephrotic syndrome (NS) have minimal change disease (MCD), which is generally responsive to steroid therapy. As a result, empirical steroid therapy is given to most children who present with idiopathic NS.",
"   </p>",
"   <p>",
"    However, about 10 to 20 percent of patients will fail to respond to initial steroid treatment. In many cases, steroid-resistant cases are due to single-gene mutations that affect glomerular podocyte differentiation and function. Patients with genetic forms of steroid-resistant nephrotic syndrome (SRNS) are usually unresponsive to immunosuppressive therapy. Thus, therapeutic decisions in children with SRNS are based on the underlying etiology.",
"   </p>",
"   <p>",
"    The causes and management of steroid-resistant idiopathic nephrotic syndrome in children will be reviewed here. The etiology, clinical manifestations, diagnosis, and initial management of NS in children are discussed separately. In addition, the management of children with steroid-sensitive NS is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Initial pharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Steroid-sensitive nephrotic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174704558\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most children with steroid-resistant nephrotic syndrome (SRNS), the underlying cause is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, advances in molecular genetics of glomerular diseases have shown single gene defects that affect glomerular podocyte differentiation and function are responsible for a quarter to a third of all pediatric cases of SRNS in many parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397715\">",
"    <span class=\"h2\">",
"     Genetic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of the following genes are the most common cause of hereditary SRNS.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NPHS1 encodes nephrin, slit diaphragm component of the podocyte",
"     </li>",
"     <li>",
"      NPHS2 encodes podocin, slit diaphragm component of the podocyte",
"     </li>",
"     <li>",
"      WT1 encodes the transcription tumor suppressor protein, which is involved in kidney and gonad development",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other less common genetic forms of SRNS are due to mutations of the LAMB2 gene (encodes lamin beta 2), PLCE1 gene (encodes phospholipase C epsilon), and TRP6 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/6\">",
"     6",
"    </a>",
"    ] (encodes transient receptor potential 6 ion channel). These gene defects are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H20#H20\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'Pierson syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H15#H15\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'Diffuse mesangial sclerosis with Drash syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H28#H28\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'TRPC6 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of genetic mutations associated with childhood SRNS was illustrated in the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a single center study of 91 consecutive German patients from 82 families with SRNS including 26 infants below three months of age. Gene mutation were found in 52 percent of the families and included mutations in the following genes, NPHS1 (n = 11), NPHS2 (n = 17), WT1 (n = 11), LAMB2 (n = 1), and TRPC6 (n = 3) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 110 Spanish patients with SRNS, genetic mutations were found in two thirds of 24 familial cases and 25 percent of 86 sporadic cases [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of a monogenetic cause of SRNS is greatest in the first year of life as illustrated in the above Spanish study with the following rates of genetic defects based on age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 3 months &ndash; 100 percent",
"     </li>",
"     <li>",
"      4 to 12 months &ndash; 57 percent",
"     </li>",
"     <li>",
"      13 months to 5 years &ndash; 24 percent",
"     </li>",
"     <li>",
"      6 to 12 years &ndash; 36 percent",
"     </li>",
"     <li>",
"      13 to 17 years &ndash; 25",
"     </li>",
"     <li>",
"      &gt;18 years &ndash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these older age groups, NPHS2 mutations were most frequently seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5651950\">",
"    <span class=\"h3\">",
"     NPHS1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPHS1 encodes nephrin, an integral membrane protein of the slit diaphragm of the podocyte. Mutations of the NPHS1 gene are most often associated with the Finnish-type congenital nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H3#H3\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'CNS of Finnish type'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, mutations of this gene have also been reported in older patients with SRNS, as illustrated in a study of 160 children with SRNS from 142 families. Once mutations in NPHS2 had been excluded, the authors identified NPHS1 mutations in two related and nine unrelated patients (age range between six months to 11 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/7\">",
"     7",
"    </a>",
"    ]. Initial renal biopsy demonstrated minimal changes in 7 cases and focal segmental glomerulosclerosis in 3. Five patients progressed to ESRD at a mean age of 13 years (range 6 to 25 years). From this study, the authors concluded that about 10 percent of children with SRNS who present before five years of age will carry a NPHS1 gene mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397722\">",
"    <span class=\"h3\">",
"     NPHS2 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the NPHS2 gene that encodes for podocin, an integral membrane protein found exclusively in glomerular podocytes, are frequently observed in children with familial SRNS, less commonly in those with sporadic SRNS, and not in patients with steroid-sensitive NS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first study, NPHS2 mutation analysis was performed in 338 children from 272 families with SRNS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the 81 families with autosomal recessive SRNS, 43 percent had NPHS2 mutations (homozygous or compound heterozygous). The average age of onset of NS was 58 months.",
"     </li>",
"     <li>",
"      In 172 patients with sporadic SRNS, 11 percent had homozygous or compound heterozygous NPHS2 mutations. The average age of onset was 103 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a second study, direct sequencing of the NPHS2 gene was performed in 190 patients from 165 families with SRNS and in 124 patients from 120 families with steroid-sensitive NS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/10\">",
"       10",
"      </a>",
"      ]. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In 165 families with SRNS, 43 had homozygous or compound heterozygous NPHS2 mutations (26 percent).",
"     </li>",
"     <li>",
"      No homozygous or compound heterozygous NPHS2 mutations were noted among the steroid-sensitive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations in NPHS2 have been described in approximately 10 to 30 percent of cases of sporadic SRNS in children from Europe and the Middle East [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/9,11-15\">",
"     9,11-15",
"    </a>",
"    ]. These affected children appear to have an early onset of disease, and most progress to end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/11,13,16\">",
"     11,13,16",
"    </a>",
"    ]. Cardiac defects have also been described in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, the frequency of NPHS2 mutations is low in African-Americans with SRNS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although one might expect that patients with NPHS2 mutations would not develop recurrent disease in the transplant, recurrence has been reported, although rarely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=see_link&amp;anchor=H1107666570#H1107666570\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\", section on 'Risk factors for recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12234952\">",
"    <span class=\"h3\">",
"     NPHS3 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the phospholipase C epsilon gene (PLCE1 or NPHS3) are usually associated with congenital nephrotic syndrome and diffuse mesangial sclerosis, but may also occur in older patients. In a cohort of 139 patients (mean age 23 months, range 0 to 31 years) with early onset SRNS and diffuse mesangial sclerosis, PLCE1 mutations were found in 8 percent",
"    <span class=\"nowrap\">",
"     (6/78)",
"    </span>",
"    of FSGS cases without NPHS2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital and infantile nephrotic syndrome\", section on 'Diffuse mesangial sclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397729\">",
"    <span class=\"h3\">",
"     WT1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in WT1, the Wilms' tumor suppressor gene, have been reported in patients who present clinically with sporadic SRNS. In a European study, for example, mutational analysis of the WT1 gene was performed in 115 cases of sporadic SRNS as well as in 100 cases of steroid-sensitive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/20\">",
"     20",
"    </a>",
"    ]. Mutations in WT1 were found in 3 of 60 males (5 percent) and 5 of 55 females (9 percent) with steroid-resistant disease, although no such mutations were found in cases of steroid-sensitive NS. As a result, WT1 mutations should be looked for in all cases of idiopathic steroid resistant nephrotic syndrome regardless of gender, as all affected patients are at risk for Wilms tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12235032\">",
"    <span class=\"h3\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations of several genes, including ACTN4 encoding alpha-actinine4, TRPC6 encoding the transient receptor potential cation channel 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/22\">",
"     22",
"    </a>",
"    ], and INF2 encoding a member of the formin family of actin-regulating proteins, are responsible for autosomal dominant nephrotic syndrome with focal segmental glomerulosclerosis that generally present in adolescence and young adulthood. In African American patients, variants in the apolipoprotein L1 (APOL1) gene, which resides in close proximity to MYH9 on chromosome 22, are associated with FSGS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Genetic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143051165\">",
"    <span class=\"h3\">",
"     Syndromic SRNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syndromic forms of genetic SRNS are due to the following gene mutations. Nonrenal manifestations are helpful in determining the appropriate gene to test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H143051834\">",
"     'Genetic testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in WT1 are associated with several forms of hereditary NS including Frasier syndrome and Denys-Drash syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H15#H15\">",
"       \"Congenital and infantile nephrotic syndrome\", section on 'Diffuse mesangial sclerosis with Drash syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of the infant with ambiguous genitalia\", section on 'Genes involved in gonadal development'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Denys-Drash syndrome consists of the triad of progressive renal disease with diffuse mesangial sclerosis, male pseudohermaphroditism, and Wilms' tumor.",
"     </li>",
"     <li>",
"      Frasier syndrome is characterized by the association of male pseudohermaphroditism with female external genitalia and nephrotic syndrome with FSGS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LAMB2 is associated with the Pierson syndrome (diffuse mesangial sclerosis and ocular malformations). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H20#H20\">",
"       \"Congenital and infantile nephrotic syndrome\", section on 'Pierson syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutations in SMARCAL1 gene are associated with Schimke syndrome, which is characterized by growth retardation, T-cell deficiency, bone dysplasia, and cerebrovascular disease. Patients may develop SRNS with FSGS progressing to end stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in LMX1B gene are associated with nail-patella syndrome. About one half of patients develop proteinuria, sometimes with nephrotic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=see_link\">",
"       \"Nail-patella syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143051649\">",
"    <span class=\"h3\">",
"     Genotype and histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, the histologic findings are suggestive of a specific underlying gene defect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse mesangial sclerosis &ndash; WT1 or LAMB2 mutations (",
"      <a class=\"graphic graphic_picture graphicRef56256 \" href=\"UTD.htm?40/2/40999\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77219 \" href=\"UTD.htm?6/5/6230\">",
"       picture 2",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H10#H10\">",
"       \"Congenital and infantile nephrotic syndrome\", section on 'Diffuse mesangial sclerosis'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tubulointerstitial changes including irregular microcystic dilatation of proximal tubules are typically seen in patients with NPSH1 mutations (",
"      <a class=\"graphic graphic_picture graphicRef57870 \" href=\"UTD.htm?8/32/8709\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69624 \" href=\"UTD.htm?37/36/38470\">",
"       picture 4",
"      </a>",
"      ). However, dilation of the proximal tubules may be observed in other cases of congenital nephrotic syndrome secondary to heavy proteinuria. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link&amp;anchor=H3#H3\">",
"       \"Congenital and infantile nephrotic syndrome\", section on 'CNS of Finnish type'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologic findings that are consistent with specific gene mutations can help guide genetic testing. However, most genetic causes of SRNS have histological features that are not distinguishable from nongenetic disease, primarily focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, a renal biopsy will generally not distinguish between genetic and nongenetic forms of SRNS.",
"   </p>",
"   <p>",
"    Genetic testing is recommended in children likely to have a genetic etiology because of the histologic overlap and difference in therapeutic decisions between genetic and nongenetic disease causes of SRNS. (See",
"    <a class=\"local\" href=\"#H143051834\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H143052349\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312325\">",
"    <span class=\"h2\">",
"     Nongenetic forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2011, no underlying genetic defects were identified in about 50 to 60 percent of pediatric patients with SRNS in Europe and the Middle East [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of nongenetic forms of SRNS in patients from North America, which is a more heterogenetic population, is unknown. In patients in whom an underlying cause is unknown, it is possible that mutations in yet-to-be identified genes are responsible [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned case series of 91 children with SRNS from Germany, 41 patients did not have a mutation of any of the analyzed genes (NPHS1, NPHS2, WTI, LAMB2, TRPC6, and PLCE1) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"     3",
"    </a>",
"    ]. Kidney biopsies were performed in 40 of the 41 patients and showed the following histological diagnoses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Focal segmental glomerulosclerosis (FSGS, n = 28)",
"     </li>",
"     <li>",
"      Minimal change disease (MCD, n = 10)",
"     </li>",
"     <li>",
"      Diffuse mesangial sclerosis (n = 1)",
"     </li>",
"     <li>",
"      Mesangial proliferation (n = 1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312384\">",
"    <span class=\"h1\">",
"     THERAPEUTIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 20 percent of patients with steroid-resistant nephrotic syndromes (SRNS) will progress to end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/27\">",
"     27",
"    </a>",
"    ]. The goals of therapy for SRNS are to achieve complete resolution of proteinuria, thereby reducing the complications associated with NS, and preservation of kidney function. However, there is",
"    <strong>",
"     no",
"    </strong>",
"    currently optimal therapy for SRNS that consistently meets these two goals.",
"   </p>",
"   <p>",
"    The therapeutic options for SRNS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunosuppressive therapy, which is focused on inducing a complete remission. In some cases, there is only a partial remission with a reduction in proteinuria. Genetic forms of SRNS are particularly refractory to immunosuppressive therapy.",
"     </li>",
"     <li>",
"      Nonimmunologic therapy directed towards reducing protein excretion. Adult data have shown improved kidney survival in patients with NS who achieve a 50 percent or greater reduction in baseline proteinuria by either administration of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"      <a class=\"local\" href=\"#H143050117\">",
"       'Nonimmunologic antiproteinuric therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312543\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Remission of the nephrotic syndrome is the goal of immunosuppressive therapy, thereby reducing protein excretion and the risk of complications associated with nephrosis, and to preserve renal function.",
"   </p>",
"   <p>",
"    The following immunosuppressive agents have been used to treat SRNS with varying clinical benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alkylating agents",
"     </li>",
"     <li>",
"      Calcineurin inhibitors (CNIs)&ndash; Cyclosporin and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      mofetil",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       Rituximab",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunosuppressive therapy generally has not been shown to be effective in treating children with SRNS due to genetic causes. This was illustrated in two of the previously discussed case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the study that identified steroid-resistant patients with NPHS2 gene defects, neither",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      nor",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      induced a complete remission in 29 treated patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the previously mentioned study of 91 patients, none of the 43 patients with an identified genetic cause responded with a complete remission to cyclosporin therapy, and only two achieved a partial response. In contrast, two-thirds of the 31 patients with nongenetic SRNS responded to cyclosporin therapy including 17 patients who achieved complete remission [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with SRNS who are heterozygotic carriers for either NPHS1 or NPHS2 gene mutation may be more likely to respond to immunosuppressive therapy than homozygous patients including steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/28\">",
"     28",
"    </a>",
"    ]. However, further investigation is needed to confirm this observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397757\">",
"    <span class=\"h3\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     no",
"    </strong>",
"    data showing a beneficial effect of alkylating agents in children with SRNS. Partial or complete remissions have been reported in 20 percent of cases following a course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , but this is similar to the remission rate of nontreated patients or those who continue to receive steroid therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/27,29-32\">",
"     27,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a randomized trial from the International Study of Kidney Disease in Children (ISKDC) comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    with prednisone alone in 60 patients with SRNS and focal segmental glomerulosclerosis (FSGS) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/30\">",
"     30",
"    </a>",
"    ]. The same proportion of children in both groups went into remission by six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397764\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312879\">",
"    <span class=\"h4\">",
"     Cyclosporin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    children with SRNS has been confirmed in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/32-41\">",
"     32-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 138 children and young adults with FSGS that compared cyclosporin to a combination of oral pulse",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF), partial or complete remission was achieved in 33 of 72 (46 percent) patients who were randomly assigned to receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/42\">",
"       42",
"      </a>",
"      ]. Although the remission rate was higher in the cyclosporin group, it was not significantly different from those who were assigned the combination therapy of steroids and MMF (33 percent).",
"     </li>",
"     <li>",
"      In a meta-analysis of interventions for SRNS, an analysis of three trials (n = 49 patients) demonstrated that the administration of cyclosporin compared with placebo or no treatment increased the number of children who achieved complete remission (RR 7.66, 95% CI 1.06-55.34) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, one trial of 32 patients showed",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      was more effective than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in inducing a partial remission in children with SRNS.",
"     </li>",
"     <li>",
"      Observational studies also report a benefit of cyclosporin in combination with steroid therapy as illustrated by the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the first study conducted by the French Society of Pediatric Nephrology, 65 children with SRNS were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (150 to 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for one month followed by alternate day prednisone for five months) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/34\">",
"       34",
"      </a>",
"      ]. Complete remission was observed in 27 patients and partial remission in 4 children. Complete remission was achieved in 48 percent (21 of 45 patients) of patients with minimal change disease (MCD) and 30 percent (6 of 20 patients) with focal segmental glomerulosclerosis (FSGS). One-half of responding patients remitted within the first month of therapy, and in 17 patients, complete remission lasted from 14 to 60 months. Eight responders became steroid-sensitive when they subsequently relapsed. None of the responders progressed to end-stage renal disease (ESRD), 15 had persistent NS, 5 were in complete remission, and 2 in partial remission. Most patients with a poor outcome had FSGS.",
"     </li>",
"     <li>",
"      In a retrospective German study of 86 children with SRNS, remission rates using cyclosporin in combination with steroids were dependent upon the underlying histologic findings obtained by kidney biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/41\">",
"       41",
"      </a>",
"      ]. In the group of 52 patients with FSGS, the 25 children treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) in combination with the initial use of high dose intravenous pulse",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (300 to 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 3 to 8 days) and oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day following pulse therapy) were more likely to undergo remission compared with the 27 children with FSGS treated with cyclosporine and only oral prednisone (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every other day) (84 versus 64 percent). All 14 patients with MCD included in this study underwent remission regardless of which combination regimen was used. In contrast, none of the 20 patients with genetic or syndromic form of FSGS responded to any of the combination therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, cyclosporin does not appear to have a beneficial effect in patients with genetic forms of SRNS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above retrospective study, none of the 20 patients with genetic or syndromic form of FSGS responded to combination therapy of cyclosporin and steroid [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the previously discussed case series of 91 patients with SRNS, none of the 12 patients with genetic mutations who were treated with cyclosporin achieved complete remission with cyclosporin therapy, and only two had a partial response [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"       3",
"      </a>",
"      ]. In contrast, 17 of the 31 patients without an identifiable genetic defect who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy achieved complete remission, and 4 had a partial response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who are responsive to cyclosporin therapy, there is a high relapse rate following the cyclosporin withdrawal. This results in prolonged administration of cyclosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/43\">",
"     43",
"    </a>",
"    ], which increases the risk of nephrotoxicity. In patients who require ongoing cyclosporin therapy to maintain remission, the plasma creatinine concentration should be monitored regularly, and serial renal biopsies should be performed to detect nephrotoxicity. Because histologic signs of cyclosporin nephrotoxicity are observed without clinical evidence of renal function impairment, we routinely perform a renal biopsy in asymptomatic patients after 18 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended cyclosporin dose is 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day divided into two oral doses. The dose should be adjusted to maintain trough whole blood levels between 100 and 200",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and the level should not exceed 200",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397771\">",
"    <span class=\"h4\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that the beneficial effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    is similar to that of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. In small clinical trials that compared tacrolimus to cyclosporine therapy in patients with SRNS, rates of remission between the two agents were similar up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. Tacrolimus was associated with a lower rate of relapse, fewer cosmetic side effects, and a lower blood cholesterol level.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and corticosteroid therapy has a higher rate of remission compared to intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . This was illustrated in a multicenter trial of 131 children with SRNS that compared relapse rates in children who received the combination therapy of tacrolimus and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    for 12 months compared with those who received six monthly intravenous infusion of cyclophosphamide. Children treated with a combination therapy of tacrolimus and corticosteroid had a higher complete or partial remission rate (52 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are needed to confirm whether",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    offers any advantage over cyclosporin in the management of patients with SRNS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397778\">",
"    <span class=\"h3\">",
"     Mycophenolate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data demonstrate inconsistent results regarding the efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) in patients with SRNS as demonstrated by the following small studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above mentioned clinical trial of 138 patients with FSGS, partial or complete remission was achieved in 22 of 66 patients (33 percent) who were randomly assigned to the combination therapy of oral pulse",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      and MMF [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Observational studies of children with SRNS also report potential benefit of MMF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 52 Brazilian children with steroid and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      resistant NS, 12 patients (22 percent) achieved complete remission, 19 (35 percent) partial remission, and in 21 (39 percent) patients there was no response [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study from China of 24 children less than two years of age with SRNS, MMF in combination with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      at an initial dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      was associated with complete remission in 15 patients, partial remission in six patients, and no response in the remaining three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/55\">",
"       55",
"      </a>",
"      ]. Steroid therapy was tapered in a step-wise manner.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast, two small trials report limited benefit of MMF in patients with SRNS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More consistent data indicating a beneficial effect without significant adverse effects are needed before MMF can be routinely recommended to treat children with SRNS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397785\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains uncertain whether",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    , an anti-CD20 B cell monoclonal antibody, is beneficial in the treatment of SRNS.",
"   </p>",
"   <p>",
"    Several case series have reported that the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    to glucocorticosteroid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CNI therapy improves remission rates in patients with SRNS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. In one case series that included patients with SRNS and steroid dependent patients, treatment with rituximab and alternate day steroid therapy resulted in complete remission in 9 of 33 patients with SRNS (including two adult patients), and partial remission in seven other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/60\">",
"     60",
"    </a>",
"    ]. Four patients also received concomitant therapy with a CNI, and the two adult patients received",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. Side effects included mild infusion related reactions of chills and myalgias, and no serious adverse event was observed.",
"   </p>",
"   <p>",
"    In contrast, an open-label clinical trial of 31 children with SRNS demonstrated that the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    to the standard therapy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and CNI therapy did not reduce proteinuria compared with control patients treated with standard therapy alone at three months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/61\">",
"     61",
"    </a>",
"    ]. Three patients in both groups entered remission during the study period. These six patients who entered remission were initial steroid responders but late nonresponders. No patient with early steroid resistance entered remission in either treatment arm.",
"   </p>",
"   <p>",
"    Serious adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    include infusion-related reactions (hypotension, fever, and rigors), serious infections, and progressive multifocal leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, there is one published case report of death associated with rituximab therapy in a child with nephrotic syndrome due to lung fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link&amp;anchor=H2#H2\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, we do not recommend the routine use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    in treating children with SRNS until there are data demonstrating that it is both effective and safe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631397792\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;More aggressive combination regimens have been tried in relatively small numbers of patients. Data are too limited to determine whether these therapies were efficacious and safe.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One regimen included",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/64\">",
"       64",
"      </a>",
"      ]. Lasting remission was observed in only 7 of 21 patients, starting six months to three years after initiation of treatment.",
"     </li>",
"     <li>",
"      Combination therapy of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      in 14 patients who were resistant or intolerant of cyclosporin therapy resulted in complete remission in all nine patients with steroid-dependent NS and two of the four patients with SRNS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/65\">",
"       65",
"      </a>",
"      ]. One of the patients with SRNS due to focal segmental glomerulosclerosis developed end-stage renal disease.",
"     </li>",
"     <li>",
"      Another regimen combines intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      pulses (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose, initially given every other day and then tapered to weekly and monthly dosing), oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day), and, if proteinuria does not improve by the week two of pulse therapy, an alkylating agent is added [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/66-68\">",
"       66-68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study utilizing this protocol, 21 of 32 children went into remission [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/68\">",
"       68",
"      </a>",
"      ]. The five-year incidence of end-stage renal disease was approximately 5 percent versus 40 percent in historical controls [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/68\">",
"       68",
"      </a>",
"      ]. A poor outcome was associated with segmental sclerosis on renal biopsy prior to pulse therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/69\">",
"       69",
"      </a>",
"      ]. Side effects included nausea during the infusion of pulse",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      in almost all, impaired growth in four (one of whom caught up with cessation of therapy), small cataracts that did not interfere with vision in five, and infections in two (cellulitis and Herpes zoster). There were no cases of abdominal striae, diabetes mellitus, or aseptic necrosis of bone.",
"     </li>",
"     <li>",
"      An abstract report of 15 children with FSGS was unable to confirm the efficacy of this regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/70\">",
"       70",
"      </a>",
"      ]. A mean of 15 pulses were given, and eight patients also received an alkylating agent. At the end of the study, only four patients maintained remission, and five had a poor outcome with progression to end-stage renal disease or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These regimens are not recommended because the potential limited benefit is outweighed by the significant adverse events associated with these therapeutic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143050117\">",
"    <span class=\"h2\">",
"     Nonimmunologic antiproteinuric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult data have shown improved kidney survival in patients with NS who achieve a 50 percent or greater reduction in baseline proteinuria. Interventions to reduce protein excretion have mainly focused on angiotensin antagonism by either angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar observational data in children also show angiotensin antagonism reduces protein excretion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one small study of nine children with steroid-resistant FSGS, ACE inhibitor or ARB therapy plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      resulted in a 72 percent decrease in proteinuria from baseline values at six months that was maintained for a minimum period of 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 52 children with persistent proteinuria (mean protein excretion 3.3 g per day), administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/19/40247?source=see_link\">",
"       losartan",
"      </a>",
"      , an ARB, reduced proteinuria by 34, 64, and 67 percent at mean follow-up of 0.4, 0.7, and 2.5 years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/72\">",
"       72",
"      </a>",
"      ]. Only 9 of 22 patients with baseline nephrotic range proteinuria had persistent nephrotic range proteinuria at last follow-up.",
"     </li>",
"     <li>",
"      In a study of 25 children with SRNS, the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"       enalapril",
"      </a>",
"      reduced protein excretion in a dose-related manner [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/73\">",
"       73",
"      </a>",
"      ]. After eight weeks of high doses of enalapril (0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into two doses), the median protein excretion was reduced by 63 percent. In comparison, a lower dose (0.2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      for eight weeks reduced median protein excretion by 35 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no data in children regarding the long-term prognosis of progression to chronic kidney disease with the use of ACE inhibitors or ARBs. Nevertheless, based on evidence from the adult literature, these agents are widely used as antiproteinuric therapy in children with SRNS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACE inhibitor and ARBs should be terminated if hyperkalemia cannot be controlled or the plasma creatinine concentration increases more than 30 percent above the baseline value. Female patients of childbearing age must be counseled regarding the teratogenic effects of these agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link&amp;anchor=H1161932#H1161932\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\", section on 'Approach to treatment in women of childbearing potential'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The partial response to CNI therapy in patients with genetic forms of SRNS has been attributed in part to its nonimmunologic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. These include antiproteinuric afferent arteriole vasoconstriction and possibly prevention of the degradation of the actin organizing protein synaptopodin and downregulation of TRPC6, a transient receptor potential channel that increases calcium influx in the podocytes. The combination of angiotensin antagonism therapy (ie, ACE inhibitors or ARBs) and CNI has resulted in partial remission in patients with SRNS and is commonly used in patients who have been refractory to other immunosuppressive therapy or those with SRNS due to genetic disorders. However, nephrotoxicity is a significant adverse effect of prolonged CNI therapy, which may be exacerbated with the concomitant use of an ACE inhibitor or ARB. If used, monitoring of renal function is needed including measurements of serum creatinine and serial renal biopsies. (See",
"    <a class=\"local\" href=\"#H631397764\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143050263\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment decisions are based on the underlying etiology determined by renal histology and genetic screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143051826\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for steroid-resistant nephrotic syndrome (SRNS) includes a renal biopsy to determine the underlying histology and possibly genetic screening. Therapeutic decisions are based on the histologic diagnosis and whether the cause of the nephrotic syndrome (NS) is due to a genetic etiology. (See",
"    <a class=\"local\" href=\"#H143052349\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A renal biopsy should be performed in a child with SRNS to confirm the diagnosis of idiopathic nephrotic syndrome. Renal biopsy may show three patterns: minimal changes, diffuse mesangial proliferation, and focal and segmental glomerulosclerosis (FSGS). These histological variants of nephrosis may be found alone or in any combination on sequential biopsies in the same patient. Histologic findings may be characteristic of specific genetic mutations and help guide genetic testing.",
"   </p>",
"   <p>",
"    A report of the International Study of Kidney Disease in Children showed that among 354 patients with idiopathic nephrotic syndrome, 55 patients did not respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , 45.5 percent had minimal change disease, 47.5 percent had FSGS, and 7.0 percent had diffuse mesangial proliferation. This study also found among the 37 patients with FSGS, 70.3 percent did not respond to steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143051834\">",
"    <span class=\"h3\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because immunosuppressive therapy generally has been shown to be not as effective in treating children with SRNS due to genetic causes, it is important to identify patients with genetic disease so that unnecessary exposure to immunosuppressive agents and their side effects can be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3,5,20,23,26,78\">",
"     3,5,20,23,26,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that increase the likelihood of an underlying genetic cause of SRNS include the following (see",
"    <a class=\"local\" href=\"#H631397715\">",
"     'Genetic mutations'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of SRNS [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/3,5\">",
"       3,5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presentation in the first year of life [",
"      <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parental consanguinity",
"     </li>",
"     <li>",
"      Syndromic SRNS (see",
"      <a class=\"local\" href=\"#H143051165\">",
"       'Syndromic SRNS'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In our center, we perform genetic testing for all patients with SRNS because screening is readily available in our research laboratory. For other settings in which genetic testing is not readily available, we suggest screening should be performed for all patients with a familial history of steroid-resistant NS (SRNS), patients whose parents are consanguineous, children less than one year who present with SRNS, and in all patients with syndromic SRNS. For the remaining patients with SRNS, we consider the utility of performing genetic screening based on the histology, and age of the patient.",
"   </p>",
"   <p>",
"    In patients in whom there is a strong suspicion for a genetic etiology, a step-wise screening approach is warranted given the number of different gene defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. The order of testing is determined by the likelihood of involvement of a specific gene as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age of presentation &ndash; For patients with congenital nephrotic syndrome, screening for mutations for NPHS1 should first be performed, followed by testing for NPHS2 mutations. For older children, screening should begin with identifying NPHS2 mutations.",
"     </li>",
"     <li>",
"      Presence of extrarenal abnormalities &ndash; LAMB2 screening for patients with ocular abnormalities, and WT1 screening for those with ambiguous genitalia.",
"     </li>",
"     <li>",
"      Type of histologic lesions &ndash; WT1 or LAMB2 screening for patients with a histologic diagnosis of diffuse mesangial sclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Gene testing for NPHS1, NPHS2, and WT1 mutations is commercially available. The laboratory directory for Gene tests supported by the National Institutes of Health provides a voluntary listing of commercial and academic laboratories throughout the world that offer molecular genetic testing (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some have suggested that, to avoid unnecessary exposure to steroid therapy, all children with a first episode of the NS should be screened for NPHS2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/10\">",
"     10",
"    </a>",
"    ]. However, given that over 85 percent of children with idiopathic NS are steroid-sensitive and only approximately one third of steroid-resistant patients have a genetic mutation, less than five percent of all cases would have a genetic basis for idiopathic pediatric NS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/78\">",
"     78",
"    </a>",
"    ]. As a result, we do not currently recommend genetic testing for all children with idiopathic nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143052349\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143052364\">",
"    <span class=\"h3\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with SRNS caused by genetic disorders, we do",
"    <strong>",
"     not",
"    </strong>",
"    administer additional immunosuppressive therapy because it is not effective and has significant adverse effects. Although data are lacking in children, we treat these patients with persistent proteinuria with angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) based on data from studies in adults. (See",
"    <a class=\"local\" href=\"#H312543\">",
"     'Immunosuppressive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H143050117\">",
"     'Nonimmunologic antiproteinuric therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H312646\">",
"    <span class=\"h3\">",
"     Nongenetic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to steroid-resistant idiopathic NS",
"    <strong>",
"     not",
"    </strong>",
"    due to a genetic defect is uncertain. The therapeutic approach for several specific histologic diagnoses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=see_link\">",
"     \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=see_link\">",
"     \"Evaluation and treatment of membranoproliferative glomerulonephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112410232\">",
"    <span class=\"h4\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, an initial combination of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    is given to children with steroid-resistant minimal change disease or focal glomerulosclerosis, provided they have normal glomerular filtration rate. If there is a response to therapy, we begin to taper steroid therapy to minimize or reduce steroid toxicity. In nonresponsive patients, we administer angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) to reduce protein excretion.",
"   </p>",
"   <p>",
"    Other experts in the field will begin either an ACE inhibitor or ARB when the diagnosis of SRNS is initially made. However, because ACE inhibitors or ARBs may increase the nephrotoxicity of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , we prefer to wait to see if the patient responds to the combination therapy of cyclosporine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    prior to adding an angiotensin antagonistic agent.",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the administration of alkylating agents based on evidence that shows no additional benefit over placebo therapy and a poorer response rate compared with CNIs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/30,53\">",
"     30,53",
"    </a>",
"    ]. We also do not suggest the",
"    <strong>",
"     routine",
"    </strong>",
"    use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"     rituximab",
"    </a>",
"    because there remains a paucity of data showing these are effective and safe agents in the treatment of children with SRNS. However, as noted above, others in the field have shown that MMF in combination with oral pulse",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may be beneficial in achieving remission. These drugs (alkylating agents, MMF, and rituximab) should only be used under the supervision of a clinician with expertise in treating children with SRNS. (See",
"    <a class=\"local\" href=\"#H631397757\">",
"     'Alkylating agents'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H631397778\">",
"     'Mycophenolate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H631397785\">",
"     'Rituximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112410240\">",
"    <span class=\"h4\">",
"     KDIGO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO), an international organization focused on improving the outcome of patients with kidney disease, globally developed guidelines to manage children with steroid-resistant NS, which is similar to our approach discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?20/54/21354/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcineurin inhibitor (CNI) therapy is administered for at least six months in combination with low-dose corticosteroid therapy. If there is no response, CNI is discontinued. If there is either a partial or complete remission, it is continued for at least 12 months. (See",
"      <a class=\"local\" href=\"#H631397764\">",
"       'Calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACE inhibitor or ARB therapy. (See",
"      <a class=\"local\" href=\"#H143050117\">",
"       'Nonimmunologic antiproteinuric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not respond to CNI therapy, consider the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, high-dose corticosteroids, or a combination of the two. Alkylating agents (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) are",
"      <strong>",
"       NOT",
"      </strong>",
"      recommended to treat children with steroid-resistant nephrotic syndrome. Data are insufficient to determine whether",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      should be used to treat these patients. (See",
"      <a class=\"local\" href=\"#H631397778\">",
"       'Mycophenolate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H631397757\">",
"       'Alkylating agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H631397785\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174704431\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten to 20 percent of children with idiopathic nephrotic syndrome will fail to respond to initial empirical steroid therapy. These children with steroid-resistant nephrotic syndrome (SRNS) are at increased risk for developing end-stage renal disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Steroid response'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link&amp;anchor=H174702423#H174702423\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\", section on 'Outcome based upon response'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increasingly, genetic mutations have been shown to cause SRNS in a substantial number of patients. Mutations of the NPHS1, NPHS2, and WT1 genes are the most commonly identified genetic defects observed in pediatric SRNS. (See",
"      <a class=\"local\" href=\"#H631397715\">",
"       'Genetic mutations'",
"      </a>",
"      above.) However, in most pediatric patients with SRNS, no underlying cause is currently identified. In these patients, the most common histological diagnosis based on kidney biopsies was focal segmental glomerulosclerosis followed by minimal change disease. (See",
"      <a class=\"local\" href=\"#H312325\">",
"       'Nongenetic forms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals for SRNS therapy are to attain complete resolution of proteinuria, thereby reducing the complications associated with nephrotic syndrome, and preserve kidney function. Therapeutic options include immunosuppressive and nonimmunologic antiproteinuric therapies. (See",
"      <a class=\"local\" href=\"#H312384\">",
"       'Therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Immunosuppressive therapy that has been used in children with SRNS includes alkylating agents, calcineurin inhibitors (CNIs),",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      . Immunosuppressive therapy has not generally been effective in children with SRNS due to genetic causes. (See",
"      <a class=\"local\" href=\"#H312543\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angiotensin antagonism by angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) reduces protein excretion in patients with SRNS. However, there are no data in children regarding the long-term prognosis of progression to chronic kidney disease with the use of these agents. (See",
"      <a class=\"local\" href=\"#H143050117\">",
"       'Nonimmunologic antiproteinuric therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242979235\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following management approach in children with SRNS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest performing a kidney biopsy in all children with SRNS to determine the underlying histology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H143051826\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest performing genetic screening in patients with SRNS in whom there is a strong suspicion for a genetic etiology (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This would include all patients with a family history of SRNS, all congenital cases, patients whose parents are consanguineous, and all patients with syndromic SRNS. (See",
"      <a class=\"local\" href=\"#H143051834\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with SRNS caused by genetic disorders, we recommend no additional immunosuppressive therapy because it is not effective and has significant adverse effects (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In these patients, we suggest the administration of either an ACE inhibitor or ARB to reduce protein excretion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H143052364\">",
"       'Genetic causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H312384\">",
"       'Therapeutic interventions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Optimal treatment of steroid-resistant NS not due to a genetic disorder is unknown. (See",
"      <a class=\"local\" href=\"#H312543\">",
"       'Immunosuppressive therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H312646\">",
"       'Nongenetic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In children with nongenetic SRNS, we suggest a combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , provided they have normal glomerular filtration rate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In unresponsive patients to the combination of a CNI and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      , we suggest the administration of either an ACE inhibitor or ARB to reduce protein excretion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other experts in the field advocate administering ACE inhibitor or ARB when the diagnosis of SRNS is initially made. We prefer to see whether the patient responds initially to the combination therapy of CNI and prednisone because concomitant use of an angiotensin antagonist will increase the nephrotoxicity of the CNI. (See",
"      <a class=\"local\" href=\"#H312879\">",
"       'Cyclosporin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H143050117\">",
"       'Nonimmunologic antiproteinuric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend the use of alkylating agents in the treatment of pediatric SRNS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H631397757\">",
"       'Alkylating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       not",
"      </strong>",
"      suggest the routine use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/50/12072?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil to treat patients with SRNS because it has not been shown to be more effective in this group of patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We also do",
"      <strong>",
"       not",
"      </strong>",
"      suggest the routine use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/47/34551?source=see_link\">",
"       rituximab",
"      </a>",
"      because of the lack of consistent data demonstrating efficacy and safety in children with SRNS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These agents should only be used under the direction of a clinician with expertise in treating children with SRNS. (See",
"      <a class=\"local\" href=\"#H631397778\">",
"       'Mycophenolate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H631397785\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/1\">",
"      Haack D, Sch&auml;rer K, Asam-Tauscher A, Vecsei P. Glucocorticoid receptors in idiopathic nephrotic syndrome. Pediatr Nephrol 1999; 13:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/2\">",
"      Kim JS, Bellew CA, Silverstein DM, et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005; 68:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/3\">",
"      B&uuml;scher AK, Kranz B, B&uuml;scher R, et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2010; 5:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/4\">",
"      Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/5\">",
"      Sant&iacute;n S, Bullich G, Taz&oacute;n-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/6\">",
"      Gigante M, Caridi G, Montemurno E, et al. TRPC6 mutations in children with steroid-resistant nephrotic syndrome and atypical phenotype. Clin J Am Soc Nephrol 2011; 6:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/7\">",
"      Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/8\">",
"      Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/9\">",
"      Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/10\">",
"      Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/11\">",
"      Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/12\">",
"      Karle SM, Uetz B, Ronner V, et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/13\">",
"      Frishberg Y, Rinat C, Megged O, et al. Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children. J Am Soc Nephrol 2002; 13:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/14\">",
"      Caridi G, Bertelli R, Di Duca M, et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/15\">",
"      Berdeli A, Mir S, Yavascan O, et al. NPHS2 (podicin) mutations in Turkish children with idiopathic nephrotic syndrome. Pediatr Nephrol 2007; 22:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/16\">",
"      Fuchshuber A, Jean G, Gribouval O, et al. Mapping a gene (SRN1) to chromosome 1q25-q31 in idiopathic nephrotic syndrome confirms a distinct entity of autosomal recessive nephrosis. Hum Mol Genet 1995; 4:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/17\">",
"      Frishberg Y, Feinstein S, Rinat C, et al. The heart of children with steroid-resistant nephrotic syndrome: is it all podocin? J Am Soc Nephrol 2006; 17:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/18\">",
"      Chernin G, Heeringa SF, Gbadegesin R, et al. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2008; 23:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/19\">",
"      Boyer O, Benoit G, Gribouval O, et al. Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. J Med Genet 2010; 47:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/20\">",
"      Ruf RG, Schultheiss M, Lichtenberger A, et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004; 66:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/21\">",
"      Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol 2006; 21:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/22\">",
"      Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/23\">",
"      Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol 2010; 25:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/24\">",
"      Clewing JM, Antalfy BC, L&uuml;cke T, et al. Schimke immuno-osseous dysplasia: a clinicopathological correlation. J Med Genet 2007; 44:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/25\">",
"      Zivicnjak M, Franke D, Zenker M, et al. SMARCAL1 mutations: a cause of prepubertal idiopathic steroid-resistant nephrotic syndrome. Pediatr Res 2009; 65:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/26\">",
"      Niaudet P. Genetic forms of nephrotic syndrome. Pediatr Nephrol 2004; 19:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/27\">",
"      Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/28\">",
"      Caridi G, Gigante M, Ravani P, et al. Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. Clin J Am Soc Nephrol 2009; 4:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/29\">",
"      Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/30\">",
"      Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996; 10:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/31\">",
"      Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid-resistant focal segmental glomerulosclerosis: a reappraisal. Clin Nephrol 1984; 22:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/32\">",
"      Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010; :CD003594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/33\">",
"      Mahmoud I, Basuni F, Sabry A, et al. Single-centre experience with cyclosporin in 106 children with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/34\">",
"      Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994; 125:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/35\">",
"      Gregory MJ, Smoyer WE, Sedman A, et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol 1996; 7:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/36\">",
"      Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993; 8:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/37\">",
"      Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/38\">",
"      Ingulli E, Singh A, Baqi N, et al. Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/39\">",
"      Chishti AS, Sorof JM, Brewer ED, Kale AS. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001; 38:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/40\">",
"      Plank C, Kalb V, Hinkes B, et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Pediatr Nephrol 2008; 23:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/41\">",
"      Ehrich JH, Geerlings C, Zivicnjak M, et al. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/42\">",
"      Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/43\">",
"      Hamasaki Y, Yoshikawa N, Nakazato H, et al. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis. Pediatr Nephrol 2013; 28:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/44\">",
"      Habib R, Niaudet P. Comparison between pre- and posttreatment renal biopsies in children receiving ciclosporine for idiopathic nephrosis. Clin Nephrol 1994; 42:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/45\">",
"      Kengne-Wafo S, Massella L, Diomedi-Camassei F, et al. Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. Clin J Am Soc Nephrol 2009; 4:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/46\">",
"      Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/47\">",
"      Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006; 26:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/48\">",
"      Gulati S, Prasad N, Sharma RK, et al. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008; 23:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/49\">",
"      Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 2009; 53:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/50\">",
"      Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010; 25:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/51\">",
"      Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009; 24:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/52\">",
"      Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012; 27:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/53\">",
"      Gulati A, Sinha A, Gupta A, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012; 82:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/54\">",
"      de Mello VR, Rodrigues MT, Mastrocinque TH, et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/55\">",
"      Li Z, Duan C, He J, et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/56\">",
"      Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/57\">",
"      Mendiz&aacute;bal S, Zamora I, Berbel O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/58\">",
"      Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 2008; 23:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/59\">",
"      Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007; 356:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/60\">",
"      Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/61\">",
"      Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012; 23:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/62\">",
"      Pradhan M, Furth S. Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope? J Am Soc Nephrol 2012; 23:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/63\">",
"      Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009; 24:1753.",
"     </a>",
"    </li>",
"    <li>",
"     Trompeter RS. Steroid resistant nephrotic syndrome: A review of the treatment of focal segmental glomerulosclerosis in children. In: Recent Advances in Pediatric Nephrology, Murakami K, Kitagawa T, Yabuta K, Sakai T (Eds), Excerpta Medica, Amsterdam 1987. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/65\">",
"      Aizawa-Yashiro T, Tsuruga K, Watanabe S, et al. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol 2011; 26:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/66\">",
"      Tune BM, Mendoza SA. Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 1997; 8:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/67\">",
"      Mendoza SA, Reznik VM, Griswold WR, et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990; 4:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/68\">",
"      Tune BM, Kirpekar R, Sibley RK, et al. Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 1995; 43:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/69\">",
"      Kirpekar R, Yorgin PD, Tune BM, et al. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. Am J Kidney Dis 2002; 39:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/70\">",
"      Guillot AP, Kim MS. Pulse steroid therapy does not alter the course of focal segmental glomerulosclerosis (abstract). J Am Soc Nephrol 1993; 4:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/71\">",
"      Montan&eacute; B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/72\">",
"      Ellis D, Vats A, Moritz ML, et al. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 2003; 143:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/73\">",
"      Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/74\">",
"      MacHardy N, Miles PV, Massengill SF, et al. Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 2009; 24:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/75\">",
"      Gellermann J, Stefanidis CJ, Mitsioni A, Querfeld U. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol 2010; 25:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/76\">",
"      Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 2010; 25:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/77\">",
"      Malina M, Cinek O, Janda J, Seeman T. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation. Pediatr Nephrol 2009; 24:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/78\">",
"      Niaudet P. Podocin and nephrotic syndrome: implications for the clinician. J Am Soc Nephrol 2004; 15:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/54/21354/abstract/79\">",
"      Lombel RM, Hodson EM, Gipson DS. Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO. Pediatr Nephrol 2013; 28:409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16711 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21354=[""].join("\n");
var outline_f20_54_21354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H174704431\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174704350\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174704558\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631397715\">",
"      Genetic mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5651950\">",
"      - NPHS1 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397722\">",
"      - NPHS2 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12234952\">",
"      - NPHS3 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397729\">",
"      - WT1 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12235032\">",
"      - Other genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143051165\">",
"      - Syndromic SRNS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143051649\">",
"      - Genotype and histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H312325\">",
"      Nongenetic forms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H312384\">",
"      THERAPEUTIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H312543\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397757\">",
"      - Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397764\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H312879\">",
"      Cyclosporin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H631397771\">",
"      Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397778\">",
"      - Mycophenolate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397785\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631397792\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143050117\">",
"      Nonimmunologic antiproteinuric therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143050263\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143051826\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143051834\">",
"      - Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H143052349\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143052364\">",
"      - Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H312646\">",
"      - Nongenetic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H112410232\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H112410240\">",
"      KDIGO guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H174704431\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242979235\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16711|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/2/40999\" title=\"picture 1\">",
"      Renal pathology of late diffuse mesangial sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/5/6230\" title=\"picture 2\">",
"      Renal pathology of early diffuse mesangial sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/32/8709\" title=\"picture 3\">",
"      Renal Bx congenital NS of the Finnish type - tubular changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/36/38470\" title=\"picture 4\">",
"      Renal Bx - congenital NS of the Finnish type",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13594?source=related_link\">",
"      Evaluation and treatment of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24506?source=related_link\">",
"      Evaluation of the infant with ambiguous genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1973?source=related_link\">",
"      Nail-patella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_54_21355="Classification of iodine status";
var content_f20_54_21355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of iodine status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Median urinary iodine concentration (mcg/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Corresponding approximate iodine intake (mcg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iodine nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;20",
"       </td>",
"       <td>",
"        &lt;30",
"       </td>",
"       <td>",
"        Severe deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-49",
"       </td>",
"       <td>",
"        30-74",
"       </td>",
"       <td>",
"        Moderate deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-99",
"       </td>",
"       <td>",
"        75-149",
"       </td>",
"       <td>",
"        Mild deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100-199*",
"       </td>",
"       <td>",
"        150-299",
"       </td>",
"       <td>",
"        Optimal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200-299",
"       </td>",
"       <td>",
"        300-449",
"       </td>",
"       <td>",
"        More than adequate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;299",
"       </td>",
"       <td>",
"        &gt;449",
"       </td>",
"       <td>",
"        Possible excess",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For pregnant women, urinary iodine concentrations of 150 to 249 mcg/L are considered adequate.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ICCIDD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21355=[""].join("\n");
var outline_f20_54_21355=null;
var title_f20_54_21356="Laboratory studies in child with status epilepticus";
var content_f20_54_21356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory studies in child with status epilepticus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Patient population",
"      </td>",
"      <td class=\"subtitle1\">",
"       Studies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       All patients",
"      </td>",
"      <td>",
"       Serum electrolytes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum calcium, phosphate, and magnesium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brain imaging (CT or MRI)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EEG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epilepsy patients maintained on anticonvulsants",
"      </td>",
"      <td>",
"       Anticonvulsant level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Febrile patients",
"      </td>",
"      <td>",
"       CBC with differential",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urinalysis, urine culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CSF culture (once seizures stopped and if brain imaging excludes increased intracranial pressure)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Poisoned patient",
"      </td>",
"      <td>",
"       Urine screen for cocaine, amphetamines, and PCP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aspirin level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Venous or arterial pH and pCO2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EKG once seizures stop",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"11\">",
"       Infants &lt;6 months of age*",
"      </td>",
"      <td>",
"       Blood gas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plasma ammonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Plasma amino acids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PT, PTT",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serum AST, ALT, LDH, Alkaline phosphatase",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood lactate and pyruvate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urinalysis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urine for reducing substances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urine organic acids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urine amino acids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Check newborn urine screening results if infant from country where instituted",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging; EEG: electroencephalogram; CBC: complete blood count; PCP: phencyclidine; PT: prothrombin time; PTT: partial thromboplastin time; AST: aspartate transferase; ALT: alanine transferase; LDH: lactate dehydrogenase.",
"     <br>",
"      * Consultation with pediatric neurologist and/or metabolic specialist strongly encouraged.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21356=[""].join("\n");
var outline_f20_54_21356=null;
var title_f20_54_21357="ICD versus antiarrhythmic drug AVID trial";
var content_f20_54_21357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ICD improves survival in patients with life-threatening ventricular arrhythmia--data from the AVID trial",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 252px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AVID trial included 1016 patients with a history of ventricular fibrillation, ventricular tachycardia, or syncope thought to be due to arrhythmia. The patients were randomly assigned to an implantable defibrillator (ICD) or antiarrhythmic therapy (amiodarone or sotalol). Survival was significantly higher with an ICD (89 versus 82 percent at one year, 82 versus 75 percent at two years and 75 versus 65 percent at three years).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The Antiarrhythmics Versus Implantable Defibrillator (AVID) Investigators. N Engl J Med 1997; 337:1576.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_54_21357=[""].join("\n");
var outline_f20_54_21357=null;
var title_f20_54_21358="Contents: Head and neck infections";
var content_f20_54_21358=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Head and neck infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Head and neck infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ocular infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/18/24873\">",
"           Bacterial endophthalmitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/33/13849\">",
"           Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/13/8409\">",
"           Epidemiology, diagnosis, and management of trachoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27751\">",
"           Preseptal cellulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/49/33561\">",
"           Retinal vasculitis associated with systemic disorders and infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39112\">",
"           Treatment of endogenous endophthalmitis due to Candida species",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/40/5767\">",
"           Tuberculosis and the eye",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Odontogenic infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/53/20313\">",
"           Complications, diagnosis, and treatment of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/30/16873\">",
"           Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18777\">",
"           Gingivitis and periodontitis in adults: Classification and dental treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/3/21559\">",
"           Cervicofacial actinomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10649\">",
"           Clinical features and treatment of uvulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/4/35913\">",
"           Cochlear implant infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/21/11608\">",
"           Differential diagnosis of a neck mass",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23145\">",
"           Septic dural sinus thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/14/22758\">",
"           Suppurative parotitis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Otitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/62/39913\">",
"           Acute otitis media in adults (suppurative and serous)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/35/8760\">",
"           Acute otitis media in children: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29642\">",
"           Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21514\">",
"           Acute otitis media in children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/47/20216\">",
"           Malignant (necrotizing) external otitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/40/22153\">",
"           Otitis media with effusion (serous otitis media) in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pharyngeal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36569\">",
"           Deep neck space infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4826\">",
"           Epiglottitis (supraglottitis): Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/16/12553\">",
"           Epiglottitis (supraglottitis): Treatment and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31705\">",
"           Peritonsillar cellulitis and abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35622\">",
"           Submandibular space infections (Ludwig's angina)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/22/35176\">",
"           Tonsillectomy in adults: Indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/38/6761\">",
"           Tonsillectomy in adults: Surgery",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sinusitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/48/39688\">",
"           Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2297\">",
"           Acute sinusitis and rhinosinusitis in adults: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/36/8775\">",
"           Fungal rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/58/26537\">",
"           Microbiology and antibiotic management of chronic rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11674\">",
"           Orbital cellulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27751\">",
"           Preseptal cellulitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-61A2EDCD9E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_54_21358=[""].join("\n");
var outline_f20_54_21358=null;
var title_f20_54_21359="Contents: Disorders of bone";
var content_f20_54_21359=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Disorders of bone",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Disorders of bone",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/26/11687\">",
"           Bone disease in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17593\">",
"           Bone disease with hyperthyroidism and thyroid hormone therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/51/43829\">",
"           Endocrine dysfunction in the nephrotic syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hereditary disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/45/21209\">",
"           Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/9/38040\">",
"           Osteogenesis imperfecta: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/36/26185\">",
"           Osteogenesis imperfecta: Management and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hyperparathyroidism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8872\">",
"           Approach to therapy in multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41495\">",
"           Classification and genetics of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/16/22794\">",
"           Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/19/1338\">",
"           Clinical manifestations of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/26/5545\">",
"           Diagnosis and differential diagnosis of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/13/3287\">",
"           Hungry bone syndrome following parathyroidectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/47/8954\">",
"           Management of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13688\">",
"           Parathyroid carcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40387\">",
"           Parathyroid cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21416\">",
"           Parathyroid hormone assays and their clinical use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36744\">",
"           Parathyroid hormone secretion and action",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/41/30361\">",
"           Pathogenesis and etiology of primary hyperparathyroidism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/60/18377\">",
"           Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple endocrine neoplasia syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/61/38871\">",
"           Multiple endocrine neoplasia type 1: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteomalacia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/9/11416\">",
"           Clinical manifestations, diagnosis, and treatment of osteomalacia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/54/27494\">",
"           Epidemiology and etiology of osteomalacia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/23/36213\">",
"           Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/33/22040\">",
"           Denosumab for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/55/11128\">",
"           Diagnosis and evaluation of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/25/6553\">",
"           Epidemiology and etiology of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/42/37545\">",
"           Evaluation and management of aromatase inhibitor-induced bone loss",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/35/42553\">",
"           Evaluation and treatment of premenopausal osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/55/29561\">",
"           Osteoporosis after solid organ or stem cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37178\">",
"           Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29354\">",
"           Osteoporotic fracture risk assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42583\">",
"           Overview of dual-energy x-ray absorptiometry",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/26/15786\">",
"           Parathyroid hormone therapy for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/53/3929\">",
"           Pathogenesis of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42855\">",
"           Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/4/11333\">",
"           Pharmacology of bisphosphonates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/36/17994\">",
"           Prevention and treatment of glucocorticoid-induced osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/21/33113\">",
"           Prevention of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40393\">",
"           Screening for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/32/41481\">",
"           Selective estrogen receptor modulators for osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/28/44487\">",
"           Use of biochemical markers of bone turnover in osteoporosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36969\">",
"           Antiepileptic drugs and bone disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42519\">",
"           Bone physiology and biochemical markers of bone turnover",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/21/9562\">",
"           Drugs that affect bone metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/58/33706\">",
"           Medical consultation for patients with hip fracture",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/54/30569\">",
"           Metabolic bone disease in inflammatory bowel disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29830\">",
"           Metabolic bone disease in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34906\">",
"           Normal skeletal development and regulation of bone formation and resorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28346\">",
"           Osteonecrosis (avascular necrosis of bone)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paget disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/50/7978\">",
"           Clinical manifestations and diagnosis of Paget disease of bone",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/22/10602\">",
"           Treatment of Paget disease of bone",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal osteodystrophy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/43/28343\">",
"           Bone biopsy and the diagnosis of renal osteodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9273\">",
"           Indications for parathyroidectomy in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33690\">",
"           Treatment of hyperphosphatemia in chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/56/40842\">",
"           Bisphosphonates in the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/10/43173\">",
"           Calcitonin in the prevention and treatment of osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/56/12170\">",
"           Calcium and vitamin D supplementation in osteoporosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32473\">",
"           Epidemiology and etiology of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39754\">",
"           Overview of the management of osteoporosis in postmenopausal women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/58/31657\">",
"           Treatment of osteoporosis in men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vitamin D",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/18/38184\">",
"           Causes of vitamin D deficiency and resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9462\">",
"           Metabolism of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/3/39990\">",
"           Overview of vitamin D",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/21/3417\">",
"           Treatment of vitamin D deficiency in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31193\">",
"           Vitamin D and extraskeletal health",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E8158485AD-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f20_54_21359=[""].join("\n");
var outline_f20_54_21359=null;
